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General Introduction  




In recent years, the amount of research into right ventricular (patho)physiology increased 
dramatically. Whereas, not too long ago, the right ventricle was regarded a dispensable part 
of human circulation,1, 2 investigations demonstrated that a normal right heart is essential for 
a functional and regulated cardiovascular system.3 One of the first areas of research in which 
the importance of right ventricular function was noted, was congenital heart disease.4–7 
Patients with defects in cardiac development, frequently present with right ventricular 
dysfunction, either as a result of the defect itself or as a consequence of surgical procedures, 
necessary to correct the birth defect.8, 9 Pulmonary hypertension is another disease in which 
dysfunction of the right ventricle is frequently observed10 and prognosis mainly depends on 
preservation of right ventricular function.11 Furthermore, it became apparent that not only 
dysfunction of the left ventricle, but also the right ventricle is of importance in patients with 
ischemic heart disease,12 indicating the relevance of normal right heart function for the full 
scope of cardiovascular disease.
Not long after recognition of the right heart as a critical part of normal heart function, 
fundamental investigations demonstrated that the right and left ventricle have a different 
developmental origin.13–15 Moreover, developmental research showed that the right and left 
ventricle not only have a different morphology, but also have distinct molecular charac-
teristics.16–18 Such observations underscored that although both ventricles form part of the 
same heart, left and right ventricular disease may require a different approach in terms of 
functional assessment as well as treatment.19, 20 More importantly, this established research 
in the field of right ventricular disease, from fundamental developmental investigations to 
randomized clinical trials, as an independent entity within cardiovascular science.
right ventricular development
Before six weeks of gestation, the primitive embryonic human heart exists of an inlet portion 
which directs return of venous blood, a primary heart tube that propels blood in a peristaltic 
motion and an outflow tract that directs blood into the direction of the primitive aorta (Fig-
ure 1).21, 22 In this primitive stage the right ventricle still has to develop. One of the first steps 
in right ventricular development is the addition of an extra-cardiac population of cells desig-
nated second heart field (yellow area in Figure 1). These cells migrate into the heart to form, 
amongst others, the right ventricle.23 Concurrent with primary right ventricular development, 
the interventricular septum expands and divides the heart into two separate ventricles. As 
soon as the heart is septated, clear differences can be observed on a morphological level 
between the left and right ventricle.24 Whereas the left ventricle seems to start compaction 
in a relatively early phase, the right ventricle remains thin-walled. So far, it is unclear which 
mechanisms play a key role in the difference between left and right ventricular compaction. 
Although it is known that interstitial fibroblasts induce ventricular compaction and remodel-
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ing during embryonic development,25 it remains to be elucidated whether the interaction of 
interstitial fibroblasts with surrounding myocardium is different in the right as compared to 
the left ventricle. Such developmental keys could help to understand why specific medical 
therapies have beneficial effects in the left and not in the right ventricle.
Simultaneous with right ventricular development, remodeling of the cardiac outflow tract 
occurs. Whereas first the primitive aorta and pulmonary trunk are connected to the right ven-
tricle with a common outflow tract, a tightly regulated process leads to, amongst others: 1. 
Septation of the aorta and pulmonary artery, 2: Normal positioning of the pulmonary trunk in 
the ventral-superior position, 3: Connection of the aorta to the left ventricle.26 Dysregulation 
of this delicately orchestrated process results in common congenital cardiac defects such as 
transposition of the great arteries and tetralogy of Fallot.21 Although outflow tract develop-
ment is understood roughly,21 the genetic pathways that guide right ventricular outflow tract 
remodeling and normal development of aorta and pulmonary artery, are largely unknown.27 
Recognition of these pathways would aid the identification of gene mutations responsible 
for the aforementioned congenital outflow tract defects.
Figure 1. Early cardiac development. Panel A: The primary heart tube with an inlet portion, blue vessel 
and an outlet portion, red vessel. The yellow area demarcates the second heart field. Panel B: Migration of 
second heart field-derived cells into the heart to form the right ventricle (yellow shading in the upper part 
of the heart tube). The pro epicardial organ (red arrow), which is also derived from the second heart field, 
protrudes into the celomic cavity. These cells migrate onto the heart and form the epicardial sheet. Adapted 
from Gittenberger-de Groot et al.22
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the right ventricle in adults
The right ventricle is located behind the sternum and has a complicated morphology. The 
tricuspid valve has a partly right-posterior orientation, whereas the pulmonary artery has a 
largely left-cranial orientation. With the apex positioned between the tricuspid valve (inlet) 
and the pulmonary artery (outlet), the right ventricle has a triangular shape (figure 2).28
A general definition of right heart function is currently lacking. Nevertheless, it is generally 
accepted that that the right ventricle has to pump a certain volume of blood into the pulmo-
nary circulation with a certain pressure in order to provide adequate pulmonary perfusion 
and to sustain optimal cardiac output.29 Furthermore, the right ventricle plays a key role in 
volume regulation. Increases in right ventricular preload result in temporary (and subtle in 
physiological conditions) ventricular dilatation. Consequently, sarcomere length increases 
which leads to improvement of myocardial contraction.30 Ultimately, right ventricular (and 
therefore cardiac) output increases to adjust to the altered loading conditions.31 Being a thin-
walled and compliant chamber, the right ventricle is equipped for responding to changes in 
volume loading, which forms an integral part of its function.28, 32
Figure 2. Adult right ventricular anatomy. 
Panels A-D show the right ventricle in a 
progressively superior view as indicated 
on the torsos. The free walls of the right 
and left ventricle have been removed. 
Anatomical landmarks are indicated by 
colored asterikses. Red asteriks: pulmo-
nary artery; Blue asteriks: right ventricu-
lar apex; Orange asteriks: tricuspid valve. 
Connection of the three asterikses in 
panel A demonstrates why the shape of 




The three-dimensional architecture and the important effect of loading conditions on 
the right heart make it challenging for physicians to assess right ventricular performance. 
Currently, no techniques are available that assess all aspects of right ventricular function. 
Therefore, we rely on functional measurements that are able to assess only a few characteris-
tics of right heart function at the same time.28
right ventricular imaging techniques
The introduction of echocardiography and, more importantly, cardiovascular magnetic reso-
nance imaging, was the motor behind the fast increasing knowledge about right ventricular 
function. Although early echocardiographic techniques made it possible to study some of the 
characteristics of the right ventricle,33 the anatomy and morphology made study of the right 
ventricle difficult. In recent years, the quality of echocardiography increased considerably.34 
This made it possible to study right heart function using a two-dimensional technique. Stud-
ies demonstrated that simple echocardiographic measurements of right ventricular function 
(Figure 3 A, B) were associated with patient outcome.35–37 Drawback of these measurements 
was the fact that they ignored the complex right heart anatomy.38 Novel methods such as 
right ventricular strain measurement (Figure 3 D) provided detailed information about 
abnormal segmental contraction patterns.39, 40 It, however, remains to be studied what the 
additional value of these, more complex, measurements is. Furthermore, three-dimensional 
echocardiography offers the opportunity to assess right ventricular volumes more precisely,41, 
42 however it is only possible in a limited number of patients due to the position of the right 
ventricle in the thorax.38 Another important step-forward in functional assessment was the 
description of myocardial performance index43, 44 by Tei et al. (Figure 3 C), which measures the 
effectiveness of right ventricular contraction.
The introduction of cardiovascular magnetic resonance imaging provided, for the first 
time, the opportunity to investigate right ventricular volumes within its anatomical, three-
Figure 3. Echocardiographic assessment of right ventricular function. Panel A: Tricuspid Annular Plane 
Systolic Excursion, or TAPSE, which measures total movement of the base of the right ventricle into the 
direction of the apex in a single plane (bracket). Panel B: Right Ventricular Fractional Area Change, or RVFAC, 
is demonstrated. This measure provides right ventricular luminal area at the end of systole as a percentage 
of the end-diastolic area. As such, RVFAC is a surrogate of right ventricular contractility. Panel C: Myocardial 
performance index was first described by Tei et al..43 They defined the performance of a ventricle (either left 
or right) as the time-fraction during which contraction (black box + hatched box) actually leads to ejection 
of blood (hatched box) into the circulation. In situations of right ventricular overload, lower part of panel 
C, the “effective” ejection time reduces signified by shortening of the hatched box. Panel D: Assessment of 
right ventricular strain. In this technique, the right ventricle is divided into equal segments. In each segment 
the end-systolic length is expressed as a percentage of the end-diastolic length. Dedicated echocardio-





dimensional context.45 Since magnetic resonance imaging is not hampered by abnormal 
anatomy,46 it is an excellent tool for assessment of patients with congenital heart disease and 
right ventricular dysfunction.47, 48 Besides volume measurement, magnetic resonance imag-
ing is also suitable for assessment of valvular function, specifically regurgitation, which is also 
relevant for patients with reduced right ventricular performance.49 Furthermore, whereas 
this technique was first established as a tool for application in resting conditions, it soon 
became possible to perform magnetic resonance imaging during exercise.50 It became ap-
parent that an abnormal ventricular response to exercise was frequently observed in patients 
with congenital heart disease as compared to healthy controls.51, 52 However, it remained to 
be elucidated how abnormal right ventricular response to stress was related to outcome in 
patients with congenital heart disease.
the right ventricle and electrocardiography
Another technique for right heart assessment is electrocardiography, which was first 
described in 1887 by Augustus Désiré Waller53 and made clinically applicable in 1908 by 
Willem Einthoven.54 The right ventricle is thin-walled and part of a low-pressure system in 
normal situations. Therefore electrical forces are far lower in the right as compared to the left 
ventricle. Consequently, most electrical activity, as observed on the nowadays used 12-lead 
surface electrocardiogram, is derived from the left.55 Only in situations of demarcated right 
ventricular pressure overload, distinct patterns will occur on the surface electrocardiogram.56 
Therefore most electrocardiography-derived right ventricular disease criteria lack sensitiv-
ity.57 Nonetheless, simple electrocardiographic measurements are helpful in specific situa-
tions. E.g., lengthening of QRS duration can be used in patients with tetralogy of Fallot to 
detect right ventricular volume overload due to pulmonary regurgitation.58 Moreover, QRS 
duration is known to reduce after pulmonary valve replacement in patients with a dilated 
right ventricle.59 Possibly, the ECG may be helpful in the assessment of patient outcome after 
pulmonary valve replacement in these patients.
Furthermore, electrocardiogram-derived vectorcardiography (Figure 4) greatly improved 
the sensitivity of criteria for right ventricular pressure overload.57 It was demonstrated in 
pulmonary hypertensive rats, that specific vectorcardiographic characteristics changed in 
response to right ventricular pressure overload, even before hypertrophy occurs.60 Thereafter 
clinical investigations in a selected population of patients with pulmonary arterial hyperten-
sion showed partial reversibility of these vectorcardiographic characteristics in response to 
treatment.61 However, after the first promising results of ECG-derived vectorcardiography in 
selected groups, it was questioned if the electrocardiogram was of use in heterogeneous 
patient populations representative of clinical practice.
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Figure 4. Electrocardiographic assessment of right ventricular overload. Panel A: A standard 10 seconds, 
12-lead surface electrocardiogram with typical characteristics of right ventricular pressure overload: sinus 
tachycardia, large P-waves, rightward shift of the depolarization axis, frequent extra systoles. These typical 
changes can only be observed in a minority of patients with advanced disease.57 Panel B: An electrocar-
diogram-derived vectorcardiogram. Magnitude and orientation of the cardiac vector is depicted through-
out the (electric) cardiac cycle. As opposed to the standard electrocardiogram, the cardiac vector changes 
quickly in response to hemodynamic alterations.
CHAPTER 1
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characterizing the right ventricle
The importance of a properly functioning right heart is becoming clearer in an expanding 
number of cardiovascular and non-cardiovascular diseases.62–66 Nonetheless, there are still 
many unanswered questions about assessment of right ventricular pathophysiololgy.67 
Progress in fundamental research provides insight in right ventricular molecular and cellular 
characteristics, which may be relevant for functional analysis and evaluation of new treat-
ment modalities.68 Furthermore, the improvements in imaging techniques provided a vast 
number of novel functional measurements of which the exact clinical application has to be 
elaborated.69 Therefore, both clinical and fundamental investigations are necessary for better 
understanding and more effective treatment of right heart disease.
Aim and outline of thesis
The aim of this thesis was to further characterize the right ventricle within three different 
fields of cardiovascular research: 1. Embryonic development, 2: Noninvasive right ventricular 
imaging, 3: Right ventricular electrocardiography.
In part I, several aspects of embryonic development, relevant for normal right ventricular 
morphology and function are investigated. In chapter 2, a novel concept for normal develop-
ment of the right ventricular outflow tract is introduced. In chapter 3, the potential relevance 
of epicardium-derived cells for the difference between left and right ventricular morphology 
is discussed. Noninvasive imaging techniques are evaluated in part II. In chapter 4, the use 
of conventional semi-quantitative measurement of right ventricular function in patients 
with transposition of the great arteries is analyzed. The relevance of abnormal response to 
stress, measured with cardiovascular magnetic resonance imaging, is investigated in chapter 
5. Chapters 6–8 demonstrate how strain measurement can be used in various types of (sus-
pected) right ventricular disease. In part III, both conventional electrocardiography as well 
as computerized vectorcardiography is described in patients with right ventricular disease. 
A case-study of conventional electrocardiographic assessment of right ventricular pressure 
overload is provided in chapter 9. The prognostic value of QRS duration in patients with 
tetralogy of Fallot who undergo pulmonary valve replacement, is demonstrated in chapter 
10. Chapter 11 and 12 discuss the application of ECG-derived vectorcardiography in normal 
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In the adult heart, morphological and functional differences of right ventricle (RV) and left 
ventricle (LV) are apparent. We hypothesized that variability in contribution of epicardium-
derived cells (EPDCs) to the developing RV and LV might explain these differences. The aim 
of this study was to assess normal and disrupted formation of the compact myocardial layer 
of the RV and LV in mice.
methods and results
Epicardial sheet formation and contribution of EPDCs were studied in wildtype and TGFβ2-
null embryonic mice (E9.5–14.5) using expression patterns of WT1 and a Cre-activated WT-1 
reporter model. After epicardial covering of the heart tube, EPDCs were observed first in the 
inner curvature and RV wall. WT-1 expressing cells were abundantly observed in the wall of 
both ventricles at E13.5, more pronounced within the LV correlating with more pronounced 
thickening of the LV compact myocardial layer. In TGFβ2-null mice, formation and migration 
of EPDCs was severely diminished, although an epicardial sheet was formed. Differences in 
RV and LV myocardial thickness as observed in wildtype, were absent in TGFβ2-null mice.
conclusions
Spatio-temporal differences in contribution of EPDCs to RV versus LV myocardium were 
observed during development. Compact myocardial layer formation starts upon migration 
of EPDCs into the ventricles and is more pronounced in the LV. Disruption of EPDC migration 
results in absence of normal myocardial thickening, only significant in the LV. This suggests 
that EPDC-myocardial interaction in the LV differs from that in the RV, which may explain 
occurrence of lateralized cardiomyopathies as isolated LV non-compaction and may prove 
relevant for development of cell-based and drug-based therapies.
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introDuction
Right ventricular (RV) function is an important determinant of survival in a large number 
of cardiovascular diseases.1–3 Therapies aimed at long-term improvement of RV function are 
scarce.4 In addition, medical therapies which proved to be beneficial in left ventricular (LV) 
disease are generally not useful in the dysfunctional RV.5, 6 Therefore, dedicated cell-based 
therapy might be of interest for the treatment of RV disease.7, 8 Proper understanding of the 
differences between the LV and RV on a morphological and molecular level is important for 
development of these therapies.
In the past decade the identification of the second heart field (SHF) showed that the 
ventricles have a different developmental origin.9–11 Early in cardiovascular development, 
the heart exists of a primary heart tube with a venous and an arterial pole.12 Through migra-
tory processes from the SHF, cells are added to the arterial (and venous) pole of the heart.9 
Whereas the primary heart tube provides the majority of cells of the LV, the SHF provides 
most cellular components of the RV.10, 13 This different origin (primary versus SHF) may pro-
vide a developmental explanation for the observed differences between the adult LV and 
RV.14 The epicardium has concerted interactions with both ventricles during specific stages 
of development, which is bound to have implications for functioning of the adult heart.15, 
16 The epicardium is derived from the pro-epicardial organ (PEO) which is an element of the 
caudal part of the SHF and expresses, amongst others, WT-1, TGFβ2, Id2 receptor and PDGFα 
receptor.16–18 Epicardial cells migrate from the PEO, cover the ventricles in an orchestrated 
pattern and form an epithelial sheet. The epicardial cells that cover the distal vascular part of 
the outflow tract of the heart probably originate from the arterial pole of the heart.19, 20 After 
spreading over the heart, epicardial cells go into epithelial-to-mesenchymal transition (EMT) 
forming a subepicardial layer, in interaction with the underlying myocardium,21 and migrate 
into the ventricular wall as epicardium-derived cells (EPDCs).22, 23 Inside the myocardium EPDCs 
contribute, amongst others, to vessel formation, differentiation of the Purkinje network and 
partly differentiate into interstitial fibroblasts.15, 24, 25 It was demonstrated that the latter cell-
population induces normal LV growth.25, 26 Experimental knock-out of epicardium-associated 
genes in mice showed abnormal epicardium and abnormal development of the ventricular 
myocardium.18, 27–29 Knock-out of TGFβ2, which is expressed in epicardium and is required for 
EMT, is associated with thin uncompacted myocardium,27 probably due to a lack of EPDCs. In 
vitro studies demonstrated the essential role of EPDCs in myocardial proliferation, matura-
tion and alignment.30 The crucial role of the epicardium for normal ventricular development 
and compaction is evident, as is the propensity for clinical cases of specific cardiomyopathies, 
like non-compaction cardiomyopathy and arrhythmogenic right ventricular dysplasia, to 
occur in a lateralized fashion ( i.e. left vs. right sided, respectively.31, 32 We hypothesized that 
EPDCs interact differently with the LV as compared to the RV. As a consequence, EPDCs may 
contribute to the difference in function and morphology of the postnatal LV and RV. This 
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is particularly relevant since recent studies identified the potential of EPDCs to reactivate 
embryonic differentiation programs in the adult ischemic heart.33–36
We are the first to analyse the differences in development of the RV and LV related to 
the formation of epicardium, the timing of EMT and the migration of EPDCs. The aim of the 
current study was 1: To assess whether the timing of epicardial sheet formation and EPDC 
migration is different in the RV as compared to the LV, and 2: To investigate the effect of 
disrupted epicardial development on formation of the compact layer in the RV versus the LV 
using the TGFβ2-null mouse model.
methoDs
mice
For the study of normal development, wild type mouse embryos were obtained from the 
CLB-Swiss strain. To study the fate of EPDCs, WT1CreERT2/+ and the Cre-activated reporter Ro-
sa26fsLz mice were used.37 Wt1CreERT2/+ mice were generated by gene targeting followed by 
Flp-mediated removal of a Neo resistance casette, as described previously (Zhou et al, 2008, 
also see Figure 2F). CreERT2 is a fusion protein composed of Cre recombinase and a modi-
fied variant of the estrogen receptor hormone binding domain. CreERT2 recombines floxed 
targets in the presence, but not the absence of tamoxifen (Feil et al., 1997). 2 mg tamoxifen 
(Sigma) was injected peritoneally into pregnant mice at E10.5 to induce Cre activity. Ro-
sa26fsLz (Soriano, 1999) and Rosa26mTmG (Muzumdar et al., 2007) mice were used as Cre-
dependent reporters. These mice express LacZ and membrane localized GFP, respectively, 
after Cre-mediated recombination. Upon maternal injection with tamoxifen, this reporter 
expresses B-galactosidase upon Cre-mediated recombination and thus provides a means to 
follow EPDCs after differentiation even when WT-1 is downregulated.
To investigate the effect of abnormal EPDC formation and function, the TGFβ2-null mouse 
was studied.27 TGFβ2 is abundantly expressed in epicardium38 and plays an important role 
in epicardial cell differentiation and invasion.39 This model provides an effective means to 
study the effect of abnormal EPDC formation and function, simultaneously for LV as well as 
RV development. The handling of all animals and embryos was according to the Guide for 
Care and Use of Laboratory Animals, as published by the NIH. The day the vaginal plug was 
detected, was designated embryonic day (E) 0.5. Pregnant female mice were sacrificed on 
consecutive days from E 9.5-E 14.5 and, per day, three embryos were harvested for the study.
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immunohistochemical procedures
After fixation in 4% paraformaldehyde in phosphate buffered saline (0.1 M, pH 7.2) and subse-
quent dehydration embryos were embedded in paraffin, sectioned transversely (5μm) and serially 
mounted on glass slides. Immunohistochemical staining was performed with antibodies against 
MLC-2a (1/6000, kindly provided by S.W. Kubalak, Charleston, SC); Nkx2.5 (1/4000, Santa Cruz 
Biotechnology Inc., CA, United States, SC-8697) and WT-1 (1/1000, Santa Cruz Biotechnology Inc., 
CA, United States, SC-192). The slides were first incubated for 45 min using ABC-reagent (Vector 
Laboratories, Burlingame, United States, PK 6100), and then with 400 μg/ml 3–3’di-aminobenzidin 
tetrahydrochloride (DAB, Sigma-Aldrich, St Louis, United States, D5637) dissolved in trismaleate 
buffer pH 7.6 to which 20 μl H2O2 was added. The latter incubation was done 5 min for MLC-2a and 
10 min for Nkx 2.5 and WT1. Counterstaining was done using 0.1% hematoxylin (Merck, Darmstadt, 
Germany) for 5 sec, and the slides were subsequently rinsed with tap water for 10 min. Finally, 
slides were dehydrated and mounted with Entellan (Merck, Darmstadt, Germany).
three-dimensional reconstruction and quantification
To address the timing of epicardial covering of the ventricles, the expression of WT-1 from E9.5 to 
E11.5 was 3D visualized. On each embryonic day, micrographs were made (magnification 10X) of 
serial sections to cover the whole embryonic heart from the proximal part of the great vessels on 
the cranial side, down to the inferior cardinal veins on the caudal side. The micrographs were pro-
cessed using the AMIRA software package (Template Graphics Software, San Diego, CA, United 
States) as described previously.40 First, the myocardium, the arterial and the venous pole were 
reconstructed in MLC-2a stained sections. Then, the expression of WT-1 was superimposed. To this 
purpose, the nucleus of each WT-1 positive cell, staining brown after incubation with WT-1 anti-
body, was separately indicated. Thus, the location of WT-1 positive cells in the epicardial sheet and 
in the extra-epicardial structures in relation to the underlying and surrounding tissue is provided.
Wall thickness was assessed in the apical and mid-lateral free wall of the LV and RV. Per stage 
(E10.5–14.5), micrographs were made of at least three different wild type and TGFβ2-null mouse 
embryonic hearts. In each heart, a section was selected at approximately the same level that 
included the LV and RV, the interventricular septum and the atrioventricular transition. Wall 
thickness (apical and mid-lateral, LV and RV) was measured in each section by 2 measurements 
at the mid lateral wall, and at the apical wall, respectively. Measurements were performed by 
two observers in consensus (MRMJ, RVS), blinded from the phenotype of the hearts at the time 
of measurement, using the analysis software ImageJ (Rasband, W.S., ImageJ, U. S. National In-
stitutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997–2011). Results were 
depicted and significance of differences between RV and LV in wildtype hearts, and in knockout 
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hearts, and between wild type and knockout embryos, was calculated with GraphPad Prism 
4.00 for Windows (GraphPad Software, La Jolla, CA, United States).
results
epicardial sheet formation
At E9.5, the PEO expressed WT-1 and protruded into the coelomic cavity at the caudal part of 
the heart at the sinus venosus (Figure1A). Differentiation of the sinus venosus myocardium 
had only just been initiated and the cardinal veins were still devoid of myocardium. The 
expression of WT-1 was not confined to the PEO but was also observed in the mesenchyme 
surrounding the left and right cardinal veins (Figure 1A, arrows). As became apparent from the 
three- dimensional reconstruction at this stage (Figure 1E), these WT-1 positive cells enclosed 
the left and right cardinal veins and the proximal part of the sinus venosus in a semicircular 
fashion. This area of WT-1 positive cells was also observed along the dorsal coelomic cavity 
wall and was continuous with the PEO (Figure 1). Small clusters of WT-1 positive cells were 
already detached from the PEO (Figure 1C, D) and were found at the inner curvature of the 
looping heart tube. The LV was larger in size as compared to the RV and in both ventricles, tra-
beculations were observed. The trabeculations of the LV were coarser and more pronounced 
compared to the RV. The outer layer of myocardium was thin, as no compact myocardium 
had developed, yet.
At E10.5, cardiac looping had progressed, however the heart was still in an unseptated state 
consisting of a common atrium, primitive LV and the outflow tract. Only remnants of the 
PEO were visible at the original caudal site of the heart and most WT-1 positive cells now 
attached to the heart tube to form the epicardial sheet (Figure 2D). The early epicardial sheet 
covered the primitive (common) atrium, the primitive LV and the part of the RV adjacent to 
the primary fold. Distal parts of the RV were sparsely covered with WT1-positive cells and the 
outflow tract was for the greater part uncovered (Figure 2). Pronounced expression of WT1 in 
the coelomic cavity lining was observed. Furthermore, an epicardial sheet extended from the 
coelomic cavity wall covering the distal end of the outflow tract (Figure 2A-C). Expression of 
WT1 was more prominent on the right side (putative aorta) of the outflow tract, whereas on 
the left side (putative pulmonary trunk) the expression of WT1 was almost absent (Figure 2A).
At E11.5, the PEO-derived epicardial sheet extended towards the outflow tract, leaving the 
left side uncovered, whereas on the right (aortic) side the PEO-derived and arterial pole-
derived epicardium were connected and formed a continuous sheet (Figure 2E-G).
From E12.5 the heart was fully covered, however, a lower density of WT-1 expressing cells 
was observed on the RV compared to the LV surface (Figure 2H, I), as observed from WT1Cre-
ERT2/+ at ED 13.5.
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Figure 1. E9.5. WT-1 expression in the pro-epicardial organ and putative sinus venosus. A,B: Caudal sec-
tions approximately at the level of entrance of the cardinal veins in the sinus venosus (SV). Cells of the 
pro-epicardial organ (PEO) express WT-1 (A) and not Nkx2.5 (B). WT-1 positive cells are also observed sur-
rounding the right cardinal vein (RCV) and left cardinal vein (LCV, arrows in A) C,D: Epicardial cells traverse 
the coelomic cavity and attach to the myocardial surface of the ventricle (boxed area in C, which is enlarged 
in D) Arrowheads in D indicated WT-1 positive epicardial cells. The first epicardial cells are observed at the 
inner curvature and on the left ventricular surface. E. 3D-reconstruction (left-antero-caudal view) indicat-
ing WT-1 expression (indicated by the brown cones) at the inflow part of the heart. Besides the PEO, WT-1 
expression is seen in the tissue surrounding the LCV and RCV, that are indicated in blue. Myocardium of the 
atria and ventricles is indicated in grey. The area of WT-1 expression around the cardinal veins is continuous 
with the PEO. Abbreviations: A: primitive atrium, DAo: dorsal aorta, LV: primitive left ventricle, RV: primitive 
right ventricle. Bars: 100 µm
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Figure 2. Epicardial covering of the heart at E10.5, E11.5 and E13.5. A-C. E10.5. The outflow tract (OFT) is 
covered with WT-1-expressing epicardial cells on the right side (putative aorta), whereas on the left side 
(putative pulmonary trunk), no epicardial cells are observed. Cells of the arterial pole epicardium have a 
cuboidal shape (arrowhead in upper boxed area in A, which is enlarged in B). Epicardial cells covering the 
more proximal right part of the OFT (that are pro-epicardial organ derived) have a flat, epithelial morpholo-
gy (arrowhead in lower boxed panel in A, shown enlarged in C). D. Towards the apex both the right ventricle 
(RV) and left ventricle (LV) have an epicardial covering. The left ventricle (LV) is fully covered by epicardium 
at E10.5. E. At E11.5 the left side of the OFT is still uncovered by epicardium. F,G: 3D-reconstructions of 
myocardium (light grey for RV and OFT myocardium, dark grey for LV myocardium) and epicardium (dark 
brown) demonstrating that the left side of the OFT (the putative pulmonary trunk (purple), is the latest to 
be covered by epicardium. The atria are depicted in pink. H,I: At E13.5 the PEO-derived ventricular epicar-
dium is fully developed, however the density of epicardial cells is lower at the RV surface as compared to 
the LV surface as can be observed in WT1CreERT2/+. AoS: aortic sac. Bars: panels B,C: 50μm, panels A,D,E: 100 µm
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ePDc formation and migration
From E12.5 onwards, generalized EMT throughout the epicardium of the ventricles resulted 
in a subepicardial layer covering the LV and the RV and formation of EPDCs was extensive 
(Figure 3). Migration of EPDCs was observed into RV myocardium but not into the LV (Figure 
3A-C). The expression pattern of WT1CreERT2/+ confirmed the presence of EPDCs in the thin 
myocardial layer of the RV, whereas epicardium-derived cells could not be seen in the LV 
(Figure 3G-L).
myocardial compaction
Figure 4 summarizes the process of myocardial compaction. At E11.5, both ventricles had a 
thin and uncompacted myocardial wall with loosely organized cells, while the RV was slightly 
smaller in size. The LV was the first in which reorganization of the compact myocardial layer 
could be observed at E12.5 (Figure 4A-D). This compact layer was characterized by a lower 
intensity of MLC-2a expression compared to the trabecular myocardium. At E13.5, MLC2a 
expression was of lower intensity within the compact outer layer of LV myocardium, whereas 
reduction of MLC2a expression occurred only at E14.5 in the RV (Figure 4E-H). Simultaneous 
with reduced expression of MLC2a, cellular organization changed within the LV wall. Struc-
tured layers of myocardium started to form in the LV, opposed to the loose organization in 
RV myocardium. The difference in compaction between the LV and RV was also reflected in 
myocardial thickening. Since both ventricles were thin-walled and consisted of a single or 
double layer of cells, no significant difference was observed in myocardial thickness between 
the LV and RV at E11.5 (Figure 4I). Thereafter, the LV was already significantly thicker at E12.5 
in the apical wall and from E14.5 also at mid-lateral level, increasing considerably during 
development (Figure 4I).
Simultaneous with myocardial compaction, expression of WT-1 within the ventricles 
increased, specifically in the LV where EPDCs were abundantly present in the compact myo-
cardial layer (Figure 4J-M). In the RV, some EPDCs were present in the compact myocardium, 
but also in the trabeculae, which was not seen in the LV. Differences in density of EPDcs were 
as also observed in the expression pattern of WT1CreERT2/+ at E14.5 when compaction had 
commenced in both ventricles (Figure 4N-P).
Disruption of epicardial cell migration
TGFβ2 plays an important role in EMT and migration of EPDCs,38 and expression is associated 
with regular formation of an epicardial sheet (Figure 5). Morphology of the myocardium 
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Figure 3. E12.5 EPDC formation and migration starts in the right ventricle. A: Overview section of the right 
ventricle (RV) and left ventricle (LV) at stage E12.5. The ventricles are completely covered by a WT-1 posi-
tive epicardial layer. B-C: Enlargements of the boxed areas in A, showing the right ventricle (RV) (B) and left 
ventricle (LV) (C). A subepicardial layer has started to form in both the RV and LV. EPDCs are found in solely 
in the myocardium of the RV (B, arrowheads) and not the LV (C). D,E: To confirm this observation, epicardial 
cells were followed using WT1CreERT2/+. D: overview section, E: enlargement of the boxed area in E, at the level 
of the LV. No EPDC’s are found in the myocardium. F. Schematic depiction of the Wt1CreERT2/+ mouse model. 
For description see the Methods section. G-L: Results in WT1CreERT2/+, stage E12.5. A subepicardial layer is 
present in both ventricles and migration of EPDCs into myocardium is observed in the RV (arrows in G and 
J), but not the LV (I and L). Some EPDCs were also present in the RV part adjacent to the interventricular 
septum (IVS) (J), and in the IVS itself (arrowheads in H). Bars: B,C: 50μm, other bars: 100 µm
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Figure 4. EPDCs and myocardial compaction at stages E11.5- E14.5. A-D. Myocardial compaction and thick-
ening in the left ventricle (LV) at stages E11.5-E14.5. Development of a compact myocardial layer can ob-
served starting from E12.5 and increasing in subsequent stages. E-H: Myocardial compaction and thicken-
ing in the right ventricle (RV) at stages E11.5-E14.5. A compact myocardial layer can be observed starting 
only at E14.5 in the RV. I. Quantification of myocardial thickening. Measurements at the level of mid-lateral 
wall are indicated in the left panel, and measurements at level of the apical wall are indicated in the right 
panel. There is a significant increase in wall thickness of the left ventricle during these developmental stag-
es, whereas this increase in wall thickness is not significant for the RV. At the level of the mid-lateral wall, 
the LV wall is significantly thicker than the RV wall at E14.5, whereas at the apical wall, the LV is already 
significantly thicker at E12.5. J-M: E14.5: Structural differences are observed comparing the RV and LV. In the 
RV (J,K), the compact myocardium is still relatively loosely organized as compared to the LV (L,M). Abundant 
WT1 expressing EPDC’s are observed specifically within the compact myocardial layer of the LV (M). In the 
RV some EPDC’s are also observed in the compact myocardial layer, as well as at the base of the trabeculae 
(K, arrow heads). N-P: WT1CreERT2/+. O is an overview section at the level of the RV and LV. N and O are enlarge-
ments of the boxed areas in O, at the level of the RV (N) and LV (P). Results in WT1CreERT2/+ confirmed the abun-
dant presence of EPDCs in the LV compact myocardial layer (P) and the presence of some EPDCs within the 
compact RV myocardium (N). *p<0.05; **p<0.005. Bars: 100 µm
CHAPTER 2
38
Figure 5. E13.5. TGFβ2 is required for normal EPDC migration and ventricular compaction. A,B: Overview 
sections of the heart at stage E13.5 in WT (A) and TGFβ2 knockout (B) embryos. In TGFβ2 knockout embryos 
thin myocardium is observed in both the left ventricle (LV) and right ventricle (RV). The myocardium of the 
interventricular septum (IVS) has a spongeous appearance. C-F: Overview of myocardial compaction from 
E11.5 to E14.5 in wildtype (C,E) and TGFβ2-null (D,F) mouse embryos. In TGFβ2-null mouse embryos (D,F), 
both the LV and RV myocardium is thin. Migration of EPDCs into the ventricles is severely reduced, and only 
a few EPDCs can be observed in the RV and LV (D, F, arrow heads). G: Quantification of myocardial thinning. 
Measurements at the level of mid-lateral wall are indicated in the left panel, and measurements at the level 
of the apical wall are indicated in the right panel. In contrast to wildtype, no significant difference in wall 
thickness between the RV and LV was measured in the TGFβ2 knockout embryos. The increase in LV wall 
thickness throughout development observed in wildtype, is lacking in TGFβ2 knockout embryos. In the 
midlateral wall, a significant difference in wall thickness of the LV was observed between wildtype and 
TGFβ2 knockout embryos at stages E13.5 and E14.5. In the measurements of the apical wall, a significant 
difference in wall thickness in the apical wall of the LV was observed between wildtype and TGFβ2 knock-
out from E12.5 onwards. *p<0.05; **p<0.005. RA: right atrium, LA: left atrium. Bars: 100 µm.
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was severely abnormal in TGFβ2-null embryos. Both ventricular vascular walls were thin and 
uncompacted, while the LV was most prominently affected (Figure 5A,B). In TGFβ2-null mice, 
expression of WT1 was confined to the epicardium and could only sparsely be found within 
myocardium. (Figure 5C-F).
In knockout embryos no significant differences between RV and LV ventricular wall (apical or 
mid lateral) were observed throughout development. The increase in LV apical wall thickness 
observed in wildtype, was lacking in the knockout animals (Figure 5G). Comparing wildtype 
and knockout embryos, significant differences in wall thickness between wildtype and TGFβ2-
null embryos were observed in the apical wall of the LV and from E13.5 onward this difference 
was also significant for thickness measurements in the LV mid-lateral wall (Figure 5G).
Discussion
We evaluated the difference in timing of epicardial sheet formation, EMT and migration of 
EPDCs between the LV and RV in wildtype and TGFβ2-null mouse embryos. WT1CreERT2/+ and the 
Cre-activated reporter Rosa26fsLz were used in addition to the protein expression patterns of 
WT-1. WT-1 was expressed within the mesenchyme surrounding the sinus venosus, the PEO and 
epicardium. Epicardial covering in the RV is completed later and is less dense compared to the 
LV. In the RV free wall, migration of EPDCs occurs earlier compared to the LV free wall. EPDCs, 
having an essential role in normal myocardial compaction development, are more abundant 
within LV compared to RV myocardium. Finally, due to lack of normal EMT in TGFβ2-null mouse 
embryos the number of EPDCs is severely reduced in both ventricles, but more pronounced in 
the LV, resulting in myocardial thinning which is more prominent in the LV.
A number of studies indicate the relevance of preserved RV function for survival in patients 
with cardiac disease.41–44 Although a wide range of therapeutic options is available for LV 
failure, treatment possibilities are still limited in case of RV dysfunction.4 Many differences 
between the LV and RV on morphological as well as molecular level are founded in embry-
onic development.45 The recognition of developmental processes, such as addition of cell-
populations to the embryonic heart e.g. SHF, EPDCs and neural crest cells, have contributed 
to understanding differences between the LV and RV.9, 10, 15, 22, 46 However, little attention has 
been paid to right/left differences in interaction of these cell populations. This is of particular 
interest since specific cardiomyopathies have a propensity to occur lateralised.31, 32
ePDcs and ventricular compaction
The nuclear transcription factor WT-1 is expressed in the PEO and epicardium and expression 
is down-regulated upon differentiation of EPDCs.47 Therefore, the use of reporter constructs 
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is essential to trace the fate of EPDCs after EMT.37 The current study demonstrates that WT-1 
is expressed in epicardium, but also abundantly in the venous pole of the heart at early 
developmental stages, in the area that surrounds the lumen of the left and right cardinal 
veins, where the sinus venosus myocardium will form. As a consequence WT-1 is not entirely 
epicardium-specific, but it is generally accepted that with care WT-1 can be used to study 
EPDCs.48, 49
EPDCs contribute to smooth muscle cell formation, development of the cardiac conduction 
system, composition of the annulus fibrosus and cardiac valves and formation of interstitial 
fibroblasts.22, 25, 50–53 During ventricular development, epicardium and EPDCs interact with 
underlying and surrounding myocardium on different levels depending on the stage of 
development.16 EPDCs that differentiate into interstitial fibroblasts contribute to myocardial 
proliferation and compaction.25 Since the LV and RV have a distinct developmental origin 
(first heart field vs. SHF) and a different timing in terms of growth, it is postulated that the 
interaction between epicardium and EPDCs on the one hand and myocardium on the other 
hand varies between both ventricles.
The current study shows that epicardial covering is completed later and is less dense in the 
RV compared to the LV. At E9.5, epicardial covering of the ventricles commences, and the RV 
expands quickly as a result of proliferation and addition of SHF-derived myocardium.54 At this 
stage, the RV is thin-walled and the RV myocardium is loosely organized. The epicardial sheet 
expands gradually and maintains a contiguous network of epithelial cells.16 As a consequence, 
RV expansion, which is most prominent on the left side of the OFT, surpasses extension of the 
epicardial sheet. This may explain why specifically the left side of the OFT is the latest to be 
covered by epicardium.
Invasion of EPDCs into the myocardium occurred earlier as compared to the LV, although 
epicardial covering was completed later in the RV. Furthermore, EPDCs were observed near 
the trabecular surface of the RV and not the LV. In a previous chick-quail chimera study, it was 
demonstrated that permissiveness for EPDCs is variable within the embryonic heart.55 The 
exact mechanism that regulates this variation in myocardial permissiveness is still unclear. 
We postulate that the loose organization of RV myocardium facilitates early invasion of 
EPDCs into the RV.
From E13.5 the number of myocardially located EPDCs increased dramatically, specifically 
within the LV. Previous studies demonstrated that this invasion process is essential for normal 
development of the compact myocardial layer.25, 26 EPDCs induce myocardial alignment and 
proliferation through cell-cell interaction.30 EPDCs are the primary source of cardiac inter-
stitial fibroblasts22 regulating myocardial proliferation and compaction through fibronectin 
and collagen synthesis in a process that requires β1 Integrin signalling.
26 Therefore, EPDCs are 
important for the difference in proliferation between the LV and RV. The current study shows 
that proliferation and myocardial thickening starts at E12.5 in the LV, simultaneous with the 
invasion of EPDCs. Although EPDCs were observed in the free wall of the RV, their density was 
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far more prominent in the LV. The spatio-temporal difference in EPDC invasion in the RV may 
explain why RV myocardium remains thinner as compared to LV myocardium. Alternatively, 
the lack of an epicardial contribution, more specifically EPDCs, during ventricular develop-
ment would exert strongest effects in the LV.
tgFβ2 and myocardial proliferation
Normal EMT, required for the formation of EPDCs , is a tightly regulated process that involves 
expression of several genes during specific time-intervals.16 Most of these genes serve 
multiple functions during cardiovascular development and experimental knock-out of 
epicardial genes resulted in severe malformations and embryonic lethality as observed in 
WT-1 knock-out.56 TGFβ2, expressed by epicardium, is required for normal EMT and migration 
of EPDCs.57 TGFβ2-null embryos have multiple cardiac defects, but embryonic lethality was 
not observed.27 In TGFβ2 null embryos the compact myocardial layer of the ventricles was 
abnormally thin and spongy. Hence this model is well-suited for the study of abnormal EPDC 
contribution to ventricular development. Our evaluation shows that knock-out of TGFβ2 
results in a severely reduced densities of EPDCs within the myocardium of the ventricles. 
The morphological changes were most prominent in the LV, which was expected since the 
contribution of EPDCs was more important for the LV in wildtype embryos. In the knockout 
animals, the normal difference in myocardial thickness between RV and LV disappeared, as 
quantification of myocardial thickening in the RV demonstrated similar thickness in wildtype 
and TGFβ2-null embryos, underscoring that the number of invading EPDCs is instrumental in 
myocardial architecture.
ePDcs and the difference between lv and rv myocardium
Whereas the LV largely originates from the first heart field-derived primary heart tube, the 
RV develops as a result of the addition of cellular components from the SHF.9–11 This requires 
regulated proliferation and differentiation which is partly mediated by Wnt, Hedgehog, bone 
morphogenetic protein and fibroblast growth factor (FGF) signaling pathways.58 FGF spe-
cifically is important for proliferation within the SHF, lengthening of the OFT and normal RV 
development.59 To date, a role for FGF in early development of the LV has not been identified. 
However, FGF signaling is required for normal invasion of EPDCs and for myocardial growth in 
both ventricles.25, 60 It is postulated that the multiple functions of FGF during RV development 
result in responses to EPDC-mediated FGF signaling that differ between the RV and LV.
The LV and RV express different sarcomeric genes during cardiac development.61 The dis-
tinctive origins of the LV and RV (first heart field vs. SHF) may account for these differences in 
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expression patterns, and could also be relevant for the growth potential of the ventricles.62 
Although EPDCs induce myocardial organization and proliferation, the characteristics of the 
underlying and surrounding myocardium are bound to be important.
Functional relevance of ePDcs for the treatment of cardiac disease
RV dysfunction is a recognized problem in adult patients with congenital or acquired heart 
disease.4 Most medical therapies have no or limited effect on RV function in situations of RV 
overload. In patients with transposition of the great arteries and a systemic RV, treatment 
with angiotensin receptor blockers does not improve ventricular function, whereas this effect 
is beyond dispute in patients with LV disease.5 Similarly, beta-blockade has adverse effects in 
patients with pulmonary hypertension and an overloaded RV.6
In recent investigations, it was suggested that the multipotent EPDCs may have potential 
for cell-based therapies.33, 34, 63, 64 More importantly, the paracrine function of EPDCs during 
cardiac development may be preserved in adult life, which can be relevant for the develop-
ment of novel treatment strategies in cardiovascular disease.36, 65 Our evaluation indicates that 
the interaction between myocardium and epicardium follows different patterns in the RV and 
LV. Therefore, future studies need to explore the mechanisms that guide EPDC-myocardium 
interaction in the RV and LV separately.
conclusion
WT-1 can be used to investigate the fate of EPDCs. However, data interpretation should be 
performed with diligence since WT1 is also expressed in non-epicardial cell populations. The 
RV is covered later and less densely by epicardium compared to the LV. Invasion of EPDCs 
occurs slightly earlier and with a different patterning in the RV. Myocardial thickening oc-
curs from E12.5, upon migration of EPDCs into myocardium, being more prominent in the LV 
and requires TGFβ2. In TGFβ2-null mouse embryos, migration of EPDCs into myocardium is 
severely reduced resulting in thin, uncompacted ventricles, most obvious in the LV.
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Understanding of cardiac outflow tract (OFT) remodeling is essential to explain reposition-
ing of the aorta and pulmonary orifice. In wild type embryos (E9.5–14.5) second heart field 
contribution (SHF) to the OFT was studied using expression patterns of Islet 1, Nkx2.5, MLC-2a, 
WT-1 and 3D-reconstructions. Abnormal remodeling was studied in VEGF120/120 embryos. In 
wild type, Islet 1 and Nkx2.5 positive myocardial precursors formed an asymmetric elongated 
column almost exclusively at the pulmonary side of the OFT up to the pulmonary orifice. In 
VEGF120/120 embryos the Nkx2.5 positive mesenchymal population was disorganized with a 
short extension along the pulmonary OFT. We postulate that normally the pulmonary trunk 
and orifice are pushed in a higher and more frontal position relative to the aortic orifice by 
asymmetric addition of SHF-myocardium. Deficient or disorganized right ventricular OFT 
expansion might explain cardiac malformations with abnormal position of the great arteries, 
such as double outlet right ventricle.
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introDuction
Morphogenesis of the outflow tract (OFT) is a complex and delicately orchestrated process.1–3 
During proper development of the OFT the great arteries achieve their definitive morphologic 
relationship, with the aorta situated in a central position right posterior of the pulmonary trunk. 
Maldevelopment of the OFT results in an abnormal position of the aorta and pulmonary trunk, 
observed in some forms of congenital heart disease, such as tetralogy of Fallot, transposition 
of the great arteries and double outlet right ventricle, often characterized by a side-to-side 
arrangement of the great vessels. The malpositioning of the great arteries and their respective 
orifices in these instances has major consequences, with early mortality without timely inter-
vention. Knowledge of normal OFT development is mandatory as a first step in comprehension 
of the background of these malformations, as well as to aid in early (prenatal) diagnosis.
During embryonic development the myocardium of the OFT is derived from the second 
heart field, also referred to as anterior or secondary heart field.3–5 In this paper we refer to 
this population as the anterior heart field, which includes the coelomic wall covering the 
pericardial cavity in the OFT region of the heart.3 This population of cells expresses amongst 
others Isl1, Tbx1 and Tbx3, GATA4, Nkx2.5 and WT-1.3, 6–10 Expression of some of these genes, 
including Tbx3 and Isl1, is also observed in neural crest derived cells, and a recent study 
indicates a dual origin (myocardial and neural crest cells) of Isl1 derivatives in the heart.9, 11 
Anterior heart field cells contribute to the vascular wall of the great arteries and differentiate 
into a myocardial phenotype upon migration to the myocardial OFT. While at the beginning 
of development the myocardial OFT is short, orchestrated interaction between products of 
the aforementioned genes results in continuing addition of cells from the anterior heart field 
to the OFT, which lengthens in response. Although the exact time span of cellular addition 
from the anterior heart field to the myocardial OFT is unclear, addition until embryonic day 
(E) 11.5 in mouse was previously described.12 Using immunofluorescent stainings and deposits 
of Indian ink in chick an increase of the myocardial part of the OFT up to stage HH24 has been 
demonstrated,13 corresponding to E12.5 in mouse.
The future aorta and pulmonary trunk and their respective orifices have a side-by-side position 
early in cardiac development. It is suggested that, besides lengthening, a rotational motion of 
the OFT is required for normal positioning of the aorta and pulmonary trunk and their respective 
orifices.14–16 Multiple developmental signaling factors such as Pitx2c and FGF8/10, expressed in 
the anterior heart field in an asymmetrical fashion, have been reported as potential regulators 
of this rotational motion.17 Several mutant mouse models with a phenotype that includes OFT 
malformations are currently available, including models with alterations in expression in vascular 
endothelial growth factor (VEGF) signaling. We have previously studied VEGF 120/120 mutant 
mouse embryos, that solely express the VEGF120 isoform, and found a high susceptibility of these 
embryos for OFT malformations, including tetralogy of Fallot and double outlet right ventricle.18, 19 
It was postulated that the anterior heart field-derived subpulmonary myocardium is highly sensi-
CHAPTER 3
50
tive for signaling for VEGF and Notch, which may underlie the observed malpositioning of the 
OFT vessels in the VEGF 120/120 mutants. However, a direct link with a contribution of the anterior 
heart field mesenchyme to the OFT has not been studied thus far. In general, studies in which 
the dynamics of OFT rotation are related to the expression of markers more typical for myocar-
dial precursors in the anterior heart field during consecutive developmental stages, are currently 
lacking. Hence, it is unknown how and if the anterior heart field contribution to the myocardial 
OFT could be involved in OFT rotation and whether we are dealing with an already described 
shortening of the subaortic OFT20, 21 or with a marked, relative lengthening of the subpulmonary 
OFT. The aim of the current study was to assess how the specific architecture of the anterior heart 
field could result in an asymmetric addition of OFT myocardium during cardiac development. 
We demonstrate asymmetry in contribution of myocardial precursors within the anterior heart 
field and postulate a basis for OFT rotation and for subsequent normal positioning of the aortic 
and pulmonary trunk orifice. Additionally we studied this phenomenon in VEGF120/120 embryos 
which have been described with double outlet right ventricle.
results
early myocardial outflow tract development
At embryonic day (E) 9.5 and E10.5, the OFT was not septated yet and was positioned entirely above 
the primitive right ventricle. At E9.5, the OFT consisted of a myocardial part lined on the inside by 
cardiac jelly (in subsequent stages developing to endocardial cushion tissue), and of an aortic sac, 
connecting to the pharyngeal arch arteries (Figure 1). At this stage, the pro-epicardial organ at the 
venous pole of the heart could be distinguished and expressed WT-1. No epicardial covering of 
the primitive heart tube was present yet at this stage, with the exception of a few cells (Figure 1a), 
while the coelomic wall covering the OFT was also still negative for WT-1. Nkx2.5 expression was 
observed in the ventral endoderm of the foregut, in mesenchymal cells at the level of the OFT 
as well as in the coelomic wall being more pronounced at the left side of the OFT (Figure 1b). At 
stage E10.5, faint expression of MLC-2a was observed in the mesenchyme surrounding the aortic 
sac at the left side, where lining of the coelomic cavity joins the OFT myocardium (arrow in Figure 
1c). Here MLC-2a expression intensified along the myocardial OFT towards the body of the right 
ventricle, indicating myocardial differentiation (Figure 1c). Expression of Isl1 was marked within 
the cardiac mesoderm and faded towards the differentiating myocardium of the OFT (Figure 1d). 
Nkx2.5 was strongly expressed in the anterior heart field, including the coelomic wall, and in the 
OFT myocardium at E10.5 (Figure 1f ). The expression of both Isl1 and Nkx2.5 within the anterior 
heart field mesenchyme was observed as a central cluster of cells ventral to the foregut, extend-
ing preferentially on the left side of the aortic sac and surrounding the left 6th pharyngeal arch 
artery (Figure 1d, f ), forming the region surrounding the pulmonary trunk and the future ductus 
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Figure 1. Expression patterns of 
MLC-2a, Nkx2.5 Isl-1 and WT-1 in 
myocardial and mesenchymal re-
gions of the developing outflow 
tract. Sections through the outflow 
tract of a wildtype mouse heart em-
bryonic day (E) 9.5 (a,b) and E10.5 
(c-f). a. Expression pattern of WT-1. 
Besides a few WT-1 expressing epi-
cardial cells (arrowhead), epicar-
dial covering of the heart is largely 
absent at this stage. Expression of 
WT-1 in the coelomic wall in the 
region of the outflow tract (OFT) is 
also still largely absent. b. Nkx2.5 
expression can be observed in the 
endoderm (End), as well as in the 
coelomic wall bordering the OFT 
(arrowhead), more pronounced 
on the left side as compared to 
the right. c. The myocardial marker 
MLC-2a stains the myocardium of 
the OFT. The myocardium is lined 
on the inside by endocardial cush-
ion tissue (EC). A more faint MLC-
2a staining is seen in the region of 
the second heart field mesoderm 
(arrow) being more prominent on 
the left side of the aortic sac (AoS). 
d. Expression of Isl 1 is prominent 
in the endoderm (End) and the an-
terior second heart field mesoderm 
(asterisk). It extends along the left 
lateral side of the AoS up to the 
myocardial OFT. Isl1 expression 
is also found in some of the myo-
cardial cells (M) and the coelomic 
wall lining (Coe, arrowhead in d), 
being also more prominent on the 
left side as compared to the right 
side. The faint staining in the right-
sided mesenchyme most likely 
represents vascular smooth muscle 
cells of the developing arterial wall. e. Expression pattern of WT-1. Note the expression in the region of the 
coelomic wall at the right side (arrowhead), as compared to the lack of expression in the coelomic epithelium 
at the left side (open arrow head). f. Nkx2.5 expression is markedly asymmetric (asterisk) and found more 
prominently of the left side of the OFT (future pulmonary trunk) and only sparsely on the right side (future 
aorta). Note the pronounced Nkx2.5 expression in the cells of the coelomic wall on the left side (arrowhead), 
as compared to the largely absent expression in the coelomic wall on the right side (open arrowhead). CJ: 
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arteriosus. On the right side in the cardiac mesoderm, in the region bordering the aortic wall, 
expression of Isl1 and Nkx2.5 was absent at this stage. Moreover, the faint MLC-2a staining was 
missing. A WT-1 positive coelomic wall now covered the Nkx2.5 negative mesoderm on the right 
(putative aortic) side. Lacking at this stage was a WT-1 positive coelomic wall covering the Nkx2.5 
positive population on the left (putative pulmonary) side (Figure 1e). WT-1 positive epicardial cells, 
derived from the pro-epicardial organ, were found on the atrial and ventricular myocardium.
expression of myocardial progenitor markers during septation and before 
outflow tract rotation
At E11.5, septation of the aorta and pulmonary trunk and orifice level had initiated by con-
densed mesenchyme (Figure 2a). A comparable expression pattern of Isl1, Nkx2.5, MLC-2a and 
WT-1 expression with stage E10.5 was observed. A mesenchymal column of Nkx2.5 positive 
Figure 2. Asymmetric distribution of myocardial progenitors at the level of the outflow tract. Sections and 
3D-reconstructions of an E11.5 heart. a. MLC-2a is expressed in the myocardium. The aortic sac is now 
septated indicated by the presence of condensed mesenchyme (CM) in between the ascending aorta 
(AAo) and pulmonary trunk (Pu), which are still positioned side by side with the aorta somewhat more 
to the right as compared to the pulmonary trunk. b. Histological section demonstrating colour coding of 
3D-reconstructions in d, e and h, i. Yellow: Nkx2.5 positive myocardial and vascular wall precursors. Light 
blue: endocardial cushion tissue merging with the CM of the aortopulmonary septum. Dark blue: Lumen 
of 6th pharyngeal arch artery (future ductus arteriosus) and Pu. Light red: Lumen of AAo, dorsal aorta (DAo) 
and outflow tract. Dark red: vascular wall on the aortic side. Light brown: myocardium. (Also see the colour 
coding bar in the inferior part of the figure); c. Nkx2.5 expression is marked in the mesenchyme lining the 
pulmonary wall (arrow) and merging with the subpulmonary myocardium. This phenomenon is lacking on 
the aortic side. The faint staining in the right-sided mesenchyme most likely represents vascular smooth 
muscle cells of the developing arterial wall. d, e and h, i. show 3D-reconstructions. Black lines in d indicate 
the sections of levels depicted in a,c and f-g. d. left lateral view, showing the asymmetric expression of 
Nkx2.5 in the cardiac mesoderm (yellow) around the left branch of the 6th pharyngeal arch artery (6th l, blue) 
and extending in the pulmonary depression of the saddle shaped orifice level (indicated by the dotted lines 
in d, e, h and i). This is lacking on the aortic side of the orifice (e, right lateral view) f. Nkx2.5 stained section 
at the level of the outflow tract. Note that a column of Nkx2.5 positive myocardial precursor cells is present 
exclusively on the left side, where the Pu and right ventricular outflow tract are developing. g. Histological 
section demonstrating colour coding of 3D reconstructions in d, e, h and i, as related to the histological 
section shown in f. Yellow: Nkx2.5 positive myocardial and vascular wall precursors. Light blue: endocardial 
cushion tissue. Blue: left 6th pharyngeal arch artery (6th l, future ductus arteriosus), Red: vascular wall on the 
aortic side. (Also see the colour coding bar in the inferior part of the figure), h. 3D-reconstruction, anterior 
view i. 3D-reconstruction, posterior view. For explanations and colour coding: see above. j. WT-1 staining. 
Note the WT-1 expressing cells in the coelomic wall at the right (putative aortic) side (arrowhead), as com-
pared to the low WT-1 expression on the left (putative pulmonary) side (open arrowhead). k. 3D reconstruc-
tion, left lateral view, and l. right later view, demonstrating the epicardial covering of the heart, indicated in 
brown. The remainder of the colour coding is as described above. Note the “bare” area at the left part of the 
outflow tract, that is uncovered by epicardium at this stage (open arrowhead). In contrast, the right side of 
the OFT is covered by epicardium (arrowhead). AVC: atrioventricular canal, LA: left atrium, LV: left ventricle, 
OFT: outflow tract, RA: right atrium, RV: right ventricle, 6th r: right 6th pharyngeal arch artery. Bar: 200μm.
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cells extended from the cardiac mesoderm in the anterior heart field to the left side of the 
OFT beneath the left 6th pharyngeal arch artery, where it connected to the subpulmonary 
myocardium (Figure 2a-c and f,g). 3D-reconstruction of the OFT myocardium, based on the 
expression pattern of MLC-2a, demonstrated an anterior and posterior cranial extension of 
myocardium resulting in a saddle-shaped distal myocardial OFT border (Figure 2d,e and h,i, 
dotted lines). The condensed mesenchyme of neural crest origin connects to the endocardial 
cushions at the top of the myocardial extensions.1 Mesenchymal expression of Nkx2.5 (indicat-
ed in yellow in the 3D-reconstructions) and Isl1 could be observed as a central cluster of cells 
located in the pre-pharyngeal mesoderm dorsal to the level of the OFT (Figure 2i), extending 
in the indentation between the myocardial extensions on the left side where the pulmonary 
trunk connects to the subpulmonary myocardium (Figure 2d). This area of the coelomic wall 
lacked WT-1 (Figure 2j; 3D-reconstructions of epicardial covering are shown in Figure 2 k,l). 
Nkx2.5 expression was absent in the indentation between the myocardial extensions on the 
right side in the aortic orifice region (Figure 2e) where the coelomic wall is positive for WT-1 
(Figure 2j; Figure 2k,l). Similar to E10.5, Isl1 expression in the cardiac precursor cells showed an 
asymmetric distribution favouring the pulmonary side (not shown). In the OFT myocardium 
the expression was lost whereas Nkx2.5 as well as MLC-2a was present in both the subaortic 
and subpulmonary myocardium. An interactive pdf file of a 3D-reconstruction of stage E11.5 
is provided in online Supplemental File 2a).
Positioning of the pulmonary trunk and aorta: the pulmonary push concept
At E12.5, a distinct column of Nkx2.5 expressing mesenchymal cells was found exclusively 
within the indentation at the orifice level at the pulmonary side but not in the aortic region 
(Figure 3a-c, Supplemental file 1). From stage E12.5 onwards, the entire heart was covered by 
WT-1 expressing epicardial cells. In contrast to previous stages, the coelomic epithelium at 
the left side of the outflow tract now also expressed WT-1 and, similar to previous stages, WT-1 
was expressed in the coelomic epithelium at the right side. From E12.5 to E14.5, the orifice of 
the future pulmonary trunk became progressively positioned in an anterior and rightward 
direction (Figure 3a, d, black dot and arrow). An interactive pdf file of a 3D-reconstruction of 
stage E12.5 is provided in online Supplemental File 2b).
At E14.5, the pulmonary trunk and orifice reached their definitive position, which is anterior 
to the aortic orifice (Figure 3 d-f ). The mesenchymal column of Nkx2.5 expressing cells was no 
longer present at E13.5 and E14.5, indicating that myocardial precursors are not incorporated 
anymore from the anterior heart field into the OFT. Concurrent with the repositioning of the 
pulmonary orifice, the atrioventricular canal became positioned below the aortic orifice as it 
expanded rightward during development (Compare green dot and arrow in Figure 3b and e 
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(superior views) and c and f (right lateral views)). An interactive pdf file of a 3D-reconstruction 
of stage E14.5 is provided in online Supplemental File 2c).
Abnormal development: expression of myocardial progenitor markers in the 
vegF120/120 model
To test the hypothesis of the pulmonary push concept, development of the OFT was studied 
in VEGF120/120 mouse embryos of stage E10.5. For the current study, focus was directed 
specifically at the Nkx2.5 and Isl-1 positive myocardial precursors at the OFT of the heart, 
Figure 3. Positional changes of the aorta and pulmonary artery during outflow tract development: The 
pulmonary push concept. a-c. 3D-reconstructions of stage E12.5. Colour coding: Dark blue: ductus arterio-
sus, (DA) and short pulmonary trunk (Pu). Red: ascending aorta (AAo). (Also see colour coding bar in the 
inferior part of the figure), a. Left lateral view. b. Cranial view. c. Right lateral view. The Nkx2.5 expressing 
mesenchymal cells (yellow) can be seen inserted in the pulmonary side of the indentation of the saddle 
shaped orifice (a, b) whereas this is lacking on the aortic side (b, c) where the endocardial cushions and 
condensed mesenchyme are visible (indicated in light blue). d-f. 3D-reconstructions of stage E14.5. Colour-
coding: Dark blue: pulmonary trunk (Pu) and ductus arteriosus (DA), connecting distally to the descending 
aorta (DAo). d. left lateral view. e. cranial view. f. right lateral view. Black dot and arrow (a, d) denote the 
cranio-anterior positional change of the pulmonary artery orifice from E12.5 to E14.5. The green dot (b, c 
and e, f ) denotes the pronounced expansion of the atrio-ventricular canal in a rightward direction parallel 
to the OFT towards the aortic orifice. LV: left ventricle, RV: right ventricle. Bar: 100μm.
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as compared to results obtained in wild type embryos. In wild type embryos at stage E10.5, 
a well-organized Nkx2.5 positive, Isl-1 positive cluster of cells was observed in the cardiac 
mesenchyme (Figure 4a-c, asterisk in Figure 4b), and an elongated column of Nkx2.5 positive 
cells was observed extending along the left side of the OFT (dotted area in Figure 4b). In the 
stage E10.5 VEGF120/120 embryos a large cluster of cells was also observed in the cardiac mes-
enchyme (asterisk in Figure 4e), however, in contrast to wild type, we observed an abnormal 
Figure 4. Expression of myocardial progenitor markers in the VEGF120/120 model. Results in E10.5 in wild-
type (a-c) and VEGF 120/120 (e-g) embryos. a-c: Three subsequent sections, stained for MLC-2a (a), Nkx2.5 
(b) and Isl1 (c) are shown. In wild type embryos, a group of Isl1/Nkx2.5 positive cells are located behind in 
the heart in the pre-pharyngeal mesoderm (asterisk in b). An elongated column of Nkx2.5 (b) Isl1 (c) posi-
tive cells can be observed extending along the left side of the outflow tract (OFT) (indicated by the dotted 
line in b). Upon differentiation, cells increasingly express the myocardial marker Mlc2a (a). d-f: Three subse-
quent sections in VEGF120/120 embryos, stained for MLC-2a (d), Nkx2.5 (e) and Isl1 (f) are shown. In VEGF 
120/120 embryos, the cluster of Isl1 (g) and Nkx2.5 (f) positive precursors (asterisk in f) shows an abnormal 
organisation. The column of cells extending on the left side of the OFT is only very short (compared length 
of the dotted lines in b and f). Abbreviations: AoS; aortic sac, End: endoderm, LA: left atrium, G: foregut, 6th: 
sixth pharyngeal arch artery. Bar: 100μm.
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organisation of this Nkx2.5 positive anterior heart field mesoderm in front of the pharynx. 
The extension of this population along the pulmonary side of the OFT up to the pulmonary 
myocardium was very short with only a small area facing the coelomic cavity (Figure 4d-f, 
compare the length of the dotted lines in Figure 4b and 4e).
Discussion
OFT remodeling is an essential part of heart development. Normal separation and position-
ing of the great arteries of the OFT is necessary for the heart to sustain its function as a 
central pump coordinating the blood flow through the systemic and pulmonary circula-
tions.22 Congenital OFT malformations may severely compromise normal physiology, result-
ing in hemodynamic overload, cyanosis and early death.23 Knowledge of the developmental 
processes resulting in proper OFT formation and remodeling, as well as the pivotal cells or 
cell groups involved, is essential to comprehend when and why malformations, resulting in 
congenital heart disease, occur. In recent years, the relevance of the contribution of cells 
derived from the second heart field has been attested,7, 24, 25 although the exact mechanism 
of OFT remodeling, including the final positioning of the aorta and the pulmonary trunk and 
their orifices, is unclear.
It has been shown that the anterior part of the second heart field plays a crucial role in 
normal OFT development together with neural crest and epicardium.26–28 During cardiovas-
cular development, cells from the three above-described populations are recruited to the 
linear heart tube via both the arterial and the venous pole from E9.5 onwards.29–31 It has been 
demonstrated previously that the myocardial part of the OFT comprising both the subaortic 
and subpulmonary myocardium, is derived from the second heart field.7 This myocardium 
has been shown to have a common lineage relationship to the right-and left sided head 
muscles, respectively.32
We have, based on results in the VEGF120/120 model, previously postulated that the second 
heart field-derived subpulmonary myocardium may be highly sensitive for signaling of fac-
tors like VEGF and Notch, which may underlie the observed malpositioning of the OFT vessels 
in the VEGF120/120 mutants, but did not show a direct link with a contribution of the second 
heart field mesenchyme to the OFT in this study.19
The pulmonary trunk originates from the posterior left side of the aortic sac, whereas 
the putative aorta is originally positioned on the right side.1, 28 After OFT development is 
completed, however, the pulmonary trunk has obtained a right anterior position. A dynamic 
process is required during cardiac development resulting in a rotational movement of the 
pulmonary trunk and orifice around the aorta.
A mechanism of cell death, predominantly present in the subaortic myocardium result-
ing in a shortening of the subaortic OFT, has been proposed as the mechanism for proper 
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formation of the ventriculo-arterial connections.20, 21, 33 Cell death is a well known mechanism 
in heart development and has been described to occur at the level of the OFT.34, 35 However, 
a mechanism of asymmetric active shortening of the OFT by cell death alone is unlikely to 
explain the complex positioning of the OFT and does not take into account an concomitant 
asymmetrical gaining of length of the subpulmonary myocardium, while the subaortic myo-
cardium remains relatively short from the onset.36
It was previously reported that asymmetrical expression of Fgf 8/10, Pitx2c and possibly Tbx1 
within the anterior heart field are involved in the induction of asymmetrical OFT growth.6, 37 
Experimental knock-out of these genes resulted in the association with a large variety of fun-
damental defects in OFT development.38 Especially relevant seems to be the co-expression 
Tbx1 with Pitx2, an important gene in right-left signaling, in the pharyngeal mesoderm of 
the OFT. Crossing of heterozygous Tbx1 and Pitx2 mice results in cardiac anomalies includ-
ing double outlet right ventricle.37 Experiments using right-and left sided second heart field 
labeling experiments in the chick OFT indicate contributions of second heart field precursors 
to distinct lateralized regions of the OFT.39 It was unclear whether other known markers 
of myocardial precursors within the anterior heart field demonstrate a similar asymmetric 
expression pattern that could explain the above-described dynamics of OFT remodeling. We 
have now shown that it is also applicable to Nkx2.5 and Isl1 expression. It is remarkable that 
the Nkx2.5 and Isl1 positive area of the anterior heart field was the last part of the heart to 
be covered by a WT-1 expressing coelomic epithelium i.e. the epicardium. On the aortic side, 
that is supposed to originate from the right sided pre-pharyngeal mesoderm (current study, 
and39, 40), the disappearance of the Nkx2.5 positive population at day 9.5 was followed by the 
start of expression of WT-1 in the coelomic wall. A possible interaction between Nkx2.5 and 
WT1 needs further study.
Our studies suggest that lengthening of the subpulmonary myocardium of the OFT is ac-
tive until day 12.5 which is at least one day longer than proposed in literature12, 41 but in line 
with studies in chick that have indicated contributions to the OFT up to HH24 (correlating 
with mouse day12.5), respectively.13
The aim of the current study was to assess whether anterior heart field architecture could 
provide clues relevant for normal positioning of the aorta orifice and pulmonary trunk dur-
ing mammalian heart development. The main finding of the present study, based on 3D-
reconstructions of consecutive developmental stages, was that myocardial precursor cells 
were asymmetrically positioned in the OFT during development, as they were distinctively 
observed at the pulmonary side, whereas they were almost absent at the aortic side. The 
current study shows for the first time that continued addition from the Nkx2.5 expressing 
mesenchymal myocardial precursors below the left 6th pharyngeal arch artery may push the 
future pulmonary artery orifice in an anterior and rightward direction.
In addition, we have shown that this addition was disorganized and the extension towards 
the left side of the OFT shorter than in wildtype in the VEGF120/120 model, that has a phe-
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notype in which OFT malformations are predominant.19 It was recently indicated that the 
myocardium at the base of the pulmonary trunk and the myocardium at the base of the 
aorta originate from distinct developmental portions of second heart field derived cells.40 
Clonal studies showed a larger number of cell clones in the subpulmonary region, indicative 
for a higher proliferative rate, whereas in the subaortic region clones were very small.40 The 
subpulmonary myocardium remained in a posterior position in the Pitx2c knock-out mouse 
that presents with OFT malformations such as transposition of the great arteries and double 
outlet right ventricle.14 We postulate that the dominant left-sided expression of Pitx2c induces 
the expression of Nkx2.5 within the anterior heart field, which might be disturbed in Pitx2c 
knock-out mouse embryos. In our study of the VEGF120/120 embryo we could discern the 
malpositioning of the Nkx2.5 positive mesenchymal cells at the pulmonary side of the OFT in 
line with Bajolle et al. The disorganization of the Nkx2.5 positive SHF mesenchyme in front of 
the pharynx is indicative of an abnormal differentiation of the SHF. The small area of Nkx2.5 
positive myocardial precursors covering the pulmonary side of the OFT could underlie the 
observed tetralogy of Fallot and double outlet right ventricle in the VEGF120/120 hearts19 in 
which subpulmonary myocardium is insufficiently added.
In transposition of the great arteries, the arterial orifices are positioned in almost one 
plane36, supporting the fact that addition of myocardium to the right ventricular OFT has 
either not taken place or was deficient. Similar observations have been made for mouse 
hearts with double outlet right ventricle with a marked shortening of the right ventricular 
OFT.42, 43 To date specific patterns in the second heart field for Nkx2.5 and Isl1 have not been 
reported. Results in the VEGF120/120 model in the current study support the postulated 
mechanism of a deficient and disorganized addition of myocardial precursors to the pulmo-
nary side of the OFT. An asymmetric contribution of anterior heart-field derived myocardium 
around and specifically below the left 6th pharyngeal arch artery during crucial stages of OFT 
development, provides an explanation for the dynamic process that results in positioning 
of the pulmonary artery orifice in its normal left anterior location. It must be questioned 
whether a true rotational motion, based on spiraling outflow tract ridges, occurs. The latter 
explanation has dominated the positional remodeling for several decades, and an abnormal 
torsion was considered the underlying mechanism for OFT tract abnormalities as observed in 
transposition of the great arteries.15, 16, 44, 45 This explanation for rotation of the outlet however 
has also been the subject of controversy over the past decades, and several authors have 
indicated that no such rotation occurs during normal development.1, 46–48 Given the second 
heart field contributions to OFT remodeling, new concepts for related abnormalities occur. 
Obviously, proper positioning of the great arteries needs to occur in order to achieve the nor-
mal morphological relation of the aorta and pulmonary trunk. Results of our study support 
the occurrence of rotation. We propose that, rather than a mechanism based on spiraling 
of the endocardial OFT cushions, an asymmetrical lengthening of the right ventricular OFT 
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causes the pulmonary trunk to be pushed towards its definitive position in front of the aorta, 
which is observed as a rotation.
conclusion
We conclude that the addition of Nkx2.5 positive myocardial precursors from the anterior 
heart field occurs during normal development predominantly below the left branch of the 
6th pharyngeal arch artery. We postulate that this results in a movement without spiraliza-
tion of the OFT in which, due to the continued addition of right-sided myocardium, the 
pulmonary trunk orifice is pushed in a rightward and anterior direction, which presents 
a new explanation for the rotation of the pulmonary orifice and trunk. This mechanism is 
referred to as pulmonary push, which results in a rotation of the pulmonary orifice to an 
anterior position. As the term rotation has been intrinsically used in many ways and for many 
OFT structures, we prefer the use of “pulmonary push” to describe the mechanism of OFT 
positioning. Deficient or disorganized positioning of the Nkx2.5 positive precursors, as was 
observed in the VEGF120/120 mutant, might explain cardiac malformations with side-by-side 
position of the great arteries.
exPerimentAl ProceDures
embryonic material and immunohistochemical procedures
The handling of all animals and embryos was according to the Guide for Care and Use of 
Laboratory Animals, as published by the NIH. Wildtype mouse embryos were obtained from 
the CLB-Swiss strain. In addition to studies of wildtype embryos and to test the hypothesis of 
the pulmonary push concept, VEGF120/+ mice were crossed to obtain VEGF120/120 embryos 
and VEGF+/+ wild type littermates. The day the vaginal plug was detected, was designated 
embryonic day (E) 0.5. Pregnant female mice were sacrificed on consecutive days from E9.5 
onward up until E14.5 for wildtype mice and, per day, three embryos were harvested for the 
study. For VEGF120/120 mice, stage E10.5 was studied. For further immunohistochemical 
staining, all embryos were embedded in paraffin after fixation in 4% paraformaldehyde in 
phosphate buffered saline (0.1 M, pH 7.2) and subsequent dehydration. Embryos were sec-
tioned transversely to the body axis (5μm). Due to the position of the heart in the thorax, 
the level of the outflow tract was therefore positioned in a more frontal plane. Sections 
were serially mounted on glass slides. Immunohistochemical staining was performed with 
antibodies against the myocardial marker MLC-2a (1/6000, kindly provided by S.W. Kubalak, 
Charleston, SC, United States); Nkx 2.5 (1/4000, Santa Cruz Biotechnology Inc., CA, United 
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States, SC-8697), expressed in atrial and ventricular and outflow tract myocardium, as well as 
in the mesenchyme of the second heart field; the second heart field marker Islet 1 (Isl1) (1/400, 
mouse monoclonal antibody, clone 39.4D5, Developmental Studies Hybridoma Bank) and 
Wilms Tumor 1 (WT-1) (1/1000, Santa Cruz Biotechnology Inc., CA, United States, SC-192), to 
show the coelomic wall covering and the pro-epicardial organ derived epicardium. The slides 
were first incubated for 45 min using ABC-reagent (Vector Laboratories, Burlingame, United 
States PK 6100), and then with 400 μg/mL 3-3’di-aminobenzidin tetrahydrochloride (DAB, 
Sigma-Aldrich, St Louis, United States, D5637) dissolved in trismaleate buffer pH 7.6 to which 
20 μl H2O2 was added. The latter incubation was done 5 min for MLC-2a and 10 min for Nkx 2.5, 
Isl1 and WT-1. Furthermore, counterstaining was done using 0.1% hematoxylin (Merck, Darm-
stadt, Germany) for 5 sec, and the slides were subsequently rinsed with tap water for 10 min. 
Finally, slides were dehydrated and mounted with Entellan (Merck, Darmstadt, Germany).
three-dimensional reconstruction
To describe the dynamics of OFT development within a spatial context, three-dimensional 
reconstructions were made from E9.5 to ED14.5 embryos. Micrographs of serial sections were 
processed using the AMIRA software package (Template Graphics Software, San Diego, CA) as 
described previously.49 First, the myocardium was reconstructed using the expression pattern 
of MLC-2a, after which the expression of Isl1, WT-1 and Nkx2.5, was superimposed to depict 
myocardial progenitors within the anterior heart field. Isl-1 expression was used to demarcate 
the anterior heart field, Nkx2.5 was used to identify precursors of OFT myocardium,3, 12 and 
WT-1 to show which parts of the outflow tract were covered with epicardium.
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suPPlementAl Files
supplemental file 1
Animated 3D-reconstruction demonstrating the column of Nkx2.5 expressing cells (bright 
yellow) within the heart and anterior heart field at ED 12.5. This column is rendered transpar-
ent during part of the animation to demonstrate its relation to the aorta (red) and pulmonary 
trunk (dark blue). The outflow tract and right ventricle are depicted in light-yellow, whereas 




(v’s) one can choose to eliminate different compartment from the figure. Also, by right clicking 
on the text describing the different compartments, one can chose for the option “transpar-
ent” in order to make the compartment of choice transparent to visualize the Nkx2.5 positive 
column of cells more clearly. In the lower left hand panel, other views are depicted, that will 
appear when clicking on them. These other views include a left lateral view, right lateral view, 
dorsal view and a superior view. One can also manually choose the preferred view by moving 
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In patients with a right ventricle (RV) in systemic position, tricuspid valve surgery for re-
gurgitation beyond adolescence is subject of debate. The aim of this study was to evaluate 
complications, survival and benefit of tricuspid surgery in adult patients with an atrial-level 
correction for transposition of the great arteries or congenitally corrected transposition of 
the great arteries.
methods & results
All adult patients (n=16; 7 male, 9 female; age: 35 ± 11 yrs) who underwent tricuspid valvulo-
plasty (TVP, n=8) or replacement (TVR, n=8) in the period 1999–2008 were included. Compli-
cations and survival were analyzed and post-operative changes in RV function and functional 
class were evaluated. Tricuspid regurgitation was graded 1 to 4 according to the severity, 
right ventricular dysfunction was graded 1 to 4 (1; no dysfunction – 4; severe dysfunction) and 
functional status was determined according to NYHA class.
Although complications occurred in eleven patients, all could be managed adequately. 
Three patients died 109, 180 and 659 days after surgery respectively, the first patient after TVR 
and the latter two after TVP. Overall, tricuspid valve function improved (form grade 3.1 ± 0.8 to 
0.9 ± 1.0; P = 0.001), functional class improved (from 2.7 ± 0.6 to 2.1 ± 0.8; P = 0.007), whereas 
RV function remained unchanged. After TVP, however, recurrent moderate TV regurgitation 
was frequently observed in three patients (37%).
conclusions
Mortality is low after tricuspid surgery in adult patients with mild to moderate RV dysfunction. 
In general, tricuspid valve function and functional class improve significantly after operation, 
whereas systemic RV function is preserved. TVP however, is associated with a high recurrence 
rate of regurgitation.
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introDuction
Patients with congenitally corrected transposition of the great arteries (ccTGA) and patients 
with atrially corrected transposition of the great arteries (acTGA), have a morphologically 
right ventricle (RV) that sustains the systemic circulation.1–3 In these patients, regurgitation 
of the systemic atrioventricular valve, the tricuspid valve (TV), is a common finding. When 
TV regurgitation becomes severe, it is associated with RV failure and decreased survival.4 
In adolescent or younger patients, it can be opted to treat this surgically by retraining the 
left ventricle by means of pulmonary artery banding and subsequent relocation of the left 
ventricle into systemic position. In adults beyond the second decade of life however, results 
of these operations are still mainly negative.5–7 Another surgical option, which is replacement 
or repair of the TV, is controversial, as data demonstrating favorable survival after these 
operations is currently insufficient. The only large study so far, in which beneficial effects of 
TV replacement are demonstrated, is the study by van Son et al. published in 1995, which 
reports the follow-up of 40 patients with ccTGA who were operated for TV regurgitation.8 In 
other reports, attempts to repair the TV in patients with ccTGA are described as largely unsuc-
cessful and in these reports consideration for the above described double switch procedure 
is advocated.9, 10 Study results of TV operations in patients with acTGA are even scarcer than 
in ccTGA. The general opinion in literature is that the role of TV surgery, as a treatment option 
for patients with acTGA and impending RV failure, should be limited.11 However, studies that 
focus on systematic evaluation of TV surgery in adult patients with acTGA and RV dysfunction 
are lacking.12–15 Therefore, the aim of this study was to evaluate complications, survival and 
benefit of tricuspid valvuloplasty (TVP) or replacement (TVR) as the first option in patients 




All patients, either referred form other medical centers or from the outpatient clinic of our 
center with ccTGA or acTGA, who underwent TVP or TVR for tricuspid regurgitation between 
1998 and 2008, were included in this study. Patients were considered for surgery when the 
combination of important tricuspid regurgitation (grade 3 or 4) and mild to moderate sys-
temic RV dysfunction was present on echocardiographic evaluation. RV function had to be 
sufficiently preserved, as tricuspid surgery in later stages of RV dysfunction had poor outcome 
in previous studies.8, 16 Furthermore, only those patients with functional impairment who 
were in New York Heart Association (NYHA) class 2 or 3 were regarded suitable for elective 
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tricuspid surgery. Cardiac function and anatomy was evaluated pre-operatively with cardiac 
magnetic resonance imaging or multi slice computed tomography if a recent evaluation was 
not available. These evaluations were also used to assess whether concomitant procedures, 
including baffle and/or conduit revisions, were necessary.
study protocol
Complications related to the procedure, survival and operation benefit in terms of TV compe-
tence, RV function and NYHA class were evaluated. First, primary diagnosis (ccTGA or acTGA), 
previous operations and pre-operative TV competence, RV function and NYHA class were 
noted. Secondly, the type of procedure (TVP or TVR) and concomitant procedures were docu-
mented. Thirdly, we observed post-operative complications and finally, to assess operation 
benefit, we analyzed post-operative changes in RV function, tricuspid valve competence and 
functional class during follow-up.
complications and survival
Post-operative complications were categorized into: arrhythmia, low cardiac output (defined 
as persistently low arterial pressures in the post-operative period, not responding to plasma 
volume expansion), renal insufficiency, infection and rethoracotomy. Maximum survival was 
defined as the period between the first day post-operative until the last available follow-up 
date or until the occurrence of the composite endpoint death or recurrent severe tricuspid 
regurgitation. Differences in survival were compared between the TVP and TVR procedure.
operation benefit
Echocardiography was used for the assessment of RV and TV function. For the purpose of 
this study, the echocardiograms, made pre-operatively and during periodical follow-up after 
surgery, were reviewed for RV and TV function. The echocardiographic evaluations were 
done three weeks, three months and ten months after operation. Tricuspid regurgitation 
was graded 1 to 4 according to the severity. RV function was analyzed semi-quantitatively 
and classified as either normal 1, mildly depressed 2, depressed 3 or severely depressed 4.17, 18 
Furthermore, patient functional status was assessed pre- and post-operatively according to 
NYHA class.
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operative technique
All patients were operated by the same surgeon, through median (re)sternotomy using total 
cardiopulmonary bypass and mild-to-moderate hypothermia that was combined with ante-
grade perfusion of a crystalloid cardioplegic solution. The TV was approached via either the 
right atrium (acTGA) or via the atrial septum and left atrium (ccTGA). Initially, TVP was intended 
in all patients. For this type of surgery, a classical Carpentier-Edwards or the newer Edwards 
MC3 annuloplasty ring (Edwards LifeSciences Inc, Irvine, CA, USA) was used. However, when 
pre- or intraoperatively, either the quality of the TV leaflets was regarded insufficient (eg. 
dysplastic tricuspid leaflets), or when significant leaflet tethering was present, it was decided 
to replace rather than repair the TV. Moreover, when during the operation the initial TVP did 
not result in reduction of regurgitation, the TV was also replaced within the same operation. 
For this procedure, a CarboMedics bileaflet mechanical prosthesis (Sulzer CarboMedics Inc, 
Austin, Tx, USA), a St. Jude Medical mechanical prosthesis (St. Jude Medical Inc, St. Paul, MN, 
USA) or a Medtronic Mosaic porcine bioprosthesis (Medtronic Inc, Minneapolis, Minn, USA) 
was used.
statistical analysis
SPSS (12.0.1, SPSS Inc, Chicago, IL, USA) was used for statistical analysis. Data are presented 
as mean ± standard deviation (SD), unless mentioned otherwise. Due to the small number 
of patients, the Friedman test and the Mann-Whitney U-test were used to compare pre- and 
postoperative TV function, RV function and functional class. Kaplan-Meier curves were drawn 
and the logrank test was used to compare the difference between the TVP and TVR proce-
dure. P-values <0.05 were considered statistically significant.
The authors had full access to and take full responsibility for the integrity of the data. All 
authors have read and agree to the manuscript as written.
results
Sixteen patients were operated, nine with ccTGA and seven with acTGA. Characteristics of 
these patients are summarized in Table 1. Pre-operatively, grade 3.1 ± 0.8 TV regurgitation was 
observed. Most patients exhibited mildly depressed RV function (n=12) and pre-operative 
functional class according to NYHA was 2.7 ± 0.6. An overview of how patients were operated 
is depicted in figure 1. In 14 patients the mechanism of tricuspid regurgitation was regarded 
malcoaptation of the tricuspid leaflets. This was either due to annular dilatation with intact 
leaflets (n=9) or due to structural abnormalities of the TV other than Ebstein(-like) malforma-
CHAPTER 4
78
tions (n=5). In eleven patients, TVP was initially attempted. In three cases, this procedure did 
not result in improved TV competence, and it was decided to do TVR in the same operation. 
In four patients the TV leaflets were Ebstein-like or had important other malformations and 
in one patient the tricuspid annulus was too severely dilated to perform TVP, therefore TVR 
was done directly in these cases. In nine patients, concomitant procedures, mainly conduit or 
baffle revisions (n=6), were performed.
complications and survival
In Table 2, all major, post-operative complications are summarized. One patient, operated 
acutely after explantation of an infected ICD, died 109 days after surgery. This patient suf-
fered from a multitude of complications and eventually died from therapy-refractory sepsis. 
Arrhythmia was the most frequently encountered short-term complication, occurring in 
eight patients. In one patient, recurrent ventricular fibrillation was observed post-operatively 
which required ICD implantation, five patients suffered from supraventricular tachycardia 
which was treated with cardioversion in three and with medication in two. One patient suf-
fered from sinus arrest and one patient had AV block, both treated with pacemaker insertion. 
Another complication that occurred frequently was low cardiac output caused by ventricular 


















Conduit/baffle revision 2 4
Mini MAZE procedure 3
VSD closure 1
PA banding 1
acTGA: atrial correction for transposition of the great arteries; ASD: atrial septal defect; ccTGA: congenitally 
corrected transposition of the great arteries; PA: pulmonary artery; PVR: pulmonary valve replacement; TVP: 
tricuspid valvuloplasty; TVR: tricuspid valve replacement; VSD: ventricular septal defect.
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failure (n=5), requiring placement of an intra-aortic balloon pump in three patients and 
inotropic support in two patients. One patient was operated for gastric perforation and in an-
other patient a rethoracotomy for persistent bleeding was performed. Five patients had renal 
insufficiency that required temporary dialysis with continuous veno-venous hemofiltration.
Fifteen patients were discharged in good condition after a mean duration of in hospital stay 
of 27 ± 28 days. Two patients died after discharge. One patient was successfully resuscitated 
after an episode of ventricular fibrillation 180 days after operation, but died subsequently 
from ventricular failure, without signs of recurrent TR. The other patient died from recurrent 
TR and cardiac failure 659 days after surgery, before adequate treatment could be initiated. 
Follow-up of patients ranged from 92 days to 3101 days after operation with a 1-year survival 
rate of 86.7%. Kaplan-Meier curves (Figure 2) for the composite end-point death or recurrent 
severe tricuspid regurgitation revealed that TVR exhibited better survival as compared to pa-
tients who underwent TVP; the difference in survival, however was not statistically significant 
(P = 0.09).
table 2. Post-operative complications.
complications tvP tvr total
None, n (%) 4 (25) 1 (6) 5 (31)
Arrhythmia, n (%) 3 (19) 5 (31) 8 (50)
Low Cardiac Output, n (%) 2 (13) 3 (19) 5 (31)
Renal insufficiency, n (%) 2 (13) 3 (19) 5 (31)
Infection, n (%) 1 (6) 1 (6) 2 (13)
Rethoracotomy, n (%) 1 (6) 1 (6) 2 (13)
Death, n (%) 0 1 (6) 1 (6)
TVP: tricuspid valvuloplasty; TVR: tricuspid valve replacement.












































Figure 1. Operative approach to patients. In total, 16 patients were operated, 9 ccTGA and 7 acTGA patients. 
Annular dilatation was the main mechanism of tricuspid regurgitation, but valvular abnormalities were 
also present. In three patients, the initial attempt to repair the tricuspid valve was unsuccessful and a “sec-
ondary” tricuspid valve replacement was done. acTGA, atrially corrected transposition of the great arteries; 
ccTGA, congenitally corrected transposition of the great arteries; TR, tricuspid regurgitation; TV, Tricuspid 




Overall, tricuspid function and functional class improved significantly after operation, 
whereas RV function remained stable. In figure 3 shows that tricuspid competence improved 
significantly after TVP and, as can be expected, after TVR. After TVP however, tricuspid func-
tion was not substantially improved in three patients (2 ccTGA, 1 acTGA) on post-operative 
echocardiographic evaluation. Therefore, the overall improvement of tricuspid function was 
less prominent as compared to TVR. Furthermore, three patients developed recurrent TV 
regurgitation resulting in regurgitation grade 2.6 ± 0.5 at 10.7 ± 1.9 months of follow-up after 
TVP. After TVR, on the other hand, the improvement of tricuspid competence was maintained 
at 10.7 ± 1.9 months of follow-up, as can be expected. RV function, which was classified normal 
(grade 1) to severely depressed (grade 4), remained unchanged post-operatively and at 10.7 
± 1.9 months follow-up (Figure 3). Pre-operatively, RV function was classified 2.2 ± 0.7 and at 
maximum follow-up (3.2 ± 1.9 years) RV function was 2.0 ± 0.9. Moreover, no differences in RV 
function were noted pre-operatively and during follow-up between patients who underwent 
TVP and patients who underwent TVR. Overall, NYHA class improved from 2.7 ± 0.6 to 2.1 ± 0.8 
(P= 0.007) at 3.2 ± 1.7 months after surgery. At 3.2 ± 1.9 years follow-up, functional class was 
2.0 ± 0.9. Again, there was no difference in NYHA class between TVP and TVR pre-operatively 
or during follow-up.
Discussion
In the current study we systematically evaluated complications, survival and benefit of TV 
surgery for substantial regurgitation in patients with a dysfunctional right ventricle in systemic 
position. Key findings were firstly that a high incidence of post-operative complications was 
observed. Furthermore, overall TV competence and functional class improved after operation. 
Finally, the survival characteristics of TVP appeared less favorable than those of TVR.

















TVP 8 7 5 5 3
TVR 8 7 7 6 6
Figure 2. Survival curves for the com-
posite end-point death or recurrent tri-
cuspid regurgitation. A trend towards 
less favourable survival characteristics 
for patients who underwent tricuspid 
valvuloplasty was observed, which 
was, however, not statistically signifi-
cant. TVP, tricuspid valvuloplasty; TVR, 
tricuspid valve replacement.
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The incidence of complications, related to the procedure, was high in our population. 
However, all complications were treated successfully in those patients who were operated 
electively and the presence of complications was not related to worse outcome. In the largest 
study on TV operations, so far, by van Son et al. comprising of 40 patients with ccTGA, similar 
types of post operative complications were described (arrhythmia, bleeding, infection) and a 
relation between post-operative complications and adverse outcome was also not reported.8 
In a report by Beauchesne et al. on patients with ccTGA, post-operative complications were 
again not related to post-operative outcome.19 Therefore, provided that surgical treatment 
of TV regurgitation in patients with a right ventricle in systemic position is exclusively per-

























































Figure 3. Follow-up of tricuspid function, right ventricular function and functional class. Significant im-
provement of tricuspid function was observed both after tricuspid valve replacement (TVR) as well as tri-
cuspid valve plasty (TVP). After TVP however, the improvement was less prominent and recurrent tricuspid 
regurgitation was frequently observed. Right ventricular function remained stable during follow-up and 
there was no difference between patients who underwent TVP and patients who underwent TVR. NYHA 
class improved significantly both after TVP as well as TVR. The P-values denote the significance of the im-
provement after TV surgery separately for TVP and TVR. * P<0.01 for the difference in TV competence be-
tween TVP and TVR. NYHA, New York Heart Association; RV, right ventricular; TV, tricuspid valve
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Three patients, all with previous Mustard corrections, died in our population, making up a 
1-year survival rate of 86.7 %. In one of these patients, the cause of death was TV incompetence 
and associated systemic ventricular failure after tricuspid valvuloplasty. In the other patients, 
TV incompetence and systemic ventricular dysfunction was present but not indubitably re-
lated to the cause of death (sepsis, ventricular arrhythmia). In the previously mentioned study 
by van Son et al., survival rates of 78.0% at 5 years and 60.7% at 10 years were reported.8 In 
other, smaller studies on patients with ccTGA, in which survival characteristics of TV surgery 
were reported as part of a larger study, 1-year survival rates range from 63% to 100%.10, 18–23 To 
our knowledge, no studies are available that report data solely on TV operations in patients 
with acTGA. Incidentally, survival characteristics are reported as unfavourable in small groups 
of patients (n=3), with 1-year survival rates of 25% to 33%, which is much lower than the 1-year 
survival rate in our group of acTGA patients (71.4%).13, 15, 24
In general, TVP was intended in all patients. However, in patients with structural leaflet 
malformations or severe leaflet tethering, which was noted either pre-operatively or during 
surgery, it was decided to perform TVR. In these patients, the risk for recurrent TR after TVP 
was regarded higher as compared to patients with intact tricuspid leaflets, without signs of 
tethering.25, 26 In our population, tricuspid competence demonstrated a significant improve-
ment after operation. However, the results of TVP were less promising than the results of TVR. 
After TVP, the improvement was less prominent than after TVR and the rate of recurrence of 
regurgitation was relatively high after TVP (37%). Therefore, when comparing the survival 
curves of the TVP procedure to the TVR procedure there seems to be a disadvantage for TVP 
which was, however, not statistically significant. In our population, RV function remained 
stable during follow-up and no differences in RV function were noted between patients who 
underwent TVP and patients who underwent TVR. It should be noted that in most patients, 
the pre-operative degree of RV dysfunction was generally mild (n=12), and it could be ques-
tioned whether an important improvement in RV function is expected after TV surgery. The 
sparse results of earlier studies suggest that TV surgery in early stages of RV dysfunction is 
superior to TV surgery in more advanced stages of RV dysfunction.19 Therefore, the strategy 
in most patients was to consider TV surgery on the basis of functional impairment, also when 
mild RV dysfunction was present. Although no improvement in RV function was observed on 
echocardiographic evaluation, functional class did improve in our population. A mechanism 
that may underlie this observation is that improved competence of the TV leads to more 
effective output of the systemic ventricle, whereas the ejection fraction might even decline. 
Before surgery, stroke volume is partially regurgitated back into the systemic atrium, whereas 
after surgery stroke volume completely attributes to cardiac output, leading to overall better 
function. Secondly, visual assessment of right ventricular function, although generally ac-
cepted, may not reveal subtle but important changes in RV function. Other imaging modali-
ties, like cardiac magnetic resonance imaging, may demonstrate improved rather than stable 
RV function on the long term.
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The combination of TR and progressive RV dysfunction is a frequent finding in patients 
with ccTGA or acTGA. It is associated with a rapid decline in functional class and decreased 
survival frequently necessitating surgical treatment.27 Selection of the optimal surgical strat-
egy, specifically in the “older” patients (3rd to 4th decade of life), is a complicated issue. It could 
be postulated that either relocation of the (morphologically) left ventricle in systemic posi-
tion or cardiac transplantation, is the surgical treatment of choice in these cases. However, 
results after relocation of the left ventricle into systemic position, in terms of survival and 
benefit, are discouraging in the adult TGA population.28, 29 The option of cardiac transplanta-
tion is probably the superior option from a functional point of view. Unfortunately, donor 
organs are scarcely available and cardiac transplantation can only be applied in a limited 
number of patients. Hence, cardiac transplantation as a treatment option in the approach 
to TGA patients with TR and a dysfunctional right ventricle is an exceptional solution. The 
results from our population, which is relatively old (34.2 ± 14.5 years in the ccTGA group and 
35.0 ± 5.9 years in the acTGA group), demonstrate that TVR and TVP are associated with low 
mortality and improvement of functional class. Therefore, it could be regarded as a first 
option in patients with a systemic right ventricle and TR. It should however be noted that 
survival characteristics tend to be worse after TVP, mainly caused by a high recurrence rate of 
TR. Tricuspid leaflet tethering may be the mechanism behind the recurrence of TR after TVP.
limitations
In the current study, semi-quantitative analysis of tricuspid and right ventricular function 
with echocardiography was used. Cardiac magnetic resonance imaging provides a more 
accurate modality for estimation of right ventricular function. However, an important num-
ber of patients have pacemakers and could not undergo magnetic resonance imaging. For 
consistency, we therefore chose echocardiography for comparison of data during follow-up. 
As another limitation, which is present in most studies on patients with congenital heart 
disease, the study population was small. Therefore, the results of this study remain to be 
confirmed prospectively in a larger patient population.
conclusion
Mortality is low after tricuspid surgery in patients with a right systemic ventricle. Although 
the incidence of post-operative complications is high, this should not be a reason to refrain 
from these operations. Short-term results demonstrate that tricuspid valve replacement in 
patients with a dysfunctional right ventricle is associated with an improvement of tricuspid 
valve function, stable right ventricular function and improvement of functional class. Valvulo-
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plasty, which is associated with a high recurrence rate of regurgitation, is not advisable in this 
group of patients and tricuspid valve replacement should therefore be performed preferably.
85
TRICUSPID VALVE SURGERY: REPAIR OR REPLACE?
reFerences
 1. Mustard WT. Surgical diagnosis and treatment of common paediatric cardiac anomalies. R I Med 
J 1964; 47: 332-5.
 2. Senning A. Surgical correction of transposition of the great vessels. Surgery 1959; 45: 966-80.
 3. Webb GD, McLaughlin PR, et al. Transposition complexes. Cardiol Clin 1993; 11: 651-64.
 4. Warnes CA. Transposition of the great arteries. Circulation 2006; 114: 2699-709.
 5. Duncan BW, Mee RB. Management of the failing systemic right ventricle. Semin Thorac Cardiovasc 
Surg 2005; 17: 160-9.
 6. Bove EL, Ohye RG, et al. Anatomic correction of congenitally corrected transposition and its close 
cousins. Cardiol Young 2006; 16 Suppl 3: 85-90.
 7. Mee RB. Severe right ventricular failure after Mustard or Senning operation. Two-stage repair: 
pulmonary artery banding and switch. J Thorac Cardiovasc Surg 1986; 92: 385-90.
 8. van Son JA, Danielson GK, et al. Late results of systemic atrioventricular valve replacement in 
corrected transposition. J Thorac Cardiovasc Surg 1995; 109: 642-52.
 9. Rutledge JM, Nihill MR, et al. Outcome of 121 patients with congenitally corrected transposition of 
the great arteries. Pediatr Cardiol 2002; 23: 137-45.
 10. Hraska V, Duncan BW, et al. Long-term outcome of surgically treated patients with corrected 
transposition of the great arteries. J Thorac Cardiovasc Surg 2005; 129: 182-91.
 11. Dodge-Khatami A, Kadner A, et al. In the footsteps of senning: lessons learned from atrial repair 
of transposition of the great arteries. Ann Thorac Surg 2005; 79: 1433-44.
 12. Chang AC, Wernovsky G, et al. Surgical management of late right ventricular failure after Mustard 
or Senning repair. Circulation 1992; 86: II140-II149.
 13. Myridakis DJ, Ehlers KH, et al. Late follow-up after venous switch operation (Mustard procedure) 
for simple and complex transposition of the great arteries. Am J Cardiol 1994; 74: 1030-6.
 14. Horer J, Herrmann F, et al. How well are patients doing up to 30 years after a mustard operation? 
Thorac Cardiovasc Surg 2007; 55: 359-64.
 15. Horer J, Karl E, et al. Incidence and results of reoperations following the Senning operation: 27 
years of follow-up in 314 patients at a single center. Eur J Cardiothorac Surg 2008; 33: 1061-67.
 16. Prieto LR, Hordof AJ, et al. Progressive tricuspid valve disease in patients with congenitally cor-
rected transposition of the great arteries. Circulation 1998; 98: 997-1005.
 17. Roos-Hesselink JW, Meijboom FJ, et al. Decline in ventricular function and clinical condition after 
Mustard repair for transposition of the great arteries (a prospective study of 22-29 years). Eur 
Heart J 2004; 25: 1264-70.
 18. Sano T, Riesenfeld T, et al. Intermediate-term outcome after intracardiac repair of associated 
cardiac defects in patients with atrioventricular and ventriculoarterial discordance. Circulation 
1995; 92: II272-II278.
 19. Beauchesne LM, Warnes CA, et al. Outcome of the unoperated adult who presents with congeni-
tally corrected transposition of the great arteries. J Am Coll Cardiol 2002; 40: 285-90.
 20. Westerman GR, Lang P, et al. Corrected transposition and repair of associated intracardiac defects. 
Circulation 1982; 66: I197-I202.
 21. Lundstrom U, Bull C, et al. The natural and “unnatural” history of congenitally corrected transposi-
tion. Am J Cardiol 1990; 65: 1222-9.
 22. Horvath P, Szufladowicz M, et al. Tricuspid valve abnormalities in patients with atrioventricular 
discordance: surgical implications. Ann Thorac Surg 1994; 57: 941-5.
CHAPTER 4
86
 23. Acar P, Sidi D, et al. Maintaining tricuspid valve competence in double discordance: a challenge 
for the paediatric cardiologist. Heart 1998; 80: 479-83.
 24. Cochrane AD, Karl TR, et al. Staged conversion to arterial switch for late failure of the systemic 
right ventricle. Ann Thorac Surg 1993; 56: 854-61.
 25. Fukuda S, Song JM, et al. Tricuspid valve tethering predicts residual tricuspid regurgitation after 
tricuspid annuloplasty. Circulation 2005; 111: 975-9.
 26. Fukuda S, Gillinov AM, et al. Determinants of recurrent or residual functional tricuspid regurgita-
tion after tricuspid annuloplasty. Circulation 2006; 114: I582-I587.
 27. Voskuil M, Hazekamp MG, et al. Postsurgical course of patients with congenitally corrected trans-
position of the great arteries. Am J Cardiol 1999; 83: 558-62.
 28. Poirier NC, Yu JH, et al. Long-term results of left ventricular reconditioning and anatomic correc-
tion for systemic right ventricular dysfunction after atrial switch procedures. J Thorac Cardiovasc 
Surg 2004; 127: 975-81.
 29. Quinn DW, McGuirk SP, et al. The morphologic left ventricle that requires training by means 
of pulmonary artery banding before the double-switch procedure for congenitally corrected 
transposition of the great arteries is at risk of late dysfunction. J Thorac Cardiovasc Surg 2008; 135: 
1137-44.
Chapter 5
Ventricular Response to Stress Predicts Outcome in 
Adult Patients with a Systemic Right Ventricle
Roderick WC Scherptong 
Michiel M Winter 
Sabina Kumar 
Berto J Bouma 
Igor I Tulevski 
Laurens F Tops 
Arno AW Roest 
Hubert W Vliegen 
Albert de Roos 
Maarten Groenink 
Barbara JM Mulder





Previous studies demonstrated that ventricular response to stress Cardiovascular Magnetic 
Resonance (CMR) is frequently abnormal in patients with a systemic right ventricle (RV). How-
ever, the clinical implications of these findings remained unknown. We sought to evaluate 
whether abnormal response to stress CMR predicts adverse outcome in patients with a 
systemic RV.
methods
Thirty-nine adult patients (54% male; mean age 26, range 18–65 years) with a systemic RV 
underwent stress CMR to determine the response of RV volumes and ejection fraction (EF). 
During follow-up, cardiac events, defined as hospitalization for heart failure, cardiac surgery, 
aborted cardiac arrest, or death, were recorded. The prognostic value of an abnormal re-
sponse to stress, defined as lack of a decrease in RV end systolic volume (ESV) or lack of an 
increase in RV EF, was assessed.
results
We frequently observed an abnormal response to stress, as RV ESV did not decrease in 17 pa-
tients (44%), and RV EF did not increase in 15 patients (38%). After a mean follow-up period of 
8.1 years, 8 (21%) patients had reached the composite endpoint. The inability to decrease RV 
ESV during stress was predictive for cardiac events with a hazard ratio of 2.3 (95%CI 1.19-88.72; 
p=0.034), as was the inability to increase RV EF with a hazard ratio of 2.3 (95%CI 1.31-81.59; 
p=0.027).
conclusions
Stress CMR potentially has important prognostic value in patients with a systemic RV. Patients 
with a systemic RV who show abnormal cardiac response to stress have a substantially higher 
risk of adverse outcome.
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introDuction
The number of adult patients with congenital heart disease has grown rapidly over the past 
few decades.1 A substantial portion of patients have a morphological right ventricle (RV) that 
sustains the systemic circulation, i.e. patients with a transposition of the great arteries (TGA) 
after a Mustard or Senning operation, and patients with a congenitally corrected transposi-
tion of the great arteries (ccTGA). Although mid-term survival is acceptable in these patients, 
complications are common, and frequently relate to dysfunction of the systemic RV.2 There-
fore, careful follow-up of RV function is the cornerstone in the clinical care for patients with 
either TGA or ccTGA.
Cardiovascular magnetic resonance imaging (CMR) is a widely applied imaging modal-
ity that provides a reliable diagnostic tool for the detection of depressed RV function. As 
such, CMR is frequently used to guide medical therapy and to select patients for surgical 
interventions.3;4 The use of stress CMR, either with supine bicycle ergometry or dobutamine 
infusion, could facilitate early detection of systemic RV dysfunction. Previous studies in which 
the value of stress CMR was evaluated, demonstrated that ventricular response to stress was 
frequently abnormal in patients with a systemic RV.5–8 It was observed that these patients 
often lack the ability to increase contractility during stress, even when they are asymptom-
atic.8;9 These findings suggest that stress CMR provides the possibility to detect subclinical 
RV dysfunction at an early stage, and could help identify those patients that require medical 
or surgical intervention. However, the main limitation of these studies was that the relation 
between the abnormal response to stress CMR and clinical outcome remained unclear, which 
questioned the clinical applicability of stress CMR.10 Therefore, the current study aimed to 
evaluate the relation between cardiac response to stress CMR and cardiac events in patients 
with a systemic RV.
methoDs
Patient population and study protocol
The study was a two-center investigation, and was set-up to evaluate the ventricular response 
to stress in patients with TGA or ccTGA and a systemic RV. Patients with a systemic RV (n=39; 
54% male; age 26 ± 8 years) were included in 1999 and 2000. Patients were excluded from 
participation if they were younger than 18 years, had (previous) cardiac arrhythmias, had an 
intra-cardiac device, or had concomitant cardiac lesions. All patients underwent either do-
butamine stress CMR (n=18) in the Academic Medical Centre, Amsterdam, or supine bicycle 
ergometry CMR (n=21) in the Leiden University Medical Centre.9;10 After baseline stress CMR 
evaluation, patients were regularly followed-up at the out-patient clinic for adult congenital 
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heart disease. During follow-up, the occurrence of all cardiac events were recorded. Cardiac 
events were defined as: hospitalization for heart failure, cardiac surgery, aborted out-of-
hospital cardiac arrest or cardiac death. We performed a Cox’s regression analysis in which 
the relation between the cardiac response to stress CMR and the occurrence of cardiac events 
during follow-up was assessed.
The ethics committees of the participating tertiary referral centers approved the study 
protocol, and the study protocol complies with the Declaration of Helsinki. All participating 
patients provided written informed consent. The current study was funded by an unrestricted 
educational grant from Novartis Pharma, the Netherlands. The authors are solely responsible 
for the design and conduct of this study, all study analyses, the drafting and editing of the 
paper and its final contents.
stress cmr acquisition
The supine bicycle ergometry CMR acquisition protocol has previously been published by 
Roest et al.11 In short, image acquisition was performed using a Philips Gyroscan ACS/NT 1.5 
Tesla MR scanner (Philips Medical Systems, Best, the Netherlands) in the Leiden University 
Medical Center. Exercise was performed on a MR-compatible bicycle ergometer. Volumetric 
indexes of the systemic RV were obtained from a short axis stack of 10 images with a slice 
thickness of 10 mm and a 1 mm slice gap. We used an ultra-fast, turbo field echo planar imag-
ing MR technique with the following parameters: repetition time = 14 ms, echo time = 4.8 ms, 
flip angle 30 degrees, imaging matrix 128 X 140, field of view 420 X 120 mm. The protocol was 
repeated at submaximal exercise, which was defined as 60% of peak oxygen consumption, 
as determined by stationary bike cardiopulmonary exercise testing one day prior to CMR. 
After reaching a steady heart rate, the individual performed a breath hold of 8 cardiac cycles 
to obtain 2 short-axis images. This procedure was repeated 5 times to obtain 10 short-axis 
images.
The dobutamine stress CMR acquisition protocol has previously been published by Tulevski 
et al.9 In short, image acquisition was performed using a Siemens 1.5 Tesla MR scanner (Vi-
sion, Siemens, Erlangen, Germany) in the Academic Medical Center, Amsterdam. Volumetric 
indexes of the systemic RV were obtained from a short axis stack of 12–14 images with a slice 
thickness of 10 mm and a 0 mm slice gap. We used an ultra-fast, turbo field echo planar imag-
ing MR technique with the following parameters: repetition time = R-R interval, echo time = 
4.8 ms, flip angle 20 degrees, imaging matrix 256 X 256, field of view 350 mm. Dobutamine was 
administered through a venous line with an initial dose of 5 ųg/kg/min, which was increased 
after 3 minutes by 5 ųg/kg/min every 3 minutes up to a maximal dose of 15 ųg/kg/min. The 
CMR protocol was repeated 3 minutes after reaching the maximal dose.
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Previous studies on cardiac response to stress demonstrated that healthy individuals increase 
cardiac output during exercise through a reduction in end systolic volume and a subsequent 
increase in ejection fraction.12 Therefore, we defined an abnormal response to stress as the 
inability to decrease systemic right ventricular end systolic volume during stress (end systolic 
volume at rest – end systolic volume at stress ≤ 0 ml), and/or the inability to increase systemic 
right ventricular ejection fraction during stress (ejection fraction at rest – ejection fraction 
stress ≥ 0%).
cmr image analysis
For image analysis, the MASS Analytical Software System (Medis, Leiden, the Netherlands) 
was used. Image analysis was performed by a single observer in 2009, who was blinded 
for patient characteristics and outcome. Cine loops were used to choose end diastole and 
end systole. End diastole was defined as the phase with the largest RV area and end systole 
as the phase with the smallest RV area. The slices at the base of the heart were considered 
to be in the ventricle if the blood was at least half surrounded by ventricular myocardium. 
Trabeculations and papillary muscles were considered part of the ventricular cavity.13 Four-
chamber view cine loop movies in phase and slice with the short axes views were used in 
case the distinction between the ventricles, atria and great vessels was unclear. Tracing was 
performed manually on each end diastolic and end systolic short-axis view. The sums of the 
traced contours in end diastole and end systole were used to calculate end diastolic volume 
and end systolic volume using a disc summation technique. End diastolic volume and end 
systolic volume were used to calculate stroke volume and ejection fraction. Stroke volume 
was defined as end diastolic volume – end systolic volume, and ejection fraction as [(end 
diastolic volume – end systolic volume) / end diastolic volume] X 100%. Data on reproduc-
ibility of CMR image analysis has been published previously by our group.14
statistical methods
For statistical analyses SPSS 16.0 (SPSS Inc., Chicago, Illinois) for Windows was used. A 2-tailed 
probability value of < 0.05 was used as a criterion for statistical significance. The descriptive 
data are presented as number (percentage), or as mean with standard deviation, or median 
with range, as appropriate. Chi-square and unpaired t-tests were performed to assess differ-
ences between subgroups in categorical and continuous variables, respectively. A survival 
analysis was performed to assess the relation between an abnormal response to stress at 
baseline and the occurrence of adverse events during follow-up. For this purpose, the patient 
population was divided into two groups. The first group consisted of patients who had a nor-
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mal ventricular response to stress; the second group of patients had an abnormal response 
to stress, as defined above. Kaplan-Meier survival charts were generated to depict the differ-
ence in incidence of adverse events between the two groups and Log-rank tests were used 
to assess whether the survival curves differed significantly. In addition, the prognostic value 
of an abnormal response to stress was assessed using Cox’s proportional hazard regression 
analysis. For each stress CMR-derived variable, which was categorized as either normal or 
abnormal, a univariate hazard ratio (HR) with corresponding 95% confidence intervals (CI) 
was calculated. Furthermore, the univariate HRs were adjusted for age, and sex to obtain the 
multivariate HRs.
results
Thirty-nine adult patients (54% male; mean age 26.4, range 18.4 – 65.2 years) underwent 
stress CMR at baseline. The characteristics of these patients are summarized in table 1. At 
baseline, 26 patients (67%) were in NYHA functional class I, 13 (33%) patients were in NYHA 
functional class II and none were in NYHA class III or IV. Six patients were diagnosed with 
ccTGA, and 33 patients were diagnosed with complete TGA (19 had undergone a Mustard, 
and 14 had undergone a Senning operation). Patients with ccTGA were older at the time of 
baseline stress CMR investigation, as compared to patients with an atrially switched TGA (34.3 
± 16.3 years vs. 24.9 ± 4.6 years, p<0.01). Patients who had undergone a Mustard operation 
were significantly older compared to patients who had undergone a Senning operation (26.6 
± 4.3 years vs. 22.7 ± 4.2 years; p<0.05). There were no differences in gender distribution or 
in NYHA class between the TGA and ccTGA patients, nor between patients with a previous 
Mustard and Senning operation.







TGA / ccTGA 33 / 6 6 / 2 2 / 1
Age (years) 26.4 ± 8.0 33.0 ± 13.3 42.5 ± 19.6
Male 21 (54%) 4 (50%) 2 (67%)
NYHA class I 26 (67%) 6 (75%) 1 (33%)
II 13 (33%) 2 (25%) 2 (67%)
 * Data are number of patients (percentage), or mean ± standard deviation. ccTGA: congenitally corrected 
transposition of the great arteries; NYHA: New York Heart Association; TGA: transposition of the great arter-
ies.
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ventricular response to stress cardiovascular magnetic imaging
CMR parameters are summarized in table 2. Stress CMR was well tolerated by most patients, 
as only 1 dobutamine-stress examination was discontinued due to a supraventricular tachy-
cardia with a heart rate around 260 beats/min that was managed by carotid sinus massage.6 
At baseline we found no differences in resting end diastolic volume, end systolic volume, 
stroke volume and ejection fraction between patients with an atrially switched TGA and 
patients with a ccTGA. Resting end diastolic volume was significantly larger at baseline in 
patients with a Mustard operation, compared to those with a Senning operation (158.1 ± 48.7 
ml vs. 127.8 ± 22.2 ml; p<0.05), however, no differences in end systolic volume, stroke volume 
and ejection fraction were observed between these two groups.
Overall, systemic RV end diastolic volume decreased during stress (147.6 ± 44 ml vs. 135.6 
± 51.9 ml; p=0.01), as did end systolic volume (68.0 ± 29.9 ml vs. 60.01 ± 33.9 ml; p=0.01). Sub-
sequently, systemic RV stroke volume remained unchanged (79.4 ± 22.8 ml vs. 75.5 ± 23.3 ml; 
p=N.S.). Systemic RV ejection fraction increased significantly during stress (54.7 ± 9.5% at rest 
vs. 57.3 ± 8.1% during stress; p<0.05). Furthermore, heart rate increased from 68.5 ± 12.1 beats 
per minute to 141.6 ± 33.6 beats per minute (p<0.001). There were no statistically significant 
differences in cardiac response to stress between patients with an atrially switched TGA, and 
patients with a ccTGA, nor between patients with a Mustard operation, and patients with a 
Senning operation.
An abnormal systemic RV response to stress was frequently observed. In 17 patients (44%), 
end systolic volume remained equal or even increased during exercise. In addition, 15 pa-
tients (38%), showed no increase, or a decrease in RV ejection fraction during stress, 2 of 
whom showed normal response in end systolic volume.








end diastolic volume (ml) 148 ± 44 156 ± 69 178 ± 112
end systolic volume (ml) 68 ± 30 77 ± 50 92 ± 83
stroke volume (ml) 79 ± 23 79 ± 24 86 ± 35
ejection fraction (%) 55 ± 10 53 ± 9 52 ± 14
Δ stress - rest
end diastolic volume (ml) -12 ± 28 -2 ± 18 -9 ± 29
end systolic volume (ml) -8 ± 18 3 ± 15* -2 ± 22
stroke volume (ml) -4 ± 16 -4 ± 5 -7 ± 7
ejection fraction (%) 3 ± 8 -1 ± 7 4 ± 10
Data are mean ± standard deviation. * p<0.05 in comparison with all patients.
CHAPTER 5
94
Abnormal response to stress and Future cardiac events
After a mean follow-up period of 8.1 years; range 0.5 to 9.8 years, 8 (21%) patients had reached 
the composite endpoint of hospitalization for heart failure (n=2), intra-cardiac surgery (n=2, 
both tricuspid valve replacement), aborted out-of-hospital cardiac arrest (n=1), or cardiac 
death (n=3), with an annual event rate of 2.5%. Figure 1.
Univariate analysis showed that older age at baseline was significantly associated with 
worse outcome (HR 1.1; 95% CI 1.0-1.1; p=0.02). The other baseline patient characteristics; 
sex, NYHA class at baseline, type of condition (ccTGA vs. TGA), type of operation (Mustard vs. 
Senning), and higher age (≥ 2 years) at Mustard/Senning operation, were not associated with 
the risk of cardiac events during follow-up. In addition, end diastolic volume, end systolic 
volume, stroke volume, and ejection fraction measured at rest were not predictive for future 
cardiac events, nor for cardiac death. An abnormal cardiac response to stress, on the other 
hand, was related to the occurrence of cardiac events during follow-up. As can be readily 
seen in figure 2, both the absence of a decrease in systemic RV end systolic volume during 
stress, as well as the absence of an increase in systemic RV ejection fraction during stress were 
predictive of future cardiac events. The absence of a reduction in end systolic volume was a 
risk factor for cardiac events in the univariate analysis (HR=1.58; 95% CI 0.98-24.1; p=0.054), 
and remained a risk factor for cardiac events after adjusting for age and sex (HR=2.33; 95% 
CI 1.19-88.72; p=0.034). The inability to increase ejection fraction was a risk factor for cardiac 
events in the univariate analysis (HR=1.81; 95% CI 1.23 – 30.37; p=0.027), and remained a risk 
factor in the multivariate analysis (HR=2.34; 95% CI 1.31-81.59; p=0.027). An abnormal response 
Figu re  1.  























Figure 1. Kaplan-Meier survival curve for freedom from cardiac events plotted for follow-up duration after 
stress CMR in all patients (n=39).
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to stress was not predictive for cardiac death. The stress related changes in end diastolic 
volume, increase stroke volume, and heart rate during stress, were not predictive for future 
cardiac events, nor for cardiac death.
Discussion
The present study, for the first time, demonstrates that stress CMR is a valuable prognostic 
tool in patients with a systemic RV. Patients with a systemic right ventricle, who show no 
decrease in RV end systolic volume or no increase in RV ejection fraction during stress, have 
a significantly higher risk of future cardiac events.
The diagnostic and prognostic value of stress CMR in patients with acquired heart disease 
has already been established. Dobutamine stress CMR has been proven useful to detect 
myocardial ischemia in patients with chest pain,15–18 and to predict future myocardial infarc-
tion and cardiac death in patients with coronary artery disease.19;20 Moreover, in patients with 
mildly to moderately reduced LV ejection fraction stress CMR is prognostic for future myo-
cardial infarction and cardiac death.21 On the other hand, patients without inducible ischemia 
during stress CMR, and with a resting ejection fraction > 40% are known to have excellent 
cardiac prognosis.20 Notwithstanding the knowledge on the prognostic role of stress CMR 
in patients with acquired heart disease, the predictive value of stress CMR in patients with 
congenital heart disease was unknown.22
Previous studies on stress CMR in patients with a systemic RV have demonstrated that 
these patients often show an abnormal cardiac response to stress.6;7;9 In healthy individuals, 
end systolic volume decreases, whereas end diastolic volume remains unchanged during 
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Figure 2. Kaplan-Meier survival curve for freedom from cardiac events plotted for follow-up duration after 
stress CMR. A. patients with (n=22) versus patients without (n=17) the ability to decrease systemic right 
ventricular end systolic volume (ESV) during stress. b. patients with (n=24) versus patients without (n=15) 
the ability to increase systemic right ventricular ejection fraction (EF) during stress.
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stress, causing an increase in both stroke volume and ejection fraction.12;23 Frequently, the 
systemic RV of patients with an atrially switched TGA lack the ability to increase myocardial 
contractibility during stress, as they often show no decrease in end systolic volume, and 
no subsequent increase in stroke volume and ejection fraction during stress.5;8;24 Moreover, 
it is known that patients with a systemic RV have a reduced ability to increase heart rate 
during exercise, due to chronotropic incompetence, which further diminishes the increase 
in cardiac output during stress.8;25 Overall, we found an adequate chronotropic response 
to stress, with a substantial increase in heart rate during stress in all patients. However, our 
study demonstrates that almost half of the patients could not decrease end systolic volume 
and almost one third of patients could not increase ejection fraction during stress. This is the 
first study in which an abnormal cardiac response to stress is demonstrated to be prognostic 
for future cardiac events in patients with a systemic RV. These findings suggest that impaired 
myocardial contractility during stress identifies a more deteriorated state of the systemic RV, 
and thus relates to worse patient outcome as observed in the current study.
At the time of stress CMR most patients were in NYHA functional class I, and none were 
NYHA class III or IV. Moreover, RV ejection fraction was not impaired in most patients, as 
compared to RV ejection fraction of subjects with normal cardiac anatomy.26 Survival analysis 
revealed that neither functional status nor resting RV function was predictive for the occur-
rence of adverse events. Stress CMR, however, facilitates the detection of cardiac dysfunction 
that is not apparent at rest.9 Subsequently, stress related cardiac dysfunction demonstrated 
to be predictive of adverse events during long-term follow-up, in the current study. Hence, 
stress CMR provides timely detection of systemic RV dysfunction and could thus guide early 
therapeutic intervention to prevent or decelerate further ventricular deterioration and the 
occurrence of cardiac events.27 However, sufficiently powered, prospective trials are needed 
to establish the role of early therapeutic intervention in asymptomatic or minimally symp-
tomatic patients with a systemic RV and an abnormal response to stress.
Although CMR is considered an accurate and noninvasive tool to assess systemic RV vol-
umes and function, there are some limitations for the use of stress CMR.13;28;29 For example, 
20% of patients with a systemic RV is pacemaker dependent, and an increasing number of 
patients with a failing systemic RV benefits from cardiac resynchronization therapy.30 As most 
intra-cardiac devices are considered to be CMR incompatible, these patients are unsuitable 
to undergo CMR. Moreover, studies in patients with coronary artery disease have proven 
dobutamine infusion to be safe, although ventricular ectopy and atrial arrhythmias were 
seen when administrating high doses of dobutamine (40 ųg/kg/min).21 As no trials had been 
performed addressing safety issues when performing stress CMR in patients with a systemic 
RV, we chose to administer dobutamine at a maximum dosage of 15 ųg/kg/min dobutamine, 
which is known to be sufficient to assess contractile reserve.31–33 In the present study, one 
examination was discontinued due to supra-ventricular tachycardia (260 beats per minute), 
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which was managed with carotid sinus massage. Although our study was not set-up to evalu-
ate safety issues, this was the only complication that we experienced.
limitations
As with most studies on CMR in patients with congenital heart disease, the number of pa-
tients included in the study was relatively small. Larger-scaled studies should be pursued to 
definitely establish the value of our findings. However, despite the relatively small sample 
size and possible bias in favor of healthier patients, we were still able to show that patients 
with a systemic RV, who show no decrease in RV end systolic volume or increase in RV ejec-
tion fraction during stress, have a significantly higher risk of future cardiac events. Our study 
was importantly limited by the inability to perform adequate flow measurements at the time 
of baseline data acquisition. Therefore, our data could not be corrected for potential tricuspid 
valve regurgitation, or baffle stenosis/leakage. As it is known that tricuspid valve regurgita-
tion predicts for reverse outcome in patients with a systemic RV, some of the complications 
reported in our study could have been due to tricuspid valve regurgitation, rather than to ab-
normal stress response. Another limitation is the fact that we used two different CMR image 
acquisition protocols (in the Leiden University Medical Center, and in the Academic Medical 
Center in Amsterdam), as well as two different stress protocols (dobutamine stress and physi-
cal exercise CMR).34 Nonetheless, the current study was set-up to evaluate the prognostic 
value of an abnormal cardiac response to stress for each individual patient, irrespective of 
the diagnostic modality used, and not to compare patients from different medical centers, or 
to compare two different diagnostic modalities. We excluded patients with irregular rhythms 
to avoid the risk of life-threatening arrhythmias during stress, and patients with intra-cardiac 
devices because of CMR incompatibility. This could have lead to a biased sample, favoring 
healthier patients with lower risk of cardiac events.
conclusion
Stress CMR potentially has important prognostic value in patients with a systemic RV. Patients 
with a systemic RV who are unable to decrease end systolic volume, or to increase ejection 
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The aim of this study was to evaluate the feasibility of right ventricular (RV) longitudinal peak 
systolic strain (LPSS) assessment for the follow-up of adult patients with corrected tetralogy 
of Fallot (TOF).
methods
Adult patients (n=18) with corrected TOF underwent echocardiography and CMR twice with 
a time interval of 4.2 ±1.7 years. RV performance was derived from CMR, and included RV 
volumes and ejection fraction (EF). LPSS was calculated globally (GLPSS) and in the RV free 
wall (LPSS FW), with echocardiographic speckle-tracking strain-analysis. Baseline (G)LPSS 
values were compared between patients and healthy controls; the relation between (G)LPSS 
and CMR parameters was evaluated and the changes in (G)LPSS and CMR parameters during 
follow-up were compared.
results
GLPSS and LPSS FW were significantly reduced in patients as compared to controls (-14.9 
±0.7% vs. -21.6 ±0.9% and -15.5 ±0.9% vs. -22.7 ±1.5%, p<0.01). Moderate agreement between 
LPSS and CMR parameters was observed. RV EF remained unchanged during follow-up, 
whereas GLPSS and LPSS FW demonstrated a significant reduction. RVEF showed a 1% in-
crease, whereas GLPSS decreased by 14%, and LPSS FW by 27%.
conclusions
RV LPSS is reduced in TOF patients as compared to controls; during follow-up RV EF remained 
unchanged whereas LPSS decreased suggesting that RV LPSS may be a sensitive marker to 
detect early deterioration in RV performance.
105
PEAK SYSTOLIC STRAIN IN TETRALOGY OF FALLOT
introDuction
Reliable quantification of right ventricular (RV) performance is essential during follow-up of 
patients who underwent total repair for tetralogy of Fallot (TOF).1 Currently, RV performance 
is mostly quantified with cardiovascular magnetic resonance (CMR) by assessing ventricular 
volumes and ejection fraction.2 Although CMR provides a good estimation of RV perfor-
mance, recent studies demonstrated that the relation with patient outcome is suboptimal.3 
This observation underscores the need for more sensitive parameters to adequately identify 
patients at risk for a decrease in RV performance. With the introduction of tissue Doppler 
imaging, the possibility emerged to evaluate RV myocardial function in patients with TOF 
using RV strain analysis.4 However, tissue Doppler imaging has limitations that hamper 
the application of RV strain analysis in clinical practice.5 Recently, novel echocardiographic 
strain analysis packages, based on speckle-tracking, have become available. This technology 
provides direct information on contractile performance of the right ventricle,6 which may 
potentially provide a more a sensitive measurement to detect decreases in RV function at an 
early stage in patients with TOF.
The aim of the current study was twofold. First, we evaluated whether RV peak systolic 
longitudinal strain, quantified with 2D speckle-tracking imaging, is reduced in adult patients 
with TOF as compared to normal individuals. Second, we hypothesized that reduction of 
RV peak systolic strain during follow-up can be used for early detection of a decrease in RV 
performance.
methoDs
study population and protocol
The patient population consisted of 18 adult patients who underwent total correction for TOF 
during childhood. In adulthood, these patients were regularly followed up at the outpatient 
clinic for adult congenital heart disease during a period of 4.2 ± 1.7 years. In this study period, 
medical therapy was unchanged, no surgical interventions were performed and NYHA class 
remained stable in all patients. Characteristics are summarized in Table 1.
At the age of 33.9 ± 11.2 years, these patients underwent routine evaluation with echo-
cardiography (echo) and CMR within a three-month timeframe (baseline measurement), 
followed by a recent echo and CMR at the age of 38.1 ± 11.2 years (follow-up measurement). 
The echo evaluation included a standard 2D echo and 2D speckle-tracking strain analysis to 
calculate RV global longitudinal peak systolic strain (GLPSS) and longitudinal peak systolic 
strain separately in the RV free wall (LPSS FW). From the CMR images, RV performance was 
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obtained, expressed as RV end systolic volume (RV ESV), RV end diastolic volume (RV EDV) 
and RV ejection fraction (RV EF).
First, we compared the LPSS values from the baseline echocardiograms of the TOF patients 
to that of 18 healthy controls matched for age and gender. Second, the relations between RV 
performance (derived from CMR) on the one hand, and GLPSS and LPSS FW (derived from 
echocardiography) on the other hand, were calculated. Third, we evaluated the changes in 
GLPSS, LPSS FW (echocardiography-derived; baseline vs. 4.2 ± 1.7 years follow-up) and RV 
performance (CMR-derived; baseline vs. 4.2 ± 1.7 years follow-up). Finally, we compared the 
echocardiographic changes during follow-up to the changes measured with CMR.
echocardiography
Echocardiographic imaging took place in the left lateral decubitus position on a commercially 
available system (Vivid Seven, General Electric-Vingmed, Milwaukee, Wisconsin). Besides the 
standard parasternal (long- and short-axis) and apical (2- and 4-chamber) images, additional 
apical (4-chamber) images were obtained that included the interventricular septum, the 
apex and the RV free wall up to tricuspid annulus. Images were digitally stored in the cine-
loop format for off-line analysis.
Longitudinal strain was assessed off-line, on the 4-chamber cine-loop that included the RV 
free wall, using speckle-tracking analysis. The speckle-tracking software (EchoPac 7.0.0 GE 
Medical systems, Horten, Norway) uses natural acoustic markers, or speckles, to determine 
frame-to-frame movement of myocardium. Images are subdivided into blocks of approxi-
mately 20 to 40 pixels that contain stable patterns of speckles which are followed through the 
cardiac cycle.7 In these blocks, the location of speckles is tracked with a dedicated algorithm 
that uses the sum of absolute differences and specific correlation criteria. After local tissue 
velocity vectors are derived from the spatial and temporal data of each speckle, strain can 
be assessed from temporal differences in the mutual distance of neighbouring speckles. For 
longitudinal strain assessment, the software calculates the length of a predefined segment as 
table 1. Patient Population.
tetralogy of Fallot (n=18)
male/female (n) 8/10
Age (yrs) 33.9 ± 11.2
bsA (m2) 1.8 ± 0.06
nyhA i/ii/iii/iv (n) 13/5/-/-
type of repair (n)
 Transannular patch 12
 Right ventricular patch 5
 No patch 1
Previous pulmonary valve replacement (n) 7
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a percentage of the original length, shortening of a segment is represented as negative strain 
and lengthening of a segment is represented as positive strain.
RV longitudinal peak systolic strain was calculated in a user interface by delineating the 
endocardial border from the basal septum to the apex, along the RV free wall to the tricuspid 
valve annulus. After a region of interest was then set covering the complete width of the 
myocardium, the software automatically distinguished three predefined septal segments 
and three RV free wall segments in which longitudinal peak systolic strain was calculated. 
From these segments, GLPSS was obtained, which is a factory specified weighted average 
of all six segments.8 Furthermore, RV LPSS FW was calculated as the average of the three 
free wall segments (see Figure 1). The minimum frame rate used to calculate longitudinal 
strain was 40 frames per second. Two patients, in whom the image quality was considered 
inadequate, were excluded from further analysis.
Figure 1. 2D Speckle-tracking Strain Analysis of the Right Ventricle. Right ventricular longitudinal strain 
analysis in the designated user interface. Panel A demonstrates how first the endocardial border is de-
lineated in the apical 4-chamber view. Based on this contour, the interventricular septum and the right 
ventricular free wall are tracked automatically. The user optimizes the tracking quality, by adjusting the 
aforementioned contour and by altering the region of interest (ROI), which corresponds to the width of 
the tracking (Panel b). Thereafter, the program calculates global strain (GS) based on a weighted average 
of three septal and three right ventricular free wall segments (Panel c and D). FOR COLOR EXAMPLE, SEE 




Cardiovascular magnetic resonance examinations were performed on a 1.5 T ACS-NT15 
magnetic resonance scanner (Philips Medical Systems, Best, the Netherlands.) The scanning 
protocol has been described previously.9, 10 All images were obtained during breath holds, 
with an ECG triggered gradient echoplanar technique. For calculation of ventricular volumes, 
10 to 12 consecutive slices were obtained in the transverse plane, to cover both ventricles 
from apex to base. The MASS software package (Medis, Leiden, the Netherlands), was used 
for calculation RV EDV, RV ESV and RV EF.11
statistical analysis
SPSS (SPSS® 12.0.1 for Windows, SPSS Inc., Chicago, USA) was used for statistical analysis. Data 
are presented as mean ± SD, unless mentioned otherwise. To evaluate the reproducibility 
of RV LPSS, the echocardiograms of 20 subjects (10 Fallot patients and 10 controls) were 
analyzed twice by the same observer in a random order. In addition, these echocardiograms 
were also analyzed by a second observer. Subsequently, intra- and interobserver agreement 
of GLPSS and LPSS FW was evaluated using Bland-Altman analysis. An unpaired t-test was 
used to calculate the difference between patients and healthy controls. Pearson correlation 
coefficients were computed to describe the correlation between echocardiography derived 
RV peak systolic strain and CMR derived RV function. Furthermore, the changes from baseline 
to follow-up were calculated using paired t-test analysis. P values <0.05 were considered 
statistically significant.
results
rv longitudinal peak systolic strain: Patients vs. healthy controls
Table 2 demonstrates the differences in LPSS of the RV between patients with TOF and 
healthy controls per segment. LPSS values in patients with TOF ranged from -12.3 ± 7.6% in 
the apical septum to -17.6 ± 7.1% in the RV basal free wall. In healthy controls, peak systolic 
strain was also lowest in the apical septum (-18.2 ± 8.3%), but highest in the RV mid free wall 
(-24.2 ± 10.0%). The observed difference in RV LPSS between patients with TOF and healthy 
controls was significant in all RV segments except the apical free wall (Table 2). Furthermore, 
the combined strain values GLPSS and LPSS FW were significantly lower in patients with TOF 
as compared to healthy controls.
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The intra- and interobserver agreement for both GLPSS and LPSS FW were good. The 
intraobserver variability was 0.4 ± 1.4 and 0.1 ± 1.2 (mean ± 2SD), respectively, whereas the 
interobserver variability was 0.5 ± 2.7 and 0.3 ± 1.8 (mean ± 2SD).
relation between rv performance and rv longitudinal peak systolic strain in 
toF patients
In Table 3, the relation between RV performance (as derived from CMR) and RV LPSS (as 
derived from echo) in the TOF patients is summarized. At baseline, moderate-good relations 
between RV volumes (as derived from CMR) and RV LPSS were observed. RV EDV correlated 
significantly with both GLPSS and LPSS FW, indicating reduced strain in patients with a di-
lated RV. RV ESV was not correlated with RV peak systolic strain values. RV EF was correlated 
with GLPSS and LPSS FW. At follow-up, similar correlations were observed for RV volumes and 
RV EF on the one hand, and strain values on the other hand (Table 3).
table 2. Peak Systolic Strain Values in Tetralogy of Fallot Patients vs. Healthy Controls.
toF (n=18) controls (n=18) p-value
rv lPss (segmental)
 Basal septum (%) -13.1 ± 1.1 -19.6 ± 0.7 <0.001
 Mid septum (%) -14.4 ± 1.0 -20.2 ± 0.7 <0.001
 Apical septum (%) -12.3 ± 1.8 -18.2 ± 1.9 0.03
 Apical free wall (%) -13.2 ± 2.0 -20.1 ± 2.9 0.06
 Mid free wall (%) -15.8 ± 1.0 -24.2 ± 1.6 <0.001
 Basal free wall (%) -17.6 ± 1.7 -23.9 ± 2.2 0.03
rv lPss (combined)
 GLPSS (%) -14.9 ± 0.7 -21.6 ± 0.9 <0.001
 LPSS FW (%) -15.5 ± 0.9 -22.7± 1.5 <0.001
FW: free wall; GLPSS: global peak systolic strain; LPSS: peak systolic strain; RV: right ventricle. Data are pre-
sented as mean ± SE.
table 3. Correlation between RV performance (expressed as RV Volumes and RV EF derived from CMR) and 
RV longitudinal peak systolic strain (derived from echocardiography).
glPss (r) p-value lPss Fw(r) p-value
baseline
 RV ESV (ml/m2) 0.01 NS 0.22 NS
 RV EDV (ml/m2) 0.61 0.007 0.72 0.001
 RV EF (ml/m2) -0.80 <0.001 -0.62 0.006
Follow-up
 RV ESV (ml/m2) -0.37 NS -0.17 NS
 RV EDV (ml/m2) 0.43 0.07 0.58 0.01
 RV EF (ml/m2) -0.79 <0.001 -0.68 0.002
EDV: end diastolic volume; EF: ejection fraction; ESV: end systolic volume; FW: free wall; GLPSS: global peak 
systolic strain; LPSS: peak systolic strain, RV; right ventricle.
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changes in rv performance and rv longitudinal peak systolic strain during 
follow-up
In Table 4, the changes in RV performance and RV LPSS are shown (baseline vs. 4.2 ± 1.7 years 
follow-up). First, whereas RV EF remained unchanged, RV EDV and RV ESV demonstrated 
a small, statistically significant increase, indicating that the RV in TOF patients exhibited 
gradual dilatation. Second, we observed a significant reduction in RV LPSS on both a global 
level (GLPSS) as well as in the RV free wall (LPSS FW). An example of a patient with significant 
reduction in GLPSS and LPSS FW is shown in Figure 2. To compare the changes in RV perfor-
mance and changes in RV LPSS, the overall percentual changes from baseline to follow-up 
were calculated and depicted in Figure 3. RV EDV and RV ESV respectively demonstrated a 
16 % and 17% increase, whereas RV EF increased with 1%. GLPSS decreased 14%, the largest 
changes during follow-up, however, were noted in LPSS FW (-27%).
Figure 2. Patient Example of Changes in RV Longitudinal Peak Systolic Strain in Relation to RV Performance 
on Cardiovascular Magnetic Resonance Imaging. In this patient example, RV end diastolic volume increased 
gradually from 112 ml/m2 to 120 ml/m2 over a follow-up period of three years, but RV ejection fraction 
remained unchanged (55% at baseline vs. 54% at follow-up). Global RV longitudinal peak systolic strain 
however, decreased from -15.5% to -13.6% (red circles), mainly caused by a sharp decrease in longitudinal 
peak systolic strain of the RV free wall (-17.3% at baseline vs. -12% at three years follow-up). These findings 
indicate that RV performance measured with CMR may exhibit only minimal changes (without change in 
RV EF), whereas RV LPSS already decreases. FOR COLOR EXAMPLE, SEE CHAPTER 1, FIGURE 3.
table 4. Changes in RV performance and longitudinal peak systolic strain over 4.2 ± 1.7 years follow-up. 
baseline Follow-up p-value
rv Performance
 RV ESV (ml/m2) 49.6 ± 14.5 56.5 ± 16.5 0.020
 RV EDV (ml/m2) 118.7 ± 37.8 132.5 ± 35.5 0.007
 RV EF (%) 56.8 ± 9.3 56.4 ± 10.0 0.782
rv lPss
 LPSS FW (%) -15. 5 ± 3.6 -12.0 ± 5.5 0.004
 GLPSS (%) -14.9 ± 2.8 -12.9 ± 3.7 0.001
EDV: end diastolic volume; EF: ejection fraction; ESV: end systolic volume; FW: free wall; GLPSS: global peak 
systolic strain; LPSS: peak systolic strain; RV: right ventricle.
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Discussion
The main findings in the present study were that RV LPSS is reduced in patients with TOF as 
compared to healthy controls. Furthermore, RV LPSS was correlated with RV performance. 
Finally, over the follow-up period, a significant reduction in RV LPSS was observed, both on a 
global level (GLPSS) and in the RV free wall (LPSS FW), accompanied by a slight RV dilatation, 
but in the absence of changes in RV EF.
After total repair for TOF, a gradual deterioration of RV performance is observed in most 
patients,1 which is associated with a gradual reduction of functional class and the need for 
(surgical) interventions.3 Accordingly, early detection of a decrease in RV performance is 
important in the routine follow-up of patients with TOF.
Generally, CMR is the preferred technique for quantification of RV performance, and the 
most traditional parameters include RV volumes and RV EF.12 Various CMR studies have been 
performed to evaluate the relation between RV performance and outcome in patients with 
TOF.9, 9, 10, 13 Although these studies demonstrated that a severely dilated RV with depressed RV 
EF (<35%) was associated with poor functional performance (NYHA class III) and outcome, ac-
curate prediction of adverse outcome based on CMR derived RV performance measurements 
is limited.3, 3, 14 Moreover, exercise capacity appeared a strong predictor of adverse outcome 
in patients with TOF,15 but CMR derived RV performance measurements were demonstrated 
to be poorly related with exercise capacity.13 Thus, there appears a need for more sensitive 
parameters of RV performance to allow for earlier detection of a decline in RV performance. 
In the current study, we demonstrated that echocardiography derived RV strain measure-
ments may provide this information. It was shown that RV LPSS was reduced in patients with 
TOF as compared to healthy individuals; in TOF patients, GLPSS was -14.9 ± 0.7%, as compared 
Figure 3. Changes in Right Ventricular Performance and Right Ventricular Longitudinal Peak Systolic Strain. 
The white bars represent the overall changes in RV longitudinal peak systolic strain whereas the black bars 
represent the overall changes in cardiovascular magnetic resonance derived RV volumes and ejection frac-
tion. To compare the relative magnitudes in changes between strain and volumes/ejection fraction, the 
percentual changes from baseline to follow-up (rather than the absolute changes) are shown. A significant 
change was noted for RV volumes, global longitudinal peak systolic strain (GLPSS) and longitudinal peak 
systolic strain in the RV free wall (LPSS FW). The largest changes were observed in LPSS FW.
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to -21.6 ± 0.9% in healthy controls. Although literature data on RV LPSS in adult patients with 
TOF are lacking, previous studies in children after total repair for TOF also reported reduced 
RV strain values.4, 16 In a study by Weideman et al, RV LPSS was calculated with tissue Doppler 
imaging in pediatric TOF patients and compared to healthy controls.4 The authors reported 
RV LPSS of -20% in both the interventricular septum as well as in the RV free wall. In a similar 
study by Solarz et al,16 in which strain also was calculated with tissue Doppler imaging, LPSS 
values of -17% in the RV free wall and of -21% in the interventricular septum were described. 
RV LPSS was more reduced in the current study (-14.9 ± 0.7% in TOF patients vs. -21.6 ± 0.9% 
in normal controls), which may have been related to differences in patients age between 
study populations in the present vs. former studies. The mean age of patients in the current 
study was 34 ± 3 years, whereas the mean age in the previous studies was 11 ± 3 years and 7 
± 4 years, respectively.4, 16 Furthermore, both the timing as well as the type of total correction 
is most likely different in the current study population as compared to previously described 
pediatric populations. As a consequence of the evolution of the surgical approach to TOF, the 
earlier timing of total correction over the years and the use of smaller transannular patches, 
younger patients are less prone to the development of RV dysfunction.17 In addition, differ-
ence in strain calculation technique, tissue Doppler imaging vs. speckle-tracking may provide 
an alternative explanation for the differences between the current study and former studies.
Next, the relation between RV LPSS and GLPSS derived from 2D speckle-tracking on the 
one hand, and RV performance derived from CMR parameters on the other hand was evalu-
ated in the current study. We observed moderate-good correlations between RV LPSS with 
echocardiography and RV performance assessed by CMR, both at baseline and at follow-up. 
Patients with severe RV dilatation demonstrated reduced GLPSS and LPSS FW as compared to 
patients with preserved RV dimensions (Table 3). Furthermore, patients with depressed RV EF 
had lower GLPSS and LPSS FW as compared to patients with preserved RV EF (Table 3). The re-
lation between the CMR derived RV performance measurements, and the echocardiography 
derived strain measurements was not excellent, suggesting that the two parameters provide 
different information.
This suggestion is further strengthened by the observation that despite unchanged RV EF 
on CMR over the follow-up period (RV EF 56.8 ± 9.3% at baseline vs. 56.4 ± 10.0% at follow-up, 
p = NS), the RV strain parameters exhibited already some deterioration over time (Table 4, 
Figure 3), suggesting that strain parameters may provide more sensitive information on RV 
performance as compared to the traditional RV EF and RV volumes derived from CMR.
To the best of our knowledge, this is the first study to demonstrate the course of RV strain 
deterioration in patients with TOF. One of the pathophysiological substrates, besides the 
presence of RV dilatation, underlying this subtle deterioration of RV performance is likely 
to be related to gradual formation of myocardial fibrosis.18 Babu-Narayan et al recently re-
ported that patients with corrected TOF develop fibrosis in the RV as visualized on contrast-
enhanced CMR.19 In the patient population of 92 adult TOF patients aged 32 ± 11 years, the 
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authors demonstrated that RV fibrosis was present in 99% of the patients after 4 to 41 years 
follow-up. In this study, the presence of fibrosis was not only related to RV dilatation, but also 
to the increased incidence of arrhythmias and reduced exercise capacity, indicating that RV 
fibrosis formation is an important mechanism in patients with TOF.19 Possibly, the presence of 
RV fibrosis, also explains the reduced RV LPSS values in our current population.
limitAtions
As a shortcoming of most studies in patients with congenital heart disease, the sample size 
of the current study was small. Therefore, the relation of RV GLPSS and LPSS FW to pulmo-
nary regurgitation, which is an important determinant of RV function in TOF, could not be 
investigated. Furthermore, the current observations need to be related to outcome, in order 
to demonstrate whether the changes in RV LPSS without changes in RV EF are of clinical 
relevance.
conclusion
The current findings showed that RV longitudinal peak systolic strain is reduced in TOF 
patients as compared to normal controls. Moreover, RV longitudinal peak systolic strain cor-
relates moderately with measures of RV performance on CMR. Although RV ejection fraction 
on CMR remained unchanged and only modest RV dilatation was present during follow-up, 
echo-derived longitudinal peak systolic strain measures already decreased, suggesting that 
longitudinal peak systolic strain may be more sensitive to detect changes in RV performance. 
Further studies are needed to evaluate the role of RV longitudinal peak systolic strain to 
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The presence and progressive nature of primary myocardial involvement in Marfan is 
debated. The current study aimed to evaluate the clinical relevance of left ventricular (LV) 
and right ventricular (RV) strain, in adult patients with Marfan syndrome without significant 
valvular disease.
methods and results
Adult Marfan patients (n=50; age 35.2 ±12.9 years) were followed prospectively. Echocardiog-
raphy was performed annually and existed of comprehensive assessment of ventricular and 
valvular function. Using speckle tracking imaging, the baseline strain values of the Marfan 
population were calculated and compared to the values of normal controls. The follow-up 
evaluations were used to assess changes in ventricular strain. The association between the 
incidence of adverse events (heart failure, (supra)ventricular arrhythmias and proximal aorta 
surgery) and baseline strain values was investigated.
As compared to controls, Marfan patients had significantly lower peak longitudinal LV 
strain (-18.9 ±2.3% vs. -20.1 ±1.9%, P<0.01) and RV strain (-26.9 ±5.2% vs. -29.3 ±4.25%, P<0.01). 
The absolute changes in LV longitudinal, radial and circumferential strain and RV longitudinal 
strain during a median 4 years of follow-up were 0.1 ±2.8%, 1.12 ±7.6%, 0.3 ±3.7% and 0.9 
±5.5%, respectively, which was not statistically significant. Cox regression demonstrated that 
reduced LV or RV strain was not associated with adverse outcome (supraventicular arrhyth-
mias, n=3; proximal aorta surgery, n=4).
conclusions
This study suggests that Marfan patients show lower ventricular strain and strain rate values 
as compared to healthy controls. However no relevant changes in left and right ventricular 
function occur during mid-term follow-up in Marfan patients without valvular disease at 
baseline. Although ventricular strain and strain rate are mildly reduced in Marfan syndrome, 
this did not affect outcome negatively in the current study.
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introDuction
Marfan syndrome is a systemic connective tissue disorder, caused by mutations in the fibril-
lin-1 gene.1 Besides abnormalities in the musculoskeletal and ocular systems, the cardiovas-
cular phenotype exists of widening of the aorta and pulmonary artery and of abnormalities 
in the mitral valve.2 In addition, studies into primary myocardial involvement revealed that 
ventricular function may also be impaired in Marfan patients. Several investigations in which 
conventional echocardiography was used, indicated that left ventricular (LV) diameters can 
be increased, and that LV diastolic function can be impaired.3;4 More recent analyses, in which 
myocardial deformation was assessed with novel echocardiographic techniques, demon-
strated that LV and right ventricular (RV) systolic ventricular function may also be reduced in 
patients with Marfan syndrome as compared to controls.5;6
In light of these study data, it is advocated to regularly perform follow-up echocardio-
graphic evaluations, to timely detect decreased ventricular function.7 Nonetheless, the largest 
longitudinal follow-up study so far, conducted in 234 Marfan patients, did not demonstrate 
any significant changes in LV diameters and function during a median follow-up duration 
of 6 years. 8 This questioned whether the ventricular abnormalities which were observed in 
the Marfan patient population had a progressive nature. It should, however, be noted that 
the previously mentioned study relied on conventional echocardiography, whereas recent 
investigations indicated that small changes in ventricular function may remain undetected 
using these methods. In recent years, echocardiographic speckle tracking-derived strain 
imaging was introduced as a novel modality that can be used to detect clinically relevant 
but modest changes in ventricular performance.9 The aim of the current study was threefold: 
First, to assess the difference in LV and RV performance, quantified with speckle tracking-
derived strain and strain rate imaging, between patients with Marfan syndrome and healthy 
controls; Second, to investigate the association between bi-ventricular strain and strain rate 
on the one hand and clinical outcome of Marfan patients on the other hand; Third, to analyze 
whether any relevant changes in LV and RV performance occur in patients with Marfan syn-
drome, using both conventional echocardiographic measures of ventricular function as well 
as speckle tracking-derived strain and strain rate imaging.
methoDs
study population
The study population consisted of all patients with Marfan syndrome who where prospec-
tively followed at the outpatient clinic from 1-1-2000 until 11-6-2009. Marfan syndrome 
was diagnosed according to the Ghent criteria, and genetic testing for Marfan associated 
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mutations was performed in all patients.2;10 In order to investigate whether potential changes 
in ventricular function related specifically to Marfan syndrome, only patients without signifi-
cant valvular regurgitation or stenosis were selected. Patients with significant valvular heart 
disease, including moderate and severe regurgitation and any grade of valvular stenosis were 
excluded. Valvular heart disease was evaluated with colour, continuous and pulsed wave 
echocardiographic Doppler techniques applying the reference measures indicated by cur-
rent recommendations.13 The other criteria for exclusion from the analysis were: a follow-up 
duration of less than two years, documented coronary artery disease or a history of coronary 
artery disease related events, diabetes; defined as a fasting glucose ≥ 6.1 mmol/l or receiv-
ing ant-diabetic medication, or hypertension; defined as resting systolic blood pressure 
≥ 140mmHg or diastolic blood pressure ≥ 90mmHg at multiple measurements. A compre-
hensive echocardiographic evaluation was performed annually and included assessment of 
valvular function and measurement of aorta and pulmonary artery diameters. In addition, 
function of the left and right ventricle was evaluated using conventional echocardiographic 
measures and novel speckle tracking derived strain and strain rate imaging.
First, the baseline strain and strain rate values of the Marfan patients (derived from the 
first echocardiogram) were compared to the strain and strain rate values of a normal control 
population. This population comprised of consecutive patients with no history of medical 
illness and was matched for age, sex and body surface area. All patients were referred for 
echocardiography with atypical chest pain, palpitations, or syncope without murmur and did 
not show structural heart disease. Those individuals who showed LV dilatation, had known 
hypertension, or were referred for echocardiographic evaluation of known valvular disease, 
murmur, or heart failure were excluded.
In addition, to assess whether strain-derived ventricular performance was related to 
the occurrence of adverse events in Marfan patients, all cardiovascular events were noted 
during follow-up between the echocardiograms. For that purpose, cardiovascular events 
were defined as: symptomatic heart failure, (supra)ventricular arrhythmia and elective or 
emergency proximal aorta surgery. An event was noted as symptomatic heart failure when 
patients had heart failure related symptoms (E.g. dyspnea, orthopnea) which could not be 
attributed to any other disease or evidence of heartfailure during clinical investigation (E.g. 
edema, cyanosis, etc). Arrhythmias were documented when patients were symptomatic, 
or when noted on electrocardiographic evaluation during regular follow-up. Patients were 
referred for proximal aorta surgery when the diameter at the sinus of Valsalva exceeded 5cm, 
when the aorta growth exceeded 0.5 cm/y or when a family history of aortic dissection at a 
diameter < 5 cm was present.
Finally, to analyze changes in ventricular performance over time, the baseline echocardio-
gram was compared to the last follow-up echocardiogram, which was obtained at least two 
years after the baseline evaluation.
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echocardiography
Echocardiographic imaging was performed in the left lateral decubitus position on a com-
mercially available system (Vivid Seven, General Electric-Vingmed, Horten, Norway). Images 
were acquired at a depth of 16 cm in the parasternal, apical, suprasternal and subcostal views 
using a 3.5 MHz transducer. In all patients, standard M-mode and two-dimensional images 
were obtained during breath holds and three consecutive beats were saved in regular cine-
loop format. In addition, color Doppler data were acquired in all views after optimizing gain 
and Nyquist limit. Subsequently, standard continuous and pulsed wave Doppler examina-
tions were performed. The images were analyzed offline by two independent observers, 
using dedicated software for echocardiographic analysis (EchoPac version 108.1.5, General 
Electric – Vingmed, Horten, Norway).
vascular diameters and valvular function
The diameters of the aorta were measured in the parasternal long-axis view to visualize both 
the aortic root as well as the proximal part of the ascending aorta. Diameters were measured 
leading edge to leading edge at the level of the aortic annulus, the sinus of Valsalva, the sino-
tubular junction and the ascending aorta.11 The pulmonary artery diameter was assessed on 
the parasternal short-axis view at the level of the aortic valve and the diameter was measured 
in the proximal pulmonary artery, distal from the pulmonary valve.
Using color, continuous and pulsed-wave Doppler data, valvular heart disease (regurgita-
tion and stenosis) was scored semi-quantitatively according to the guidelines of the Ameri-
can Society of Echocardiography, and was graded as absent, mild, moderate and severe.12;13 
Evaluation of valvular stenosis included a qualitative assessment of morphology and motion 
of the valvular leaflets and quantification of transvalvular gradients and effective orifice 
area based on continuous and pulsed wave Doppler recordings. Valvular regurgitation was 
evaluated using an integrative approach which includes measurement of vena contracta of 
the regurgitant jet, quantification of the regurgitant volume and effective regurgitant orifice 
area with the proximal isovelocity surface area method whenever possible, and evaluation 
of atrial and ventricular dimensions. When tricuspid regurgitation was present, pulmonary 
artery pressure was estimated using the modified Bernoulli equation. Significant (clinically 




conventional measurement of ventricular function
First, conventional quantification of LV and RV systolic function was performed. For this 
purpose, LV end-diastolic volume (EDV), end-systolic volume (ESV) and ejection fraction (EF) 
were derived using the biplane Simpson’s method.11 LV volumes were indexed for body sur-
face area according to Mosteller’s formula.14 In addition, diastolic function of the left ventricle 
was assessed using pulsed-wave Doppler of the mitral valve inflow.15 The Doppler sample 
volume was placed between the tips of the mitral leaflets and subsequently the peak early (E) 
and late (A) diastolic velocities and E-wave deceleration time (DT) were measured. Further-
more, the averaged E’ of the LV septal and lateral wall was measured with color-coded tissue 
Doppler imaging and the E/E’ ratio was calculated. Thereafter, RV function was evaluated. 
First, RV diameters were measured in the apical 4-chamber view at the level of the tricuspid 
annulus (RVD1), mid RV (RVD2) and from base-to-apex (RVD3).11 Secondly, RV fractional area 
change (RVFAC) was determined using the standard formula.11 Third, the tricuspid annular 
plane systolic excursion (TAPSE) was measured in the RV free wall by placing the M-mode cur-
sor in the lateral part of the tricuspid annulus parallel to the RV free wall, and the maximum 
systolic displacement of the RV base was measured.16
measurement of ventricular strain and strain rate
In addition to the conventional measures of ventricular performance, peak strain and strain 
rate of both the left and right ventricle were assessed off-line, using speckle-tracking analysis 
software (version 108.1.5, GE Medical systems, General Electric – Vingmed, Horten, Norway).9 
17 For the current study, the peak longitudinal strain and strain rate values were calculated 
for the left and right ventricle separately. Maximum LV longitudinal strain and strain rate 
were calculated globally as the average of 18 segments which were obtained in the apical 2-, 
3- and 4-chamber view. In addition, strain and strain rate were measured circumferentially 
and radially on short-axis images of the left ventricle on the level of the papillary muscles. 
Furthermore, peak RV longitudinal strain and strain rate were determined as the average of 
three free wall segments obtained in the apical 4-chamber view.18
statistical analysis
SPSS (SPSS® 16.0 for Windows, SPSS Inc., Chicago, USA) was used for statistical analysis. Data 
are presented as mean ± SD, unless mentioned otherwise. Intraobserver reproducibility was 
determined by repeating the strain and strain rate measurements by a single observer in 
25 randomly selected patients. The patients were again analysed by the second observer to 
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provide interobserver variability. Variability was determined using Bland-Altman analysis. An 
unpaired Student’s t-test was used to test statistical significance of the differences between 
Marfan patients and healthy controls. Cox’s proportional hazard regression analysis was ap-
plied to analyze the association between strain and strain rate, on the one hand, and the 
incidence of adverse events during follow-up, on the other hand. In these analyses, strain and 
strain rate were entered as continuous variables into the regression equation. To test whether 
changes in vascular dimensions or ventricular function were statistically significant, a paired 
Student’s t-test was performed. To analyze further whether the extent of potential changes in 
ventricular function was related to age, the study group was divided according to the mean 
age at baseline, corresponding to 35 years. Thereafter, changes in ventricular function were 
analyzed separately in the group of patients who were younger than 35 years and the group 
of patients who were 35 years or older at baseline. The difference in changes in ventricular 
function between the groups was assessed with an unpaired Student’s t-test. P values <0.05 
were considered statistically significant.
results
After exclusion of 6 patients with significant valvular disease, 5 patients with other medical 
conditions besides Marfan syndrome and 10 patients with inadequate follow-up duration 
(<2 years), 50 patients were included in the analysis. Characteristics of those patients are 
summarized in Table 1. Exactly 50% of the patient population was male and all patients were 
adult at time of inclusion. A Marfan-related genetic mutation was found in 37 patients (74%). 
table 1. Patient population. 
male/female (n) 25/25
genetic mutation(n,%) 37 (74%)
 Fibrillin-1 (n,%) 35 (70)
 Transforming growth factor 2 receptor (n,%) 2 (4%)
cardioprotective medication (n=46) 96%
 Beta blocker (n, %) 25 (50%)
 ARB (n, %) 8 (16%)
 ACE inhibitors (n, %) 2 (4%)
 Combination (n, %) 11 (22%)
baseline echocardiogram
 Age (years) 35.5 ± 13.1
 BSA (m2) 2.0 ± 0.3
Age at follow-up echocardiogram
 Age (years) 39.0 ± 13.1
 BSA (m2) 2.0 ± 0.2
Follow-up time (yrs) 3.9 ± 1.2
ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; BSA: body surface area.
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A pathologic mutation in the fibrillin-1 gene was identified in 35 patients (70 %), whereas in 2 
patients (4 %) a pathologic mutation in the transforming growth factor 2 receptor was found.
 Most patients used a beta-blocker, an angiotensin-converting enzyme inhibitor or an 
angiotensin-receptor blocker, though a combination was also frequently applied (22%; see 
Table 1). Mean age during baseline echocardiographic evaluation was 35.2 ± 12.9 years and 
the median follow-up duration was 4 years.
The age of the control group was 34.8 ± 8.1 years, which was comparable with the Marfan 
population (P=0.75). Body surface area, which was 1.94 ± 0.18 in the control population did 
not differ significantly from the Marfan patient population, (P=0.23). In addition, the number 
of male subjects was not statistically different in the control population (n=29, 58%) as com-
pared to the Marfan population (P=0.55).
The intra- and interobserver agreement for biventricular strain and strainrate assessment 
was good. The intraobserver variability of LV longitudinal strain and strainrate was 0.19 ± 2.11% 
and 0.01 ± 0.26%/s, respectively. The intraobserver variability of RV longitudinal strain and 
strainrate was 0.41 ± 1.45% and 0.03 ± 0.37%/s. The interobserver variability of LV longitudinal 
strain and strainrate was 0.40 ± 2.95% and 0.02 ± 0.21%/s, whereas the interobserver variabil-
ity of RV longitudinal strain and strainrate was 0.30 ± 1.82% and 0.01 ± 0.38 %/s, respecrively.
ventricular strain and strain rate: comparison between marfan Patients and 
healthy controls
Strain and strain rate values, in addition to standard echocardiographic measures (see 
Supplemental Table 2), of 50 healthy control subjects were compared to the strain and strain 
rate values of the 50 Marfan patients (Figure 1).
A consistent difference in longitudinal strain and strain rate values of the left and right 
ventricle was observed between patients with Marfan syndrome and healthy controls. Mean 
peak LV longitudinal strain was -20.1 ± 1.9% and strain rate was -1.07 ± 0.18%/s in normal 
controls, whereas this was -18.9 ± 2.3 % (p<0.01) and -0.99 ± 0.19%/s (p=0.03), respectively, 
in the Marfan population (Figure 1). A similar difference in mean peak RV longitudinal strain 
(-29.3 ± 4.25% vs. -26.9 ± 5.2%, p=0.01) and strain rate (-1.65 ± 0.30%/s vs. -1.48 ± 0.31%/s, 
p<0.01) was observed between normal controls and Marfan patients, see Figure 1. Mean peak 
LV circumferential strain rate was significantly lower in Marfan patients (-1.13 ± 0.24%/s) as 
compared to the control population (-1.29 ± 0.27%/s), p<0.01, whereas mean peak LV circum-
ferential strain did not demonstrate to be significantly different. Finally, mean peak LV radial 
strain and strain rate were not significantly different between the groups.
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Adverse cardiovascular events and Association with baseline strain and strain 
rate
During a mean follow-up duration of 3.9 ± 1.2 years of the Marfan population, 7 cardiovascular 
events occurred. No episodes of symptomatic heart failure were observed. Arrhythmias oc-
curred in 3 patients (6%) and existed of atrio-ventricular nodal reentrant tachycardia (n=2) 
and atrial fibrillation (n=1). Proximal aorta surgery was performed in 4 patients (8%), either 
due to aneurysmatic widening of the proximal aorta (n=2) or a type A aortic dissection (n=2). 
Univariate Cox’s regression analysis revealed that none of the baseline strain or strain rate 
values was related to the incidence of adverse events (See Table 2).
table 2. Association between cardiovascular events and biventricular strain. 
variable hr 95% ci p-value
strain
 LV longitudinal 1.08 0.74-1.58 0.68
 LV radial 0.96 0.88-1.03 0.26
 LV circumferential 1.01 0.81-1.24 0.96
 RV longitudinal 0.94 0.79-1.10 0.43
strain rate
 LV longitudinal 12.96 0.25-683.01 0.21
 LV radial 1.05 0.24-4.60 0.95
 LV circumferential 1.13 0.35-36.27 0.95
 RV longitudinal 0.46 0.04-5.50 0.54



















Figure 1. Ventricular strain and strain rate: Comparison between Marfan patients and healthy controls. 
The bars denote the means with corresponding standard deviations of the strain and strain rate values in 
normal controls and Marfan patients. The white bars represent normal controls and the black bars indicate 
Marfan patients. Strain and strain rate values were significantly higher in normal control subjects as com-
pared to Marfan patients. The difference, however, was small. Sr: strain rate.
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changes in vascular Diameters and conventional measures of ventricular 
Function
Overall, a significant increase in vascular diameters was consistently observed during follow-
up, as summarized in Table 3. A small increase in diameter was observed in the aortic valve 
annulus, sinus of Valsalva (including Z-score) and sino-tubular junction. In addition, moder-
ate widening was also noted in the ascending aorta and the trunk of the pulmonary artery. 
In contrast with vascular diameters, LV volumes and function remained unchanged during 
follow-up of the study population, as summarized in Table 2. At baseline, mean LV EDV was 
mildly enlarged, however, after correction for body surface area, mean LV EDV was within 
normal limits. LV EDV was 64 ± 19 ml/m2 at baseline and 64 ± 12 ml/m2 at follow-up, indicating 
table 3. Vascular diameters and conventional measures of ventricular function.
baseline Follow-up mean Δ p-value
vascular diameters
 Annulus (cm) 2.5 ± 0.3 2.6 ± 0.3 0.1 ± 0.3 0.01
 Sinus Valsalva (cm) 3.8 ± 0.5 4.0 ± 0.5 0.2 ± 0.3 <0.01
 Z-score (mean, range) 2.5 (-1.1-9.8) 3.2 (-1.4-10.2) 0.76 (-1.2-4.2) <0.01
 ST junction (cm) 3.1 ± 0.4 3.3 ± 0.4 0.2 ± 0.3 <0.01
 Asc Aorta (cm) 3.1 ± 0.4 3.4 ± 0.5 0.3 ± 0.4 <0.01
 Pulmonary artery (cm) 2.4 ± 0.4 2.6 ± 0.4 0.2 ± 0.3 <0.01
lv systolic function
 LV EDV (ml) 128 ± 36 133 ± 29 5 ± 24 0.19
 LV EDV index (ml/m2) 64 ± 19 64 ± 12 0 ± 20 0.89
 LV ESV (ml) 48 ± 18 49 ± 17 1 ± 14 0.49
 LV ESV index (ml/m2) 24 ± 9 24 ± 7 0 ± 9 0.73
 LV EF (%) 63 ± 6 63 ± 8 0 ± 7 0.67
lv Diastolic function
 E (m/s) 0.73 ± 0.17 0.73 ± 0.14 -0.01 ± 0.15 0.77
 A (m/s) 0.54 ± 0.12 0.56 ± 0.16 0.02 ± 0.13 0.26
 E/A 1.41 ± 0.41 1.37 ± 0.35 -0.04 ± 0.43 0.43
 E’ (m/s) 0.09 ± 0.02 0.08 ± 0.02 0.00 ± 0.02 0.20
 E/E’ 8.56 ± 2.03 9.01 ± 2.74 0.45 ± 1.87 0.11
lA dimensions
 LA diameter (cm) 3.6 ± 0.6 3.6 ± 0.7 0.0 ± 0.6 0.40
 LA index (cm/m2) 1.6 ± 0.7 1.7 ± 0.7 0.1 ± 0.8 0.37
rv systolic function
 RVD 1 (cm) 3.4 ± 0.6 3.5 ± 0.5 0.1 ± 0.6 0.26
 RVD 2 (cm) 3.5 ± 0.6 3.6 ± 0.7 0.2 ± 0.6 0.24
 RVD 3 (cm) 7.4 ± 0.9 7.5 ± 1.0 0.1 ± 1.0 0.63
 RVFAC (%) 39 ± 7 39 ± 7 1 ± 9 0.62
 TAPSE (cm) 2.1 ± 0.5 2.1 ± 0.5 0 ± 0.4 0.62
Asc: ascending; EDV: end diastolic volume; EF: ejection fraction; ESV: end systolic volume; LV: left ventricu-
lar; RVD 1: tricuspid annulus diameter; RVD 2: mid right ventricular diameter; RVD 3: base-to-apex diameter; 
RVFAC: right ventricular fractional area change; ST: sino-tubular; TAPSE: tricuspid annular plane systolic ex-
cursion.
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that LV EDV was not subject to changes. Analogously, no relevant changes in LV ESV and LV 
EF were observed. Mean LV ESV was 24 ml/m2 and mean LV EF was 63% both at baseline and 
at follow-up. In addition to systolic LV function parameters, no changes in the measures of LV 
diastolic function or left atrial diameter were noted during follow-up (Table 3).
In concordance with LV systolic and diastolic function, no changes in RV function as 
measured with conventional echo measures were noted. During follow-up, a non-significant 
increase of 0.1 ± 0.6 cm of the tricuspid annulus, of 0.2 ± 0.6 cm in the mid RV and of 0.1 ± 
1.0 cm of the base-to-apex diameter, was found. In addition, RV function, as estimated with 
TAPSE and RVFAC, demonstrated to be unchanged at follow-up (Table 3).
changes in biventricular strain and strain rate
Full assessment of LV and RV strain was performed at baseline and at follow-up in the patient 
population. A summary of strain characteristics is provided in Table 4.
Mean peak LV longitudinal strain was -18.9 ± 2.3 %, at baseline, with a maximum longi-
tudinal strain rate value of -0.99 ± 0.19 %/s. At follow-up, peak LV longitudinal strain was 
-18.8 ± 2.5 and strain rate was -1.01 ± 0.16, showing that a similar strain pattern was observed 
at follow-up. In addition, LV radial and circumferential strain and strain rate also remained 
unchanged during follow-up, as noted in Table 4. For the right ventricle, the mean peak 
longitudinal strain value was -26.9 ± 5.2 % at baseline and -26.0 ± 4.9% at follow-up and the 
mean strain rate value was -1.48 ± 0.31 %/s at the baseline evaluation and -1.43 ± 0.40 %/s, at 
follow-up, indicating that RV performance did not deteriorate.
To further investigate whether any relevant changes in myocardial performance occurred 
in the study population, patients were stratified according to the mean age at the baseline 
echocardiographic evaluation, which was 35 years. Patients who were younger than 35 years 
table 4. Changes in strain and strain rate of the left and right ventricle. LV: left ventricular; RV: right ven-
tricular.
baseline Follow-up mean Δ p-value
lv longitudinal
 Strain (%) -18.9 ± 2.3 -18.8 ± 2.5 0.1 ± 2.8 0.79
 Strain rate (%/s) -0.99 ± 0.19 -1.01 ± 0.16 -0.02 ± 0.20 0.55
lv radial
 Strain (%) 38.3 ± 14.4 39.4 ± 12.8 1.12 ± 7.6 0.66
 Strain rate (%/s) 1.64 ± 0.55 1.77 ± 0.53 0.13 ± 0.63 0.17
lv circumferential
 Strain (%) -20.5 ± 4.0 -20.2 ± 4.3 0.3 ± 3.7 0.60
 Strain rate (%/s) -1.13 ± 0.24 -1.15 ± 0.27 -0.02 ± 0.28 0.64
rv longitudinal
 Strain (%) -26.9 ± 5.2 -26.0 ± 4.9 0.9 ± 5.5 0.28
 Strain rate (%/s) -1.48 ± 0.31 -1.43 ± 0.40 0.05 ± 0.38 0.42
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of age (n=27), were compared to patients who were 35 years or older (n=23). The changes in 
strain during follow-up were then compared between both age groups, as depicted in Figure 
2. In the patients who were younger than 35 years of age at the baseline evaluation, similar 
strain and strain rate values were observed at baseline and at follow-up. Analogously, no 
changes in strain and strain rate values were observed in the patients who were 35 years or 
older during the baseline evaluation.
Discussion
In the current study, LV and RV performance was followed in a population of Marfan patients 
without significant valvular disease, using novel and conventional echocardiographic tools. The 
key findings were that patients with Marfan syndrome have impaired biventricular longitudinal 
strain and strain rate values although RV and LV ejection fraction were preserved; in addition, 
none of the occurring cardiovascular events was related to ventricular performance in this se-
lected cohort of patients with Marfan syndrome; Finally, the increase in vascular diameters dur-
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Figure 2. Left and right ventricular strain and strain rate stratified by age at baseline. Means and standard 
deviations of the strain and strain rate values in the Marfan patients at baseline and at follow-up. Patients 
<35 years at baseline are represented by the grey boxes with dashed connecting lines, whereas the patients 
≥35 years during the baseline evaluation are represented by the black triangles with uninterrupted con-
necting lines. There was no difference in strain and strain rate values between patients who were <35 years 
and patients ≥35 years during the baseline evaluation. In addition, no significant changes were observed 
during follow-up. LV: left ventricular; RV: right ventricular; Sr: strain rate.
129
BIVENTRICULAR PERFORMANCE IN MARFAN SYNDROME
Assessment of lv and rv performance in marfan syndrome
The Marfan associated mutations in the fibrillin-1 gene7 and alterations in transforming 
growth factor β-signaling pathways19 ensue in a deterioration of the cardiac connective tissue 
integrity. These abnormalities have been previously associated with impairment of LV and 
RV performance in Marfan syndrome6;20 and it is advocated in the guidelines to screen for 
ventricular dysfunction periodically in patients with Marfan syndrome.21
To date, the two studies that prospectively followed LV performance in Marfan patients 
without significant valvular regurgitation demonstrated no significant changes in LV func-
tion over time. In the first study, by Chatrath et al., it was demonstrated in a small population 
of 36 children and adults with Marfan syndrome, that the left ventricle did not change in size 
during follow-up.22 In a far larger study, by Meijboom et al., which included 234 adult Marfan 
patients, it was shown that LV diameters and fractional shortening did not change.8
The present study confirmed that LV volumes and ejection fraction did not change during 
a median follow-up duration of 4 years. In addition, LV diastolic function, assessed with LV 
inflow characteristics and tissue velocities, did not demonstrate any changes during follow-
up. Furthermore, the present study demonstrated that RV diameters and function remained 
unchanged during follow-up. This indicates that conventional assessment of both LV and 
RV function does not reveal any relevant changes during a median follow-up of 4 years. 
Nonetheless, until now, it remained unknown whether the assessment of myocardial tissue 
properties with novel echocardiographic techniques demonstrates significant changes in LV 
and RV performance in Marfan patients during follow-up. Therefore, longitudinal follow-up 
of novel echocardiographic indices of ventricular performance, based on speckle tracking-
derived strain and strain rate, were analyzed for the first time in the current Marfan popula-
tion. These analyses demonstrated that LV and RV performance did not change in the study 
population and further stratification of the population into older and younger patients, could 
also not reveal any relevant changes in ventricular performance during follow-up.
ventricular performance and clinical outcome in marfan syndrome
A significant difference in LV and RV performance was observed between Marfan patients 
and a population of healthy controls in the current study. Peak LV and RV strain and strain 
rate values were significantly lower in Marfan patients, which confirms the findings from 
previous studies.5;6 However, as heart failure symptoms are uncommon in Marfan patients, 
the clinical relevance of this difference depends on potential progressiveness of ventricular 
dysfunction and on the incidence of ventricular dysfunction-related events. Previous studies 
that aimed to evaluate the natural history of ventricular function in Marfan syndrome did not 
provide information on the incidence of ventricular dysfunction-related events. In the cur-
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rent population, adverse cardiovascular events occurred in 7 patients. None of these events 
(AV nodal reentrant tachycardia, atrial fibrillation and proximal aorta complications) is known 
to be related to the presence of ventricular dysfunction in Marfan patients.23 In addition, no 
episodes of symptomatic heart failure were observed in the current analysis. Therefore, it 
could be postulated that the observed difference in ventricular strain values between nor-
mal controls and Marfan patients did not demonstrate to be clinically relevant in terms of 
progressive ventricular deterioration or patient outcome. The results of the Cox’s regression 
analysis in the present evaluation confirmed that there is no relation between ventricular 
performance and clinical outcome.
Numerous studies have shown that dilatation of the aorta and pulmonary artery is one 
of the key aspects of the cardiovascular phenotype of patients with Marfan syndrome.24;25 
Progressive widening of, specifically, the proximal aorta is a regular phenomenon, which 
causes most of the cardiovascular complications of the disease.26 In the current study, widen-
ing of the aorta and pulmonary artery was also observed. In addition, most of the events 
that occurred during follow-up were related to the proximal aorta. This underscores that 
the progressive nature of the disease was present in the currently evaluated patient popula-
tion. Progressive impairment of ventricular performance, on the other hand, could not be 
demonstrated in the study population, which was free of significant valvular disease. This 
may indicate that, in contrast with the vascular phenotype of Marfan syndrome, ventricular 
dysfunction does not have a strongly progressive nature. Possibly, another cardiac stressor 
besides the presence of Marfan syndrome is required to evoke deterioration of ventricular 
function in Marfan patients. E.g., the presence of significant valvular regurgitation may be 
crucial to induce overt ventricular dysfunction. This concept is underscored by animal studies 
in which the function of fibrillin-1 was investigated. In this study on rats, fibrillin-1 expression 
was specifically enhanced when myocardial stress was induced, indicating that a lack of fibril-
lin-1 function may not become apparent under normal, physiological conditions.27
Although the present study does not demonstrate progressive ventricular dysfunction, mea-
sured with biventricular strain and strainrate, careful follow-up is warranted in Marfan patients. 
Since strain and strainrate measurement provide a sensitive technique to detect subtle changes 
in ventricular performance, regular assessment of these measurements over a longer follow-up 
period could be useful. This, however, needs to be confirmed in future studies.
limitations
In the current study, patients with other conditions besides Marfan syndrome were excluded 
from the analysis, since the study was aimed at investigating Marfan-related deterioration of 
ventricular performance only. Potentially, this may have led to a selection-bias towards inclu-
sion of patients with a mild cardiovascular phenotype. It could be postulated that moderate 
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valvular disease in patients with Marfan syndrome may lead to more rapid deterioration of 
ventricular function as compared to controls. Such observations cannot be made from the 
current study population. To address this point, future studies should also include Marfan 
patients with variable forms of valvular and non-valvular cardiac disease.
In addition, most of the patients used cardioprotective medication such as beta-blockers, 
angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Long-term use of 
these medications may prevent ventricular deterioration in patients with Marfan syndrome. 
However, since the number of patients without medication was low, the effect on ventricular 
function could not be assessed separately.
Furthermore, it would be interesting to assess whether any association exists between 
the type of fibrillin-1 or transforming growth factor β 2 receptor mutation and bi-ventricular 
strain patterns. Since a large variety of Marfan associated mutations exists, the current patient 
population was regarded too small to evaluate such a relationship.
In the current evaluation, 2D speckle tracking was used to assess biventricular strain and 
strain rate. For reliable analysis, sufficient image quality and frame rate is required. In the 
current population, speckle tracking analysis could be performed in all patients. It should 
however be noted that this may not be possible in patients with extensive thoracic deformi-
ties.
conclusion
In our study, patients with Marfan syndrome had significantly lower mean peak left and right 
ventricular strain and strain rate values as compared to healthy control subjects. However, 
most events that occur during follow-up do not appear to be related to ventricular dysfunc-
tion and there is no association between the incidence of adverse outcome and reduced 
ventricular strain and strain rate. In addition, despite progressive dilatation of the aorta and 
pulmonary artery, no relevant changes in left and right ventricular performance occur during 
mid-term follow-up of patients with Marfan syndrome in whom significant valvular disease 
is absent at baseline.
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supplemental table 1. Vascular diameters and conventional measures of ventricular function in Marfan 
patients as compared to controls.
marfan controls p-value
vascular diameters
 Annulus (cm) 2.5 ± 0.3 2.1 ± 0.2 <0.01
 Sinus Valsalva (cm) 3.8 ± 0.5 3.2 ± 0.4 <0.01
 ST junction (cm) 3.1 ± 0.4 2.6 ± 0.2 <0.01
 Pulmonary artery (cm) 2.4 ± 0.4 1.7 ± 0.2 <0.01
lv systolic function
 LV EDV (ml) 128 ± 36 116 ± 19 0.04
 LV EDV index (ml/m2) 64 ± 19 59 ± 8 0.09
 LV ESV (ml) 48 ± 18 43 ± 15 0.13
 LV ESV index (ml/m2) 24 ± 9 22 ± 7 0.22
 LV EF (%) 63 ± 6 64 ± 3 0.29
lv Diastolic function
 E (m/s) 0.73 ± 0.17 0.78 ± 0.13 0.10
 A (m/s) 0.54 ± 0.12 0.57 ± 0.13 0.23
 E/A 1.41 ± 0.41 1.47 ± 0.39 0.45
 E’ (m/s) 0.09 ± 0.02 0.11 ± 0.03 <0.01
 E/E’ 8.56 ± 2.03 7.13 ± 1.6 <0.01
rv systolic function
 RVD 1 (cm) 2.7 ± 0.3 <0.01
 RVD 2 (cm) 3.1 ± 0.2 <0.01
 RVD 3 (cm) 7.3 ± 0.3 0.45
 RVFAC (%) 42 ± 5 0.02
 TAPSE (cm) 2.4 ± 0.3 <0.01
Asc: ascending; EDV: end diastolic volume; EF: ejection fraction; ESV: end systolic volume; LV: left ventricu-
lar; RVD 1: tricuspid annulus diameter; RVD 2: mid right ventricular diameter; RVD 3: base-to-apex diameter; 
RVFAC: right ventricular fractional area change; ST: sino-tubular; TAPSE: tricuspid annular plane systolic ex-
cursion.
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Data on the association between right ventricular (RV) function and adverse events after 
acute myocardial infarction (AMI) are scarce. The purpose of the current study was to evalu-
ate the relation between RV function and adverse events, in patients treated with primary 
percutaneous coronary intervention (PCI) for AMI.
methods and results
Consecutive patients admitted with AMI treated with primary PCI underwent echocardiogra-
phy within 48 hours of admission to assess left ventricular and RV function. RV function was 
quantified with RV fractional area change (RVFAC), tricuspid annular plane systolic excursion 
(TAPSE) and RV strain. The endpoint was defined as a composite of all-cause mortality, rein-
farction and hospitalization for heart failure. All patients (n=621) were followed prospectively 
and during a mean follow-up of 24 months, 86 patients reached the composite endpoint. 
RVFAC, TAPSE and RV strain were all univariable predictors of worse outcome. After multivari-
able analysis, only RVFAC (HR 0.96, 95%CI 0.92–0.99) and RV strain (HR 1.08, 95%CI 1.03–1.13) 
independently predicted the composite endpoint. In addition, RV strain provided incremen-
tal value to clinical information, infarct characteristics, left ventricular function and RVFAC.
conclusions
RV function provides strong prognostic information in patients treated with primary PCI for 
AMI.
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introDuction
The prognosis of patients after acute myocardial infarction (AMI) is determined by the inter-
action of a large number of factors. Besides the importance of clinical parameters, several 
studies have described the use of two-dimensional (2D) echocardiography for the identifica-
tion of patients who are at risk of adverse outcome.1 These investigations revealed that the 
presence of left ventricular (LV) dysfunction, on 2D-echocardiography shortly post-AMI, is 
one of the most important prognostic parameters.2, 3 Therefore, noninvasive assessment of LV 
function has become essential for post-AMI risk stratification.
The relevance of right ventricular (RV) function, on the other hand, is poorly defined in 
post-AMI patients. The involvement of the RV during inferior AMI has been defined as a strong 
predictor of major complications and in-hospital mortality.4, 5 Some evidence is available that 
RV dysfunction is associated with an adverse prognosis in post-AMI patients with moderate to 
severe LV dysfunction.6, 7 In patients who undergo primary percutaneous coronary interven-
tion (PCI), however, the degree of LV dysfunction is generally mild and the clinical relevance 
of RV dysfunction in that currently growing population of post-AMI patients is unknown. 
Therefore, the aim of the current study was to investigate the relation between RV function 
and adverse events, in post-AMI patients treated with primary PCI. In addition to traditional 
measurements that are recommended to quantify RV function with 2D-echocardiography, 
RV strain was assessed. This novel technique enables direct quantification of myocardial 
deformation and is a sensitive tool to detect RV dysfunction.8–11
methoDs
Patient selection and study Protocol
Since February 2004, consecutive patients admitted with AMI, treated with primary PCI were 
included in an ongoing registry. All patients were treated according to the institutional 
AMI protocol, which is driven by the most recent guidelines.1 This protocol, designed to im-
prove care around AMI, includes structurized medical therapy and outpatient follow-up, as 
described previously.12 In addition, 2D-echocardiography is performed within 48 hours of 
admission. This echocardiogram was used to assess LV and RV function. All patients were 
followed prospectively and the occurrence of adverse events was noted. Patients of whom 
more than 6 months follow-up data were lacking, were considered as lost to follow-up, and 




Images were obtained with patients in the left lateral decubitus position using a commer-
cially available system (Vivid 7, General Electric-Vingmed, Horton, Norway). Data acquisition 
was performed at a depth of 16cm in parasternal and apical views using a 3.5-MHz transducer. 
During breath hold, M-mode and 2D-images were obtained and 3 consecutive beats were 
saved in cine-loop format. Analysis was performed offline by 2 independent observers using 
dedicated software (EchoPac version 108.1.5, General Electric-Vingmed). The reference limits 
of all echocardiographic parameters were defined according to the American Society of 
Echocardiography’s Guidelines.13
The LV end-systolic volume (LVESV), end-diastolic volume (LVEDV) were assessed and LV 
ejection fraction (LVEF) was calculated using the biplane Simpson’s method.13 In addition, 
the LV was divided into 16 segments and each segment was analyzed individually and scored 
based on its motion and systolic thickening (1=normokinesis, 2=hypokinesis, 3=akinesis, 
4=dyskinesis). Subsequently, wall motion score index (WMSI) was calculated as the sum of 
the segment scores divided by the number of segments scored.13
Left atrial (LA) size was quantified by calculating the volume according to the ellipsoid 
model.13 Severity of mitral regurgitation (MR) was graded semiquantitatively from the jet area 
of color-flow Doppler data and by measuring the width of the vena contracta. MR was char-
acterized as: mild=jet area/LA area < 20% and vena contracta width < 0.3 cm, moderate=jet 
area/LA area 20% to 40% and vena contracta width 0.3–0.69 cm, and severe=jet area/LA area 
> 40% and vena contracta width ≥ 0.7 cm.14
Tricuspid regurgitation (TR) severity was graded based on jet/right atrial area ratio. When 
the jet area occupied < 10% of the right atrial area, TR was graded as trivial, when it occupied 
10% to < 20% as mild, when it occupied 20% to < 33% as moderate, and when it occupied ≥ 
33% as severe.15 In addition, the diameter of inferior vena cava and its respiratory variation 
were measured 1.0–2.0 cm from the junction with the right atrium in the subcostal view, as 
recommended by the guidelines.13
To assess diastolic function, pulsed-wave Doppler of the mitral valve inflow was obtained 
by placing the sample volume between the tips of the mitral leaflets. Peak early (E) and late 
(A) diastolic velocities and deceleration time (DT) were measured. The E/E’-ratio was obtained 
by dividing E by E’, which was measured using color-coded tissue Doppler imaging at the 
septal side of the mitral annulus in the apical 4-chamber view.16–18
right ventricular Function Analysis
RV fractional area change (RVFAC) was analyzed by tracing the RV end-diastolic area (RVDA) 
and end-systolic area (RVSA) in the apical 4-chamber view using the formula: (RVDA−RVSA)/
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RVDA×100.13 Tricuspid annular plane systolic excursion (TAPSE) was measured in the RV free 
wall. In the 4-chamber view, the M-mode cursor was placed through the tricuspid annulus in 
such a way that the annulus moved along the M-mode cursor and the total displacement of 
the RV base from end-diastole to end-systole was measured.19
Peak systolic longitudinal strain of the RV free wall was measured in the 4-chamber view 
using speckle-tracking analysis.20 This novel software analyzes motion by tracking frame-to-
frame movement of natural acoustic markers in 2 dimensions. All images were recorded with 
a frame rate of > 40fps for reliable analysis. The RV endocardial border was manually traced 
at end-systole and the automatically created region of interest was adjusted to the thickness 
of the myocardium. Peak systolic longitudinal strain was determined in the 3 segments of 
the RV free wall (basal, mid and apical) and RV strain was calculated as the mean value of 
all segments. Segments were discarded if tracking was of poor quality. Strain analysis was 
feasible in 85% of segments.
statistical Analysis
Continuous data are presented as mean±standard deviation and categorical data are 
presented as frequencies and percentages. Differences in characteristics between patient 
groups were evaluated using the unpaired Student’s t-test and chi-square test.
The primary aim was to assess the association between RV function and adverse events 
after adjusting for clinical and echocardiographic covariates. Separate multivariable models 
were constructed for RVFAC, TAPSE and RV strain using Cox proportional hazards analysis to 
evaluate the individual prognostic importance of the different RV function measurements. 
Selection of parameters for consideration for entry  in the multivariable models was based 
both on clinical judgment and univariable statistical significance. Based on these consid-
erations, adjustments in the multivariable models were made for  age, Killip class ≥ 2, right 
coronary artery (RCA) as culprit vessel, multivessel disease, peak cardiac troponin T (cTnT) 
level, LVEF, WMSI, E/E’-ratio and moderate or severe MR. Peak creatine phosphokinase level 
and LVESV were not included in multivariable analyses to avoid co-linearity with peak cTnT 
level and LVEF.
In addition, multiple variable analysis was performed for all events individually. Nonfatal 
reinfarction was defined based on criteria of typical chest pain, elevated cardiac enzyme 
levels, and typical changes on the electrocardiogram.21 Hospitalization for heart failure (HF) 
was defined as hospitalization for new onset or worsening HF. As only a small number of 29 
patients reached the endpoint of HF, no further subdivision was made for the cause of HF.
To further investigate the clinical relevance of RV dysfunction, the population was stratified 
into 2 groups according to RV function. For RVFAC and TAPSE, cut-offs were defined accord-
ing to the guidelines; 32% and 1.5 cm, respectively.13 The normal value of RV strain has been 
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reported to be -29.3±3.6%.22 Patients were therefore divided according to the mean value 
plus 2SDs, which is the lower limit of normal RV strain (-22.1%). Event rates were plotted in 
Kaplan-Meier curves for the composite endpoint and the study population divided by the 
previously mentioned cut-offs, and groups were compared using the log-rank test. The date 
of last contact for patients without events was used in Kaplan-Meier analysis. Finally, univari-
able and multivariable Cox proportional hazards analyses were performed for RVFAC, TAPSE 
and RV strain, dichotomized by the cut-offs.
The incremental value of RV function in addition to known risk factors for adverse outcome 
(age, Killip class ≥ 2, RCA as culprit vessel, multivessel disease, peak cTnT level, LVEF, WMSI, 
E/E’-ratio and moderate or severe MR), was established. For this purpose, those characteris-
tics were entered in the Cox proportional hazard model in a stepwise fashion. Subsequently, 
RVFAC and RV strain were entered individually. In addition, RV strain was entered into the 
model of RVFAC, to test further incremental value. Global chi-square values including signifi-
cance levels were calculated.
All statistical tests were two-sided, and a P value <0.05 was considered statistically signifi-
cant.
results
Patient characteristics and Follow-up
A total of 682 patients were included. Nine (1.3%) patients died before echocardiographic 
assessment could be performed, and in 22 (3.2%) patients echocardiographic assessment was 
not available within 48 hours of admission due to logistic reasons. Thirty patients (4.4%) were 
lost to follow-up and were excluded from further analysis. The study population consisted of 
the remaining 621 consecutive patients admitted with AMI treated with primary PCI. Tables 1 
and 2 summarize the clinical and echocardiographic characteristics of the population. Mean 
age was 60±12 years and most patients were men (78%). Mean LVEF, RVFAC, TAPSE and RV 
strain were 45±8%, 37±9% and 1.7±0.2 cm and -22±7%, respectively.
Fifty-seven patients (10%) presented with congestive HF defined as Killip class ≥ 2. Patients 
with congestive HF had significantly lower TAPSE (1.6±0.2 cm vs. 1.7±0.2 cm, P=0.01) and RV 
strain (-19±6% vs. -22±7%, P=0.02). No differences were observed in RVFAC and patients with 
and without congestive HF (37±10% vs. 37±9%, P=0.71).
The RCA was the culprit vessel in 217 patients (35%). No differences in RVFAC (36±9% vs. 
38±9%, P=0.07), TAPSE (1.7±0.2 cm vs. 1.7±0.2 cm, P=0.28) and RV strain (-21±7% vs. -22±7%, 
P=0.38) were observed in patients with and without inferior AMI.
LV dysfunction (defined as LVEF < 40%) was observed in 151 patients (24%). When compar-
ing RV function in patients with and without LV dysfunction, no significant differences were 
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observed in RVFAC (37±9% vs. 38±9%, P=0.31) and RV strain (-21±7% vs. -22±7%, P=0.09). 
However, TAPSE was significantly lower in patients with LV dysfunction compared to patients 
without LV dysfunction (1.6±0.2 cm vs. 1.7±0.2 cm, P=0.02).
TAPSE was the only RV function measurement that differed significantly in patients with 
multivessel disease compared to patients without multivessel disease (1.6±0.2 cm vs. 1.7±0.2, 
P=0.03).
During a mean follow-up of 24±15 months, 86 patients (14%) reached the composite 
endpoint: 51 patients died (8%), 16 patients (3%) had a nonfatal reinfarction and 29 patients 
(5%) were hospitalized for HF. Differences in clinical and echocardiographic characteristics 
between patients who reached the composite endpoint and patients who remained event-
free are shown in Tables 1 and 2.







P (event vs. 
event-free)
Age (years) 60±12 65±14 60±11 0.001
Male gender 486 (78%) 67 (78%) 419 (78%) 0.93
Killip class ≥ 2 57 (10%) 26 (33%) 31 (6%) <0.001
Current smoking 313 (51%) 42 (49%) 271 (51%) 0.83
Diabetes 61 (10%) 14 (16%) 47 (9%) 0.03
Family history of CAD 253 (41%) 28 (33%) 225 (42%) 0.11
Hyperlipidemia 125 (20%) 19 (22%) 106 (20%) 0.64
Hypertension 190 (31%) 34 (40%) 156 (29%) 0.05
Prior myocardial infarction 45 (7%) 13 (15%) 32 (6%) 0.002
RCA culprit vessel 217 (35%) 22 (26%) 195 (36%) 0.05
Multivessel disease 300 (49%) 53 (63%) 247 (46%) 0.004
TIMI flow 0.11
0–1 5 (1%) 2 (2%) 3 (1%)  
2 28 (5%) 6 (7%) 22 (4%)  
3 588 (95%) 78 (91%) 510 (95%)  
Peak CPK level (U/l) 2508±2116 4014±3046 2266±1815 <0.001
Peak cTnT level (μg/l) 7.1±7.0 12.8±11.3 6.2±5.5 <0.001
Medication at 6-months follow-up
ACE inhibitor/ARB 575 (98%) 55 (98%) 520 (98%) 0.82
Antiplatelets 588 (100%) 56 (100%) 532 (100%) 1.00
Beta-blocker 538 (92%) 52 (93%) 486 (91%) 0.70
Statin 578 (98%) 55 (98%) 523 (98%) 0.96
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; CAD: coronary artery disease; 




right ventricular Function and Association with outcome
Table 3 shows the significant univariable predictors of the composite endpoint. In addition to 
clinical characteristics and echocardiographic measurements of LV function, RV function sig-
nificantly predicted worse outcome. RVFAC, TAPSE and RV strain were univariable predictors 
of the composite endpoint. After adjusting RVFAC, TAPSE and RV strain for other variables 
that predicted adverse outcome, RVFAC and RV strain independently predicted the occur-
rence of the composite endpoint (Tables 4 and 5). However, TAPSE did not remain significant 
in the multiple variable analysis (HR 0.88, 95%CI 0.16–4.81, P=0.88).
In addition, analysis was performed for RVFAC, TAPSE and RV strain dichotomized according 
to normal and abnormal RV function with the above described cut-offs. Univariable analysis 
performed with the cut-offs demonstrated a HR of 2.22 (95%CI 1.39–3.54, P=0.001) for RVFAC. 
For TAPSE and RV strain, HRs of 4.00 (95%CI 2.45–6.53, P<0.001) and 3.43 (95%CI 1.87–6.29, 
P<0.001) were observed, demonstrating better discriminative power than RVFAC. Multiple 
variable analysis performed with the cut-offs showed smaller HRs of 1.97 (95%CI 1.10–3.55, 
P=0.02) for RVFAC, 2.19 (95%CI 1.17–4.12, P=0.02) for TAPSE and 2.18 (95%CI 1.10–4.29, P=0.03) 
for RV strain.
Kaplan-Meier curves for the cut-offs of RVFAC, TAPSE and RV strain and the composite end-
point are shown in Figure 1. The 4-year event rate in patients with RVFAC < 32% (n=145) was 








 (event vs. event-free)
LVESV (ml) 58±22 67±32 56±20 0.006
LVEDV (ml) 105±34 111±43 104±33 0.20
Left ventricular ejection fraction (%) 45±8 41±9 46±8 <0.001
Wall motion score index 1.5±0.3 1.7±0.3 1.5±0.3 <0.001
E/A-ratio 1.0±0.4 1.0±0.4 1.0±0.4 0.10
Deceleration time (ms) 211±74 199±68 213±75 0.11
E/E’-ratio 13±6 15±8 13±5 0.05
Moderate or severe MR 44 (7%) 14 (17%) 30 (6%) <0.001
Moderate or severe PR 2 (0.3%) 0 (0%) 2 (0.4%) 0.60
Moderate or severe TR 24 (4%) 5 (7%) 19 (4%) 0.17
Left atrial volume index (ml/m2) 16±6 17±6 16±6 0.29
Right ventricular diastolic area (cm2) 15±4 17±5 15±4 0.001
Right ventricular systolic area (cm2) 10±4 11±4 9±3 <0.001
RVFAC (%) 37±9 33±8 38±9 <0.001
TAPSE 1.7±0.2 1.6±0.3 1.7±0.2 0.07
Right ventricular strain (%) -22±7 -17±7 -22±7 <0.001
E/A: mitral inflow peak early velocity(E)/mitral inflow peak late velocity(A); E/E’: mitral inflow peak early 
velocity(E)/mitral annular peak early velocity(E’); LVEDV: left ventricular end-diastolic volume; LVESV: left 
ventricular end-systolic volume; MR: mitral regurgitation; PR: pulmonary regurgitation; RVFAC: right ven-
tricular fractional area change; TAPSE: tricuspid annular plane systolic excursion; TR: tricuspid regurgitation.
143
RIGHT VENTRICULAR FUNCTION AFTER MYOCARDIAL INFARCTION
29% compared to 16% in patients with RVFAC ≥ 32% (n=454, P=0.01). The incidence of adverse 
events at 4 years was 45% in patients with TAPSE < 1.5 cm (n=180) and 9% in patients with 
TAPSE ≥ 1.5 cm (n=411, P<0.001). Patients divided in RV strain < -22.1% (n=256) and ≥ -22.1% 
(n=273) demonstrated a 4-year event rate at of 23% and 7%, respectively (P<0.001).
With the exception of nonfatal reinfarction, multiple variable analysis showed that RVFAC 
and RV strain were independent predictors of all events. RVFAC demonstrated HRs of 0.93 
table 3. Cox univariable predictors for the composite endpoint. 
hazard ratio 95%ci P
Age (per 1-year increase) 1.05 1.02–1.07 <0.001
Killip class ≥ 2 (yes/no) 5.05 3.15–8.08 <0.001
Prior myocardial infarction (yes/no) 2.57 1.42–4.65 0.002
Multivessel disease (yes/no) 1.88 1.21–2.92 0.005
Peak creatine phosphokinase level (per 100-U/l increase) 1.02 1.02–1.03 <0.001
Peak cardiac troponin T level (per 1-μg/l increase) 1.08 1.06–1.10 <0.001
Left ventricular end-systolic volume (per 5-ml increase) 1.07 1.03–1.12 0.001
Left ventricular ejection fraction (per 1% increase) 0.93 0.91–0.96 <0.001
Wall motion score index (per 1-unit increase) 10.95 5.02–23.90 <0.001
E/A-ratio (per 1-unit increase) 1.87 1.09–3.21 0.02
E/E’-ratio (per 1-unit increase) 1.05 1.02–1.09 0.003
Moderate or severe mitral regurgitation (yes/no) 3.38 1.90–6.02 <0.001
RVFAC (per 1% increase) 0.94 0.92–0.97 <0.001
RVFAC < 32% (yes/no) 2.22 1.39–3.54 0.001
TAPSE (per 1-cm increase) 0.10 0.03–0.38 0.001
TAPSE < 1.5 cm (yes/no) 4.00 2.45–6.53 <0.001
Right ventricular strain (per 1% increase) 1.10 1.06–1.14 <0.001
Right ventricular strain < -22.1% (yes/no) 3.43 1.87–6.29 <0.001
E/A: mitral inflow peak early velocity (E)/mitral inflow peak late velocity (A); E/E’: mitral inflow peak early 
velocity(E)/mitral annular peak early velocity (E’); RVFAC: right ventricular fractional area change; TAPSE: 
tricuspid annular plane systolic excursion.
table 4. Cox multivariable model with right ventricular fractional area change for the composite endpoint.
hazard ratio 95%ci P
Killip class ≥ 2 (yes/no) 2.99 1.51–5.92 0.002
Multivessel disease (yes/no) 1.92 1.04–3.56 0.04
Peak cardiac troponin T level (per 1-μg/l increase) 1.05 1.01–1.08 0.008
Left ventricular ejection fraction (per 1% increase) 0.95 0.91–0.99 0.01
Right ventricular fractional area change (per 1% increase) 0.96 0.92–0.99 0.007
table 5. Cox multivariable model with right ventricular strain for the composite endpoint.
hazard ratio 95%ci P
Killip class ≥ 2 (yes/no) 3.18 1.58–6.41 0.001
Multivessel disease (yes/no) 2.03 1.07–3.86 0.03
Peak cardiac troponin T level (per 1-μg/l increase) 1.06 1.01–1.10 0.01
Left ventricular ejection fraction (per 1% increase) 0.95 0.91–0.99 0.01
Right ventricular strain (per 1% increase) 1.08 1.03–1.13 0.002
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(95%CI 0.90–0.97, P=0.001) and 0.94 (95% CI 0.89–0.99, P=0.05), and RV strain HRs of 1.10 
(95%CI 1.03–1.16, P=0.003) and 1.16 (95%CI 1.07–1.26, P=0.001) for all-cause mortality and 
hospitalization for HF, respectively. In addition, when early deaths (defined as deaths occur-
ring during index hospitalization) were excluded from multiple variable analysis, RVFAC and 
RV strain remained independent predictors of all-cause mortality (HR 0.93, 95%CI 0.89–0.97, 
P=0.001 and HR 1.07, 95%CI 1.01–1.14, P=0.04, respectively).
Figure 1. Cumulative incidence of adverse events. Patients stratified by right ventricular fractional area 
change (panel A), tricuspid annular plane systolic excursion (panel B) and right ventricle strain (panel C).
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the incremental value of right ventricular Function in Addition to traditional 
risk Factors
Global chi-square scores were calculated to assess the incremental value of RV function. RV 
function quantified by RVFAC and RV strain provided incremental value to clinical information 
(age and Killip class ≥ 2), infarct characteristics (RCA as culprit vessel, multivessel disease and 
peak cTnT level) and LV systolic and diastolic function (LVEF, WMSI, E/E’-ratio and moderate 
or severe MR). In addition, RV strain was added to the RVFAC-model, which demonstrated to 
increase the predictive power of the model even further (Figure 2). Interestingly, TAPSE, did 
not have incremental value in addition to clinical information, infarct characteristics and LV 
function.
Discussion
The major finding of the present study was that RVFAC, TAPSE and RV strain were strong 
predictors of the composite endpoint all-cause mortality, reinfarction and hospitalization 
for HF. In addition, the prognostic value of several traditional risk factors including Killip 
class, peak cardiac enzymes, multivessel disease and LV function, was again confirmed. 
After adjusting for known risk factors of adverse outcome after AMI, RVFAC (HR 0.96, 95%CI 
0.92–0.99) and RV strain (HR 1.08, 95%CI 1.03–1.13) independently predicted the composite 
endpoint. In addition, the cut-off for RV strain at < -22.1% was associated with an adjusted HR 
of 2.18 for the occurrence of the composite end-point. Moreover, RV strain < -22.1% provided 
Figure 2. Incremental value of right ventricular function. Bar graph illustrating the incremental value of 
right ventricular function (depicted by chi-square value on the y axis). The addition of right ventricular 
fractional area change and right ventricular strain provides incremental value to known risk factors for 
adverse outcome, related to clinical information (age, Killip class ≥ 2), infarct characteristics (RCA as culprit 
vessel, multivessel disease, peak cTnT level) and LV function (LVEF, WMSI, E/E’-ratio, moderate or severe MR).
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incremental value over clinical information, infarct characteristics, LV function and RVFAC 
for the prediction of adverse outcome in post-AMI patients. However, RV function failed to 
provide prognostic information for the prediction of nonfatal reinfarction individually.
Quantification of right ventricular Function
Multiple methods have been described to quantify RV function with 2D-echocardiography. 
In clinical practice, qualitative assessment of RV function is usually performed, whether or 
not in combination with TAPSE or RVFAC.13 Both measurements are simple to perform and 
associated with prognosis, particularly in patients with LV dysfunction after AMI.6, 7, 19 In 
contrast to previous studies, the current study evaluated the importance of RV function in a 
large population of post-AMI patients, treated with primary PCI and relatively preserved LV 
function. In addition to TAPSE and RVFAC, we assessed RV strain. Although RVFAC, TAPSE, and 
RV strain are highly correlated, they measure different aspects of RV function. RVFAC is the 
most commonly used measurement to assess RV contractility. However, the measurement of 
RVFAC is experience-dependent and reproducibility is often poor. Therefore, RVFAC may not 
adequately reflect contractility. TAPSE is another frequently used measurement to assess RV 
function and reflects the longitudinal systolic excursion of the lateral tricuspid valve annulus, 
which may not fully reflect RV contractility. Strain is a novel technique that enables angle-
independent measurement of active myocardial deformation. Previous studies indicated 
that subtle but clinically relevant decreases in ventricular function can be detected using 
strain and we therefore hypothesized that this may also apply for subtle changes in RV func-
tion post-AMI.22–26 Peak RV longitudinal strain, which quantitates the maximal shortening in 
the RV free wall from apex to base, is likely to be a good estimator of RV function since 80% of 
the stroke volume is generated by longitudinal shortening of the RV free wall.27
The results of the current study point out, for the first time, that reduced strain of the RV is 
a strong independent predictor of adverse events in post-AMI patients. RV strain, even after 
correction for clinical information, infarct characteristics and LV function, demonstrated to be 
of incremental value in addition to RVFAC. In addition, RV strain may detect RV dysfunction 
earlier than RVFAC as the Kaplan-Meier estimates showed earlier divergence for RV strain 
than RVFAC (Figure 1).
TAPSE has been found to correlate with LVEF, which is an important predictor of adverse 
outcome in AMI patients and thus may explain the earlier separation on the graphs. This 
indicates that RV strain may be superior to traditional measures of RV function, for the predic-
tion of adverse events after AMI.
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right ventricular Function and outcome
In the past, the clinical importance of RV function has been underestimated. Although RV 
dysfunction was reported to recover to some extent after AMI, recently the value of RV 
function for the prediction of long-term outcome has been well recognized in patients with 
inferior AMI and LV dysfunction.28, 29 Mehta et al. showed in a meta-analysis that patients with 
RV involvement in inferior AMI were at increased risk of adverse events and demonstrated 
that RV involvement is not due to more extensive infarction of the LV.30 In post-AMI patients 
with LV dysfunction, Zornoff et al. and Anavekar et al. confirmed that RV function is weakly 
correlated with LV function and demonstrated that RV function quantified with RVFAC was 
independently associated with an increased risk of mortality and HF.6, 7
In the current study, RV function was studied extensively with assessments currently used 
in clinical practice (TAPSE, RVFAC) and novel speckle-tracking derived strain. All measure-
ments of the RV were related to adverse prognosis. After adjusting for other variables that 
predicted adverse outcome, RVFAC and RV strain independently predicted the occurrence of 
the composite endpoint (all-cause mortality, reinfarction and hospitalization for HF. TAPSE, 
on the other hand, was a strong univariate predictor of adverse events, but did not remain 
significant in multivariable analysis. The prognostic value of TAPSE in AMI patients was inves-
tigated by Samad et al. In 194 AMI patients TAPSE was an independent predictor of mortality 
after adjustment for LVEF and age.19 However, in the GISSI-3 echo substudy which included 
500 AMI patients, TAPSE was significantly associated with LVEF, which may explain why TAPSE 
did not provide incremental value to clinical information, infarct characteristics and LV func-
tion and why TAPSE was not an independent predictor of adverse outcome.29
right ventricular strain
Although, strain was primarily developed for the measurement of LV deformation, previ-
ous reports have demonstrated the usefulness of RV strain in several populations to detect 
subtle changes in RV function.9–11 Measurement of longitudinal strain of the RV is a reliable 
method for the assessment of RV function, since 80% of the stroke volume is generated by 
longitudinal shortening of the RV free wall.27 To our best knowledge, this is the first study to 
examine the value of RV strain in post-AMI patients. RV strain provided incremental value 
to traditional measurements of RV function and the quantification of RV strain is simple to 




The results of the current study suggest that routine assessment of RV function should be 
implemented in the follow-up of AMI patients. RV strain measured early after AMI appeared 
to be superior to RVFAC and TAPSE for the risk stratification of AMI patients and could facili-
tate in the identification of patients who are at risk for adverse events.
limitations
RV infarction complicates about 50 percent of inferior AMI. ST-segment elevations and Q-
waves in the right precordial leads have shown to have a high diagnostic accuracy for RV 
infarctions. Unfortunately, in the present study right precordial leads were not applied dur-
ing electrocardiography, however, no significant differences RV function parameters were 
observed in patients with and without inferior infarction.
For the current study, the cut-off for RV strain was chosen at 2SDs from the normal RV strain 
in a group of 60 healthy subjects.22 Normal limits of RV strain, derived from larger populations 
are currently lacking. Therefore, future research should aim at defining normal limits for RV 
strain and validating these cut-offs in relation to clinical endpoints.
Although, RV function at baseline was a good predictor of outcome in AMI patients, 
the predictive value of RV function at different periods after AMI could not be addressed. 
Changes in RV function could occur in the first weeks after AMI and serial assessment of RV 
function would be interesting.
conclusion
RV function provides strong prognostic information in AMI patients treated with primary PCI. 
RV strain is an independent predictor of all-cause mortality, reinfarction and hospitalization 
for HF. In addition, RV strain provides incremental value over clinical information, infarct 
characteristics, LV function and RVFAC. Quantitative assessment of RV function with RV strain 
may improve the risk stratification of patients after AMI.
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A 54-year-old female was referred to our centre for further evaluation of recently established 
severe pulmonary hypertension. Six months prior to presentation to the cardiologist of the 
referring centre, the patient had first experienced exertional dyspnoea. At the time of presen-
tation to the referring cardiologist, the patient’s ECG showed signs of an increased right heart 
load. Interestingly, this patient had undergone a thorough cardiac evaluation in the referring 
centre seven years before when she presented with severe hyperthyroidism. At that time 
there were no symptoms or signs of pulmonary hypertension on ECG, echocardiography, or 
at heart catheterisation. Thorough evaluation in cooperation with the referring centre dem-
onstrated that this patient was suffering from idiopathic pulmonary arterial hypertension, 
a rare form of pulmonary hypertension. We conclude this report with a discussion on the 
potential use of the ECG for the diagnosis of increased right heart load.
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cAse
In August 2005, a 54-year-old female was referred to our centre for additional evaluation 
into the aetiology of recently established severe pulmonary arterial hypertension (PAH). The 
patient had first experienced exertional dyspnoea six months prior to presentation to the 
referring cardiologist. There was no history of cardiac or pulmonary disease, but this patient 
had undergone an extensive cardiac evaluation seven years before, after a single episode 
Figure 1. A. ECG of the patient at first presentation, seven years before the diagnosis of PAH, demonstrated 
a regular sinus rhythm of 65 beats/min, a QRS axis of 36°, normal P waves, conduction intervals within 
normal limits, and an inverted T waves in leads II, III, aVF and V1 to V6. In short, there was no reason to 
suspect an increased right heart load at the time, based on this ECG. B. The ECG recorded at the time of 
renewed presentation showed a regular sinus rhythm of 84 beats/min, a QRS axis of 90°, the R wave in lead 
V1 measured 6 mm in the absence of an S wave, and there were diffuse repolarisation abnormalities, all in 
agreement with an increased right heart load. Given this second ECG, especially with an ECG available from 
several years before, further investigation regarding an increased right heart load is warranted.
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of syncope. At that time, the ECG showed a sinus rhythm, a QRS axis of 36°, normal P waves, 
conduction intervals within normal limits, and inverted T waves in leads I, III, aVF and V1 to 
V6 (figure 1A). Because of the observed repolarisation abnormalities, a series of additional 
tests was performed. Apart from severe hyperthyroidism, there were no cardiac or pulmo-
nary abnormalities found at echocardiography (tricuspid and pulmonary valve regurgitation 
gradients were within normal limits, there was no right atrial or ventricular dilatation, right 
ventricular hypertrophy, or paradoxical septal bowing), left heart and coronary catheterisa-
tion, or pulmonary function tests. At renewed presentation, the ECG now showed a QRS axis 
of 90°, the R wave in lead V1 measured 6 mm in the absence of an S wave, and there were 
diffuse repolarisation abnormalities, all in agreement with an increased right heart load 
(figure 1B). At bicycle ergometry the patient performed 120 W (88% of predicted), without 
evidence of exercise-induced ischaemia. A pulmonary perfusion scan showed no signs of 
pulmonary embolism. Coronary angiography again revealed normal coronary arteries. The 
patient (height: 170 cm, weight: 90 kg) now had a normal thyroid function, and was not taking 
any medications. Haemodynamics at right heart catheterization are presented in figure 2. 
Pulmonary pressures and pulmonary vascular resistance approached systemic values, signi-
fying that the degree of right heart load was severely elevated in this patient.
According to the guidelines, 1 the patient was further evaluated, eliminating possible 
aetiological factors in a stepwise fashion. Our patient denied past use of anorexigens or 
Figure 2. Haemodynamics recorded at baseline (left) and at follow-up (right). Despite the fact that the sys-
tolic pulmonary artery pressure is increased after one year of treatment, PVR has decreased due to an im-
proved cardiac output (from 5.5 l/min to 7.9 l/min). Essentially, right ventricular function seems improved, 
generating higher pulmonary artery pulse pressures and an increased cardiac output.
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intravenous drugs. There were no relatives with similar symptoms or established pulmonary 
hypertension. There was a history of alcohol abuse, but our patient had managed to refrain 
from drinking alcohol for several years, and an abdominal echo showed normal hepatopetal 
flow in the portal vein, essentially excluding presence of portal hypertension. The patient 
consented to a HIV test, which was negative. The echocardiogram showed no signs of left 
ventricular dysfunction or incompetence of the aortic and mitral valve, hence there was no 
indication that the pulmonary hypertension as secondary to left-sided heart disease. Pul-
monary function tests showed a mild obstruction pattern with a diffusion capacity of 68%, 
corrected for alveolar volume. Arterial blood gas analysis rendered the following values: O2 
saturation 97% (94 to 99%), pH 7.47 (7.35 to 7.45), pCO2 4.2 kPa (4.5 to 6.0 kPa), pO2 10.9 kPa 
(10.6 to 13.3 kPa), base excess -0.4 mmol/l (-2 to 2 mmol/l) and bicarbonate concentration 
22 mmol/l (22 to 29 mmol/l). Nocturnal oximetry showed no signs of desaturation or sleep 
apnoea. Additional CT imaging of the lungs and pulmonary arteries showed no signs of 
interstitial lung disease or thromboembolic disease, but dilatation of the right atrium, right 
ventricle, and central pulmonary arteries was striking (figure 3).
Since no satisfactory explanation could be found for the pulmonary arterial hypertension, 
the patient was classified as having idiopathic PAH. Despite the impressive level of PAH, treat-
ment would not be reimbursed, given the relatively mild symptoms of the patient (NYHA 
functional class II). Since the severity of the disease led us to believe that refraining from treat-
ment would lead to deterioration in the near future, we suggested that the patient should 
consider taking part in a clinical trial evaluating the benefit of an endothelin antagonist. The 
patient gave informed consent, and reported an improvement in her overall well-being dur-
ing the first months of treatment. After one year of treatment pulmonary artery pressures 
Figure 3. A. CT image which clearly shows the marked dilation of the right atrium and right ventricle, 
whereas the left atrium and left ventricle are considerably smaller. B. CT image of the aorta and pulmonary 
arteries. The diameter of the common pulmonary artery is almost twice that of the ascending aorta, and the 
right and left pulmonary arteries are also dilated. The severe dilatation of the pulmonary arteries indicates 
that the pulmonary arterial hypertension is not of recent onset, but a chronic condition. RA=right atrium, 
RV=right ventricle, LA=left atrium, LV=left ventricle, Ao=aorta, APC=common pulmonary artery, APD=right 
pulmonary artery, APS=left pulmonary artery.
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were virtually unchanged. However, systemic venous oxygen saturation had dramatically 
improved from 65 to 75%. Cardiac output calculated with the Fick method had increased from 
5.5 l·m-2 to 7.9 l·m-2, meaning that PVR had dropped to approximately 600 dynes·s·cm-5. The 
ECG was unchanged compared with a year before. Since this pulmonary vascular resistance 
is still much higher than the upper limit of normal (≈240 dynes·s·cm-5), the patient received 
additional treatment with a phosphodiesterase inhibitor.
PAH is a rare disease, with an estimated incidence of 2 to 16 per million.2 PAH often remains 
undetected until there are already advanced pulmonary vascular abnormalities.1,3 In recent 
years, however, awareness for this orphan disease has increased, mainly due to the advent 
of new drug therapies.4 Historically, the time interval from symptoms to diagnosis has been 
substantial for PAH patients, rendering most patients in NYHA class III or IV before treatment 
initiation.3 Although ECG abnormalities corresponding with right heart overload are present 
in the majority of PAH patients at diagnosis,3,5 the scalar ECG has been considered inadequate 
for screening.1 Recent studies in rats and humans have illustrated, however, that even a mildly 
increased right ventricular pressure load is associated with substantial changes in myocardial 
electrical properties, detectable in a standard 12-lead ECG recording.6,7 A possible explana-
tion for the reportedly lower sensitivity for right ventricular pressure overload of the ECG by 
conventional assessment is the wide range of normal ECG values, i.e. the ‘normal’ heart axis 
ranges from -30° to +90° or even to +100°, depending on the criteria used.8 In contrast to the 
wide inter-individual heterogeneity in ECG characteristics, the ECG is a very reliable tool to 
detect intra-individual changes over time.
In this particular patient, there had been an extensive cardiac evaluation several years 
before. In the meantime, the patient developed PAH and the ECG changed markedly: the 
QRS axis turned rightward, changing from 36° to 90°, the R in lead V1 became >0.5mV and was 
more pronounced than the S, and there were diffuse repolarisation abnormalities. Together, 
these abnormalities correspond with increased right heart load and right ventricular hyper-
trophy.8 This particular patient had relatively mild symptoms, given the severity of the PAH. 
The fairly stable cardiac situation was reflected by a sinus rhythm of 84 beats/min, indicating 
that stroke volume is adequate at rest.9 The absence of a ‘P pulmonale’ (P wave >0.25 mV in 
lead II) signifies that PAH has not yet induced a significant retrograde atrial overload, which 
is otherwise an ominous sign of poor prognosis.10,11 More specifically, P amplitude in lead II 
increases as a result of progressive RV hypertrophy-associated diastolic dysfunction, and RV 
dilatation-associated tricuspid regurgitation in PAH patients.12 Karliner et al. documented an 
increase in P amplitude in lead II in healthy men who ascended from sea level to a height of 
6300 meters above sea level on Mount Everest, and suffered from hypoxia-induced PAH.12 
Furthermore, QRS axis turned in a more rightward direction with increasing pulmonary vas-
cular resistance at high altitude, a phenomenon also observed in our patient. Lastly, as QRS 
duration is related to ventricular size, function, and prognosis, here was no reason to believe 
that the right ventricle was performing poorly with a QRS duration of only 76 msec in this 
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patient.13 There is fairly extensive knowledge on the ECG changes that can be observed with 
regression of right ventricular hypertrophy in developing newborns, as well as on the ECG 
abnormalities that remain present in people living at high altitudes.10 Similarly, patients in 
whom PAH attenuating treatment is very effective – such as the rare patients who respond to 
calcium channel blockers – have shown dramatic ECG changes from a pattern corresponding 
with right ventricular hypertrophy to a (near)-normal pattern.14 It is exceptionally rare that 
evolutionary ECG changes due to the development of PAH can be assessed. This is under-
standable, since PAH is an uncommon disease. Furthermore, PAH often presents relatively 
early in life, meaning patients lack cardiopulmonary comorbidity, and therefore prior ECG 
recordings. 2 Nevertheless, recording ECGs in patients at risk for developing PAH might be a 
cost-effective way of screening or longitudinal case-finding in selected groups of patients. 
Screening for PAH in patients at risk, such as patients with a genetic predisposition, HIV infec-
tion, portal hypertension, or systemic sclerosis, has been subject to debate for some time. 1 
While results of clinical trials regarding earlier onset of treatment are awaited, critics claim 
that such screening is impracticable without properly validated tools. However, the results of 
improved ECG detection of increased right ventricular pressure load may well bring screen-
ing within reach.7 Of course, pre-selecting patients at risk for pulmonary arterial hypertension 
will remain necessary, given the rarity of the disease. Now that the groups of patients at risk 
have been well identified,1,2,15 there is ample opportunity to evaluate the diagnostic value of 
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The aim of this study was to analyze whether QRS duration, before and after pulmonary valve 
replacement (PVR), is related to long-term outcome in patients with tetralogy of Fallot (TOF).
background
Key factors which determine outcome after PVR in adult TOF patients are largely unknown. 
Recognition of such factors assists the identification of patients at increased risk of adverse 
events.
methods
Adults who previously underwent total correction for TOF (n=90; age 31.4 ±10.3 years) and 
required PVR for pulmonary regurgitation were included. QRS duration was measured pre-
operatively and six months after PVR. The post-operative changes in QRS duration were 
calculated. Adverse events (death, re-PVR, ventricular tachycardia and symptomatic heart 
failure) were noted during follow-up.
results
During 5.5 ±3.5 years follow-up, 13 adverse events occurred. The 5-year event-free survival 
rate was 76% in patients with a pre-operative QRS duration >180 ms and 90 % in patients 
with a QRS duration ≤180 ms (p=0.037). In patients with a post-operative QRS duration >180 
ms, 5-year event-free survival was 71%, whereas it was 91% in patients with a post-operative 
QRS duration ≤180 ms (p=0.004). After multivariate correction, a post-operative QRS dura-
tion >180 ms (hazard ratio 3.685, 95%CI 1.104-12.304, p<0.05) and the absence of a reduction 
in QRS duration post-PVR (hazard ratio 6.767, 95%CI 1.704-26.878, p<0.01), was significantly 
associated with adverse outcome.
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conclusions
Severe QRS prolongation, pre- or post-PVR, and the absence of a reduction in QRS duration 
after PVR, are major determinants of adverse outcome during long-term follow-up of patients 
with TOF.
introDuction
Progressive pulmonary regurgitation (PR) is a common complication after total surgical cor-
rection of tetralogy of Fallot (TOF).1 Longstanding PR leads to right ventricular (RV) dilatation, 
which in turn causes RV dysfunction and reduced exercise tolerance.2, 3 Pulmonary valve 
replacement (PVR) provides an adequate surgical therapy for PR as it leads to improvement of 
RV function and the patient’s functional class.4 Numerous studies indicated the beneficial ef-
fects of PVR in terms of improvement of RV volume and ejection fraction shortly after PVR.5–7 
In addition, it was demonstrated that RV de- and repolarization characteristics improve after 
PVR, partly in response to the reduction in RV volumes.8, 9 Specifically QRS duration, which 
is strongly associated with RV function and prognosis in TOF,10 tends to reduce after PVR.8 In 
addition, it is known that TOF patients with severely prolonged QRS duration (>180ms) are 
at risk for adverse events.11 Nevertheless, it is unclear whether an association exists between, 
on the one hand, pre-PVR QRS duration and post-PVR changes in QRS duration and, on the 
other hand, long-term outcome after PVR. Consequently, the clinical relevance of pre- and 
post-PVR QRS duration, and of changes in QRS duration after PVR, is presently unknown. The 
current study aimed to assess how pre-operative QRS duration and post-operative changes 
in QRS duration are related to outcome during long-term follow-up after PVR in TOF patients.
methoDs
study population
In a prospective, multicenter cohort study, adult patients after prior total repair for TOF, who 
had undergone a PVR for PR, were followed.12, 13 In all patients, primary surgical repair was 
performed during childhood. The indications for PVR were moderate to severe PR in combi-
nation with RV dilatation and impaired New York Heart Association (NYHA) functional status.4 
A standard 12-lead ECG was obtained immediately before and 6 months after PVR. If an ECG 
was not available at one of the time points, patients were excluded from further analysis. 
All patients were followed annually at the out-patient clinic and the occurrence of adverse 
events was noted during follow-up after PVR. Adverse events were defined as: death due 
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to any cause, re-operation for recurrent pulmonary regurgitation, symptomatic heart failure 
and ventricular arrhythmias.
surgical procedures
PVR was performed through median sternotomy. After release of adhesions, total cardiopul-
monary bypass was started. A cryopreserved pulmonary homograft was implanted, usually 
on beating heart. If necessary, small residual ventricular septal defects were suture closed 
and RV outflow tract (RVOT) reconstruction was performed as described previously.12 In ad-
dition, when pre-operative assessment revealed significant tricuspid regurgitation, tricuspid 
annuloplasty was performed.14
electrocardiographic analysis
 Electrocardiograms (ECGs) were stored digitally and exported from the ECG database man-
agement system for off-line analysis with the MATLAB-based (The MathWorks, Natick, MA) 
computer program LEADS (Leiden, the Netherlands). Details about the calculation methods 
used in LEADS have been reported previously.15 The software averages a digitized version of 
the standard 12-lead surface ECG into a representative single-beat ECG in which all 12 leads 
are superimposed. The software is equipped with a cross-hair editor interface that allows 
magnification of the ECG and thereby facilitates accurate measurement of QRS duration ac-
cording to the Minnesota criteria for population based ECG studies.8 All ECGs were analyzed 
by a single observer blinded for the patient’s clinical status and operation results. The cut-off 
for severely prolonged QRS duration was set at 180ms.10, 11
statistical analysis
SPSS (16.0.2. SPSS Inc., Chicago, IL) was used for statistical analysis. Graphpad Prism (4.00 
for Windows, Graphpad Software Inc., La Jolla, CA) was used to obtain life tables and cor-
responding Kaplan Meier survival curves. First, pre- and post-operative QRS duration and 
NYHA functional class were compared using a paired t-test.
Secondly, the association between QRS duration and the occurrence of adverse events dur-
ing post-operative follow-up was assessed using Cox’s proportional hazard regression analy-
sis. Univariate hazard ratios were calculated with corresponding 95% confidence interval (CI) 
for the following variables: 1) pre- and post-operative QRS duration as a continuous variable, 
in ms; 2) pre- and post-operative QRS duration as a categorical variable, ≤ 180 ms or > 180 ms; 
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3) changes in QRS duration, from pre- to post-operative, as a continuous variable, in ms; 4) 
changes in QRS duration, from pre- to post-operative, as a categorical variable, expressed as 
the presence or the absence of reduction in QRS duration. Afterwards, the hazard ratios were 
adjusted for age at PVR (below or above the median age of 30 years) and the presence of 
concomitant procedures during PVR, to obtain the multivariate HRs.
Third, the annualized event rates were assessed in patient subgroups based on the pre- 
and post-operative QRS duration (≤ 180 ms or > 180 ms) in addition to the post-operative 
changes in QRS duration (reduction or no reduction). The number of observed events was 
normalized to100 patient years in each subgroup to facilitate comparison between groups. 
Afterwards the 95% CI of the observed event rate was calculated and the difference in event 
rate was compared to the overall event rate by assuming that the number of observed events 
has a Poisson distribution.
Finally, to visualize the difference in event free survival between different QRS duration 
patient categories, Kaplan-Meier curves were drawn and logrank statistics were calculated 
for the following three patient subgroups: 1) pre-operative QRS duration ≤ 180 ms or > 180 ms; 
2) post-operative QRS duration ≤ 180 ms or > 180 ms; 3) changes in QRS duration, expressed 
as the presence or absence of a post-operative reduction in QRS duration. Separate Kaplan-
Meier curves were obtained in which death, symptomatic heart failure and ventricular ar-
rhythmias were included as an end-point and re-PVR was excluded.
Where appropriate, data are reported as mean ± standard deviation (SD), number (%) or as 
hazard ratio (HR) with (95% CI). P values <0.05 were considered statistically significant.
results
Ninety-nine consecutive corrected TOF patients who underwent PVR at adulthood were 
considered for the study. Nine patients were excluded because of missing ECGs and the 
remaining 90 patients were all included in the study (Table 1). PVR was performed at an age 
of 31.4 ± 10.3 years and pre-operative NYHA functional class was 2.4 ± 0.7. The size of the 
implanted homografts was 25.6 ± 1.6 mm and concomitant surgical procedures, mostly RVOT 
reconstructions, were required in 42 patients (47%, Table 1).
clinical outcome
No patients were lost to follow-up. After PVR, NYHA functional class improved from 2.4 ± 
0.7 to 1.3 ± 0.6, p<0.001. During a mean follow-up duration of 5.5 ± 3.5 years (range 1.1 – 17.9 
years), 13 adverse events occurred (Figure 1A). The observed event free follow-up was 100% 
at 1 year, 96% at 2 years, 89% at 5 years, and 78 % at 10 years (Figure 1B). During follow-up, 
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table 1. Patient population. 
Patients 90
sex
 Male 53 (59)
 Female 37 (41)
characteristics initial repair
 Age (years) 5.8 ± 5.5
 Transannular patch 62 (69)
 RV patch 9 (10)
 RV to PA conduit 5 (6)
 No patch 14 (16)
characteristics Pvr
 Pre-operative NYHA class 2.4 ± 0.7
 Age (years) 31.4 ± 10.3
 Homograft diameter (mm) 25.6 ± 1.6
concomitant procedures
 Patients with concomitant procedures 42 (47)
 Ventricular septal defect closure 2 (2)
 RVOT reconstruction 27 (30)
 Tricuspid valvuloplasty 17 (19)
Qrs duration
 Pre-operative (ms) 158 ± 29
 Changes from pre- to post-operative (ms) -4 ± 17*
 Post-operative (ms) 154 ± 32
Numbers correspond to n (%) or mean ± SD. NYHA: New York Heart Association; PA: pulmonary artery; PVR: 
pulmonary valve replacement; RV: right ventricular. *p = 0.027 for the difference between pre- and post- 
operative QRS duration.










































































Figure 1. Patient population and follow-up characteristics. Overview of the events that occurred during 
follow-up of the study population (A) and the overall Kaplan-Meier survival curve of the patients (B). The 
numbers below signify patients at risk. HF: Heart Failure; PAR: patients at risk; PVR: pulmonary valve replace-
ment; VT: ventricular tachycardia.
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2 patients died after respectively 1.4 years and 8.5 years due to sudden cardiac death (first 
patient) and fast-progressive, therapy refractory heart failure (second patient). Re-PVR was 
performed in 5 patients and ventricular tachycardia requiring implantation of an implantable 
cardioverter defibrillator, occurred in 4 patients.
Prediction of patient outcome using Qrs duration
Before PVR QRS duration was 158 ± 29 ms, which reduced with 4 ± 17 ms to 154 ± 32 ms six 
months after surgery, p=0.027 (Table 1).
Pre-operative NYHA functional class was not associated with pre- or post-operative QRS 
duration or the post-operative changes in QRS duration (black bars in Figure 2) and demon-
strated to improve in all patientgroups based on QRS duration (Figure 2). However, in patients 
with a QRS duration > 180 ms, either pre- or post-operative, a less prominent improvement in 
NYHA functional class was observed as compared to patients with a QRS duration ≤ 180 ms 
pre-operative (p=0.002) or post-operative (p=0.045).
Pre- and post-operative QRS duration, as well as post-operative change in QRS duration 
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Figure 2. NYHA functi nal cl ss and QRS duration. Mean pre- and post-operative NYHA functional class (y-
axis) depicted in relation to (x-axis) pre-operative QRS duration (A), post-operative changes in QRS duration 
(B) and QRS durations 6 months post-operative (C).
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pre- and post-operative QRS duration were 1.025 and 1.026, respectively, per ms increase in 
QRS duration. This indicated that a longer QRS duration either pre- or post-operatively, was 
associated with a higher incidence of adverse events. Furthermore, the change in QRS dura-
tion from pre-operative to six months after PVR, was also related to post-operative outcome. 
The crude HR for the occurrence of adverse events was 0.978 per ms change in QRS duration, 
demonstrating that a post-operative reduction in QRS duration was associated with a lower 
incidence of adverse events during follow-up. After multivariate correction, pre- and post-
operative QRS duration and post-operative changes in QRS duration remained significantly 
related to the incidence of adverse events. Specifically a post-operative QRS duration >180 
ms or the lack of a reduction in QRS duration, post-operatively, were strong predictors of 
adverse events with multivariate HRs of 3.685 and 6.767, respectively.
To further explore the association between QRS duration and event-free survival after PVR, 
the study population was subdivided based on QRS duration (pre- and post-operative; ≤ 180 
or > 180 ms), and post-operative change in QRS duration (reduction or no reduction), which 
yielded 8 subgroups (Table 3). Subsequently, the annualized event rate, normalized to 100 
patient years, was calculated for the overall study population and for the 8 subgroups (Table 
table 2. Prediction of outcome using QRS duration.
 univariate  multivariate*
hr 95% ci hr 95% ci
Pre-operative† 1.025§ 1.001-1.051 1.024§ 1.000-1.049
Pre-operative > 180ms 3.187§ 1.007-10.084 3.408 0.969-11.982
Post-operative† 1.026|| 1.011-1.043 1.024|| 1.008-1.041
Post-operative > 180ms 4.668|| 1.461-14.914 3.685§ 1.104-12.304
Change in QRS duration‡ 0.978§ 0.958-0.998 0.979§ 0.959-0.999
No reduction in QRS duration 5.891|| 1.585-21.894 6.767|| 1.704-26.878
 *In the multivariate model, the hazard ratio was adjusted for age (below or above the median of 30 years) 
and concomitant surgical procedures during pulmonary valve replacement, † hazard ratio per ms increase 
in QRS duration, ‡ hazard ratio per ms change in QRS duration, §p < 0.05, ||p < 0.01.
table 3. Observed annualized event rate according to QRS duration.
n Patient years events events/ 100 patient 
years
95% ci
overall 90 483.8 13 2.7 1.4-4.6
Pre-operative Qrs duration
 ≤ 180 ms + PO QRS reduction 44 241.8 0 0 NA
 ≤ 180 ms – PO QRS reduction 27 157.0 8 5.1 2.2-10.0
 > 180ms + PO QRS reduction 14 75.3 3 4.0 0.8-11.6
 > 180ms – PO QRS reduction 5 9.7 2 20.6 2.5-74.4*
Post-operative Qrs duration
 ≤ 180 ms + PO QRS reduction 52 294.8 2 0.7 0.1-2.4
 ≤ 180 ms – PO QRS reduction 21 123.7 6 4.9 1.8-10.6
 > 180ms + PO QRS reduction 6 22.4 1 4.5 0.1-24.9
 > 180ms – PO QRS reduction 11 43.0 4 9.3 2.5-23.8†
*p = 0.007 vs. the overall group, †p = 0.030 vs. the overall group. PO: post-operative.
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3). The overall event rate in the study population was 2.7 (95% CI 1.4 - 4.6) per 100 patient 
years. No events were observed in patients with a pre-operative QRS duration ≤ 180 ms, who 
demonstrated a post-operative reduction in QRS duration (n=44). On the contrary, a signifi-
cantly higher event rate was observed in patients who did not demonstrate a reduction in 
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Figure 3. Kaplan Meier Survival curves and QRS duration. Kaplan Meier survival curves in patient subgroups 
stratified by pre-PVR QRS duration (A,B); post-operative changes in QRS duration (C,D); and 6-months post-
operative QRS duration (E,F). Separate curves are provided in which re-PVR was excluded as an end-point 
(B,D,F). P-values denote the result of the logrank test.
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QRS duration and had a QRS duration > 180 ms either pre- or post-operative. In those groups, 
the event rates were 20.6 (95% CI 2.5 - 74.5; p=0.007 vs. the overall population) and 9.3 (95% CI 
2.5 - 23.8; p=0.030 vs. the overall population) events per 100 patient years (Table 3).
The Kaplan Meier survival curves (Figure 3) confirmed that patients with significantly 
prolonged QRS duration (> 180 ms) demonstrated worse event-free survival as compared to 
patients with a QRS duration ≤ 180 ms. The observed 5-year event-free survival was 76 % in 
patients with a pre-operative QRS duration > 180 ms as compared to 90 % in patients with 
a QRS duration ≤ 180 ms, p = 0.037 (Figure 3A). The observed 5-year event-free survival was 
71% in patients with a post-operative QRS duration > 180 ms as compared to 91% in patients 
with a QRS duration ≤ 180 ms, p = 0.003 (Figure 3E). Furthermore, 5-year event-free survival 
of patients in whom no reduction in QRS duration was observed six months after PVR, was 
worse as compared to patients with a reduction in QRS duration after PVR. The observed 
difference in event-free survival between those two groups was 24.5 % at 5 years, p = 0.004 
(Figure 3C). Exclusion of re-PVR as an endpoint in the Kaplan-Meier survival curve, demon-
strated that event-free survival was 4.1% percent lower in patients with a pre-operative QRS 
duration > 180 ms as compared to ≤ 180 ms, which was not statistically significant, p=0.61 
(Figure 3B). The Kaplan-Meier curves, in which the patient population was stratified accord-
ing to post-operative QRS duration (≤ 180 ms or > 180 ms) or post-operative changes in QRS 
duration (reduction or no reduction), was similar whether or not re-PVR was excluded as an 
endpoint (Figure 3D,F).
Discussion
The main findings of this study were: 1) a QRS duration >180ms, either pre- or post-operatively, 
or the lack of a reduction in QRS duration after PVR, was significantly associated with adverse 
outcome after PVR; and 2) the highest incidence of adverse events was observed in patients 
with a severely prolonged QRS duration either pre- or post-operative, without a reduction in 
QRS duration after PVR.
Progressive PR is one of the most common complications after total surgical repair of TOF. 
In response to the regurgitated volume, the right ventricle dilates to overcome the increased 
loading conditions.1, 16 Longstanding PR will eventually lead to dysfunction of the right ven-
tricle and patients may experience reduced exercise tolerance.17 In such cases, PVR with a 
competent pulmonary valve provides a satisfactory solution with excellent short-term results 
in terms of ventricular function and NYHA functional class.4, 18 Although long-term results are 
also good for PVR; a substantial number of patients still have adverse events during follow-
up.7 In the current study, event free survival was 76% after ten years which is similar to other 
studies in which long-term survival after PVR was reported.12, 19 A number of factors that are 
important for post-PVR outcome have been identified. These mainly include post-operative 
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homograft-related factors such as early recurrence of PR or pulmonary stenosis.12, 20 Interest-
ingly, in the study by Oosterhof et al.,12 which was a large follow-up study that comprised 
of 158 adult TOF patients who underwent PVR, neither the type of initial TOF correction nor 
the PVR surgical characteristics were predictive of outcome after PVR. In that study, right 
ventricular volumes and ejection fraction, assessed pre-operatively with cardiovascular mag-
netic resonance imaging, were not predictive of post-PVR outcome. Although it is known that 
QRS duration is strongly associated with outcome in TOF patients,10 no studies on the clinical 
application of QRS duration for the assessment of post-PVR outcome are available. The cur-
rent study demonstrates that pre-operative QRS duration is associated with post-operative 
outcome. Longer QRS duration was significantly associated with increased incidence of 
adverse outcome after PVR. Furthermore, severe QRS prolongation (>180ms) after PVR and 
the absence of a reduction in QRS duration demonstrated an even stronger association with 
post-operative outcome. As re-PVR has an indirect association with ventricular function12 
separate Kaplan-Meier survival curves were obtained in which re-PVR was excluded as an 
endpoint. This confirmed that QRS duration has a strong association with post-PVR outcome 
in patients with TOF.
The association between prolonged QRS duration and patient outcome in TOF was first rec-
ognized by Gatzoulis et al.10 In a study on 178 adults with a previous total repair for TOF, it was 
demonstrated that ventricular tachycardia was associated with QRS prolongation beyond 180 
ms. In addition, it was shown that patients with an enlarged right ventricle had a longer QRS 
duration. The relation between RV enlargement and QRS duration was confirmed thereafter 
in study by Book and colleagues.21 They demonstrated that prolonged QRS duration (>150 
ms), had a positive predictive value of 92% for the detection of RV dilatation on cardiovascu-
lar magnetic resonance imaging. In addition, Neffke and colleagues demonstrated that QRS 
duration was also correlated to RV mass.22 Besides the relation between QRS duration and 
ventricular function, it was shown in a study Budts et al. that lack of reduction in QRS duration 
during exercise, is significantly related to reduced exercise capacity in adult TOF patients.23 
Furthermore, previous studies have indicated reduction of QRS duration in response to PVR.8 
This reduction in QRS duration was related to the reduction in RV end diastolic volume, 
which demonstrated that PVR improved the electrophysiological characteristics of the right 
ventricle. However, to date, it remained to be investigated whether these changes in elec-
trophysiological characteristics were of relevance in terms of clinical outcome. The current 
study demonstrates for the first time that severe QRS prolongation (>180ms) either pre- or 
post-PVR, or the absence of a reduction in QRS duration post-PVR, is associated with the 
increased incidence of adverse outcome during long-term follow-up. It could be postulated 
that the patients who lack improvement in QRS duration have a poorer RV condition and 
thus exhibit a higher risk for adverse events as compared to the patients who improve in QRS 
duration after PVR. Analogous with this, the observation that longer QRS duration pre-PVR 
was associated with increased incidence of adverse events after PVR may also be related to a 
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more deteriorated RV condition already before PVR. The fact that no events were observed in 
patients with a QRS duration <180ms who demonstrated improvement of QRS duration after 
PVR, may reflect the other end of the same pathophysiological spectrum.
limitations
As with most studies on patients with congenital heart disease, a limitation of the current 
study is the relatively small number of patients. Therefore, a comprehensive multivariate Cox’s 
regression analysis, in which the HRs are adjusted for all possible confounders could not be 
obtained. Furthermore, the subgroup analysis based on pre- and post-PVR QRS duration and 
post-PVR changes in QRS duration would benefit from a larger sample-size as this increases 
the precision of the event rate estimations. A large multi-center trial with sufficient power 
for a complete analysis of possible confounders is warranted to improve the quantification 
of the event rates and to confirm the differences between the subgroups. In addition, the 
fact that QRS duration was tested continuously as well as categorically using a predefined 
cut-off, may introduce type I statistical error in the current evaluation. However, a consistent 
association between QRS duration and patient outcome was observed whether QRS duration 
was entered continuously or categorically in the regression equation.
clinical implications
The current study demonstrates that both QRS duration itself and the changes in QRS dura-
tion after PVR can be used to identify patients who are at increased risk for adverse events 
during follow-up after PVR. Therefore, the patients who have a QRS duration >180ms either 
pre- or post-PVR, and the patients who do not demonstrate improvement of QRS duration 
after PVR, may require a vigilant follow-up regimen, as those patients exhibit a high risk for 
adverse outcome. Currently, PVR is recommended when important PR and severe RV dilata-
tion occur, specifically when this coincides with reduced NYHA functional class.18, 24 As the 
current study demonstrates that severely prolonged QRS duration (>180ms) is associated 
with increased incidence of adverse outcome, it could be postulated that PVR should be 
performed before severe QRS prolongation occurs. The latter point, however, needs to be 
confirmed in a sufficiently powered clinical trial.
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conclusion
QRS duration either before or after pulmonary valve replacement and the changes in QRS du-
ration after pulmonary valve replacement are important determinants of long-term outcome 
in adults with tetralogy of Fallot and may serve as an easy screening tool to identify patients 
at high risk for adverse events after PVR.
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Normal limits of the spatial QRS-T angle and spatial ventricular gradient (SVG) are only avail-
able from Frank vectorcardiograms (VCGs) of male subjects. We determined normal limits for 
these variables derived from standard 12-lead ECGs of 660 male and female students aged 18 
to 29 years.
methods
A computer algorithm was used that constructed approximated VCG leads by inverse Dower 
matrix transformation of the 12-lead ECG and subsequently calculated the spatial QRS-T 
angle, SVG magnitude and orientation.
results
In female subjects, the QRS-T angle was more acute (females: 66 ±23°, normal 20 – 116°; males: 
80 ±24°, normal 30 – 130°; P<0.001) and the SVG magnitude was smaller (females: 81 ±23 
mV·ms, normal 39 – 143 mV·ms; males: 110 ±29 mV·ms, normal 59 – 187 mV·ms; P<0.001) than 
in male subjects. The male SVG magnitude in our study was larger than that computed in 
Frank VCGs (79 ±28 mV·ms; P<0.001).
conclusions
The spatial QRS-T angle and SVG depend strongly on sex. Furthermore, normal limits of SVG 
derived from Frank VCGs differ markedly from those derived from VCGs synthesized from the 
standard ECG. As nowadays VCGs are usually synthesized from the 12-lead ECG, normal limits 
derived from the standard ECG should preferably be used.
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introDuction
The spatial QRS-T angle and the spatial ventricular gradient (SVG) are classical electrocar-
diographic parameters that provide information on functioning of the cardiac conduction 
system and on heterogeneity in ventricular action potential durations.1, 2
The spatial QRS-T angle is the angle between the QRS- and T-axis in the plane that these 
axes form. This angle differs from the commonly calculated angle between the projections 
of QRS- and T-axes in the frontal plane. In normal subjects, repolarization in the free lateral 
wall tends to proceed in opposite direction to that of depolarization. In the septum and other 
myocardial regions, these relationships vary. Overall, the mean direction of repolarization 
(T) is closer to perpendicular rather than strictly reverse to that of depolarization (QRS).3 This 
results in an acute spatial QRS-T angle, which corresponds to a predominantly concordant 
ECG. When pathological changes occur, the ECG becomes more discordant and the spatial 
QRS-T angle widens.4 A recent study by Kardys et al. demonstrated that in the general popula-
tion the risk of cardiovascular death is higher for patients with a wide spatial QRS-T angle.2 In 
a report by Yamazaki et al., a wide spatial QRS-T angle wider was associated with an increased 
risk of cardiovascular death in a clinical population.5 Therefore, the spatial QRS-T angle is 
potentially a useful parameter for risk assessment in general and clinical populations.
The ventricular gradient (VG) is defined as the QRST integral and can be determined in any 
ECG or VCG lead 6 by calculating the total area under the curve over the QT interval (positive 
deflections are counted positive, negative deflections are counted negative). By including 
directional characteristics of the cardiac vector in the calculation, the spatial ventricular 
gradient (SVG) can be obtained. This SVG vector is the vectorial sum of the (spatial) QRS and 
T integral vectors, which have the same orientations as the QRS and T axes. Hence, the spatial 
QRS-T angle relates to the SVG in the sense that the spatial QRS-T angle is equal to the angle 
between the QRS and T integral vectors and the SVG is the vectorial sum of these vectors 
(Figure 1). From a theoretical point of view, the SVG is not influenced by changes in ventricu-
lar conduction pattern; it only changes if the distribution of the action potential morphology 
and/or duration across the myocardium is altered.1, 7, 8 In agreement with this, Mashima and 
colleagues demonstrated, in patients with left ventricular hypertrophy, that presence or 
absence of left bundle branch block was not associated with a different ventricular gradient 
magnitude.9
Gärtner et al.10 investigated whether frontal projections of the VG can discriminate health 
from cardiac disease and concluded that the VG lacks diagnostic accuracy. Simonson com-
mented on this research by stating that frontal projections of the VG do not sufficiently reflect 
electrical activity in the other directions.6 Nonetheless, after the first disappointing results 
were reported on the clinical applicability of the VG, it was largely abandoned. Unfortunately, 
this left multiple questions concerning the spatial VG unanswered and the clinical value of 
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the SVG, in combination with the spatial QRS-T angle, as general descriptors of the ECG, 
remains to be studied.
For use of these parameters in clinical practice, knowledge about normal variations and 
the availability of normal limits, derived from healthy subjects, is of unequivocal importance. 
Pioneering work in this field was done by Pipberger and colleagues. They were the first to 
publish normal limits of spatial QRS-T angle and the SVG derived from 8-electrode 3-lead 
Frank vectorcardiograms (VCGs) of 518 normal men.11, 12 Nowadays, the recording of Frank 
VCGs has passed into disuse and is replaced by VCGs that are synthesized from standard ECGs, 
using a conversion matrix.13 To the best of our knowledge, no studies have been published 
that define standard ECG-based normal limits of the spatial QRS-T angle and SVG computed 
from large samples of young healthy males and females.
Therefore, the aim of our study was to determine normal limits of the spatial QRS-T angle 
as well as the spatial ventricular gradient magnitude and orientation, as derived from synthe-
sized VCGs of young adult males and females.
Figure 1. QRS- and T-integrals, spatial QRS-T angle and ventricular gradient. The black arrows denote the 
QRS- and T integrals, which have the same orientation as the QRS- and T axes (dashed lines). The spatial 
QRS-T angle is the angle between the QRS- and T axes and the spatial ventricular gradient (SVG, grey arrow) 
is the vectorial sum of the QRS- and T integrals. The geometrical relation between iQRS, iT, spatial QRS-T 
angle and SVG is important for understanding the factors that affect the spatial ventricular gradient: the 
SVG decreases with decreasing iQRS and/or iT and with increasing spatial QRS-T angle. For further explana-
tion, see Draisma et al..1
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methoDs
The research protocol of this study was approved by our institutional Medical Ethics Committee.
subjects
In the course of their education, standard 10-second 12-lead ECGs were obtained from medical 
students of the Leiden University. Participation was voluntary and all students gave written in-
formed consent. Height and weight were measured, body mass index (BMI) was calculated, and 
body surface area (BSA) was assessed using Mosteller’s formula.14 All ECGs were scrutinized for 
normality based on the Minnesota ECG coding protocol15 by an attending cardiologist. Normal 
ECGs were included when subjects fulfilled the following criteria: age between 18 yrs and 29 yrs 
and heart rate between 50 beats per minute (bpm) and 100 bpm (Minnesota criterion 8-7, 8-8). 
All ECGs were recorded with Megacart electrocardiographs (Type 4.9, Siemens, Germany) and 
electronically stored in a Megacare ECG management system (VF 2.1, Dräger, Germany.)
electrocardiographic Analysis
ECGs were exported from the ECG database management system and analyzed with the MAT-
LAB-based (The MathWorks, Natick, USA) computer program LEADS (Leiden ECG Analysis and 
Decomposition Software).16 LEADS first detects all QRS complexes and corrects the baseline. 
Then, supervised beat selection for subsequent beat averaging is done; acceptation/rejection 
of beats is based on signal-to-noise ratio, on interbeat interval regularity and on representa-
tive QRS-T morphology. After computation of the averaged ECG complex, an averaged VCG 
complex is synthesized using the inverse Dower matrix.13, 17 In the averaged ECG complex, the 
onset of the QRS complex, the J point and the end of the T wave are detected automatically. 
The default position of the J point can be adjusted manually with a crosshair-cursor procedure, 
facilitating accurate placement according to the Minnesota ECG coding protocol. Global end of 
T is calculated in the vector magnitude signal as the intersection of the steepest tangent to the 
descending limb of the T wave and the base-line.18 Given these landmarks in time, the spatial 
QRS-T angle as well as the SVG azimuth, elevation and magnitude are computed as follows. First, 
the QRS and T integrals, iQRS and iT, are both approximated by calculating the numerical sum of 
X-Y-Z deflections (amplitudes of positive deflections are added and of negative deflections are 
subtracted) in 2 ms intervals (corresponding to 500 samples/s) covering the QRS complex and 
T wave. The spatial QRS-T angle is the angle between iQRS and iT and the SVG is calculated as the 
vectorial sum of iQRS and iT. Axis directions, defined as azimuth and elevation, are represented in 




SPSS (12.0.1, SPSS Inc., USA) was used for statistical analysis. Where appropriate, data are 
reported as mean with standard deviation (SD). Values of the spatial QRS-T angle and SVG 
were calculated separately for males and females and compared using an unpaired Student 
t-test. To identify factors that potentially explain differences in spatial QRS-T angle and 
SVG between males and females, differences in electrocardiographic characteristics (mean 
QRS vector magnitude/orientation, mean T vector magnitude/orientation, QRS integral, T 
integral) and anthropomorphic measurements (height, weight, BMI, BSA) were computed 
and compared. Moreover, Pearson correlation coefficients were calculated between the 
aforementioned electrocardiographic characteristics and the spatial QRS-T angle and SVG. 
Furthermore, Spearman rank correlations were calculated between the anthropomorphic 
measurements and the spatial QRS-T angle and SVG. Thereafter, multiple linear regression 
was used to correct male/female differences in spatial QRS-T angle and SVG for dissimilarities 
in anthropomorphic measurements between males and females.
Normal limits were set at the 2nd and 98th percentile.11 Single linear regression was used to 
calculate normal limits for SVG magnitudes depending on heart rate. Here SVG was logarith-
mically transformed to meet the assumptions for single linear regression (constant variance). 
Normal limits (2nd and 98th percentile) were obtained for the log-transformed SVG by adding 
and subtracting 2.05 times the residual SD to/from the regression equation. The obtained 
normal limits were then transformed back into the original scale.
results
ECGs were made in 804 subjects. The ECGs of 67 subjects were excluded because of techni-
cal reasons (electrode displacement, missing leads, signal noise), 22 ECGs were considered 
abnormal according to the Minnesota criteria, in 41 subjects the heart rate criteria were not 
met and 14 subjects did not meet the age criteria. Thus, the ECGs of 660 (449 female, 211 male) 
subjects were included in the analysis. The anthropomorphic and demographic characteris-
tics of this study group are presented in Table 1.
Table 2 summarizes the descriptive statistics and the observed normal limits in the form of 
the 2nd and 98th percentile of all electrocardiographic characteristics. Furthermore, a graphical 
representation of SVG orientation in relation to SVG magnitude is given in Figure 2. The mean 
values of the spatial QRS-T angle and the SVG in males differed significantly from the mean 
values of female subjects. Male subjects had significantly wider spatial angles and larger SVG 
magnitudes as compared to female subjects. Furthermore, the SVG orientation in males was 
more anterior and slightly more superior than in female subjects.
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Table 3 lists the correlations between SVG magnitude, spatial QRS-T angle and vector 
characteristics, for males and for females. A weak inverse correlation was present between 
the spatial QRS-T angle and the SVG magnitude in males and females, indicating that wide 
spatial QRS-T angles were associated with small SVGs. The mean QRS vector magnitude and 
QRS integral correlated positively with the SVG magnitude and the correlation was stronger 
in females as compared to males. Strong, positive, correlations, similar in both sexes, were 
observed between the mean T vector magnitude, the T integral and the SVG magnitude. The 
correlation between the QRS and T integrals on one hand and SVG magnitude on the other 
hand is depicted in Figure 3. QRS duration was not correlated to SVG magnitude in females, 
but demonstrated a weak positive correlation in males. JT interval was correlated with SVG 
magnitude similarly in both sexes.
The Spearman rank correlations between, on one hand, the spatial QRS-T angle and the SVG 
and, on the other hand, the anthropomorphic subject characteristics and heart rate are listed in 
table 1. Characteristics of the female and male subjects. 
Female subjects (n=449) male subjects (n=211)
Age (yrs) 19.6 ± 1.1 20.1 ± 1.6
Height (m) 1.71 ± 0.06 1.82 ± 0.07
Weight (kg) 62.8 ± 8.1 74.3 ± 10.0
BMI (kg/m2) 21.4 ± 2.4 22.2 ± 2.7
BSA (m2) 1.7 ± 0.13 1.9 ± 0.14
Heart rate (bpm) 73 ± 11 72 ± 11
BMI: Body Mass Index; BSA: Body Surface Area; bpm: beats per minute. All data are presented as mean ±SD.
table 2. Normal limits of the spatial QRS-T angle and ventricular gradient. 
Female subjects male subjects
mean sD median 2 % 98 % mean sD median 2 % 98 %
Qrs-t angle (º) 66 a 23 67 20 116 80 a 24 81 30 130
svgmagnitude (mv*ms) 81
a 23 79 39 143 110a 29 107 59 187
svgazimuth (º) -13
a 14 -15 -38 20 -23a 15 -24 -52 13
svgelevation (º) 30
a 8 30 12 48 27a 9 28 8 47
Qrs duration (ms) 87a 8 86 70 104 94a 9 94 76 112
mean Qrs vector (μv) 405a 131 395 182 724 499a 174 501 179 939
Qrs axisazimuth (º) 37 24 37 -16 96 41 27 27 -16 90
Qrs axiselevation (º) 32 12 32 3 57 30 12 32 1- 53
Qrs integral (mv*ms) 34.8a 11.3 34.0 15.9 62.3 46.5a 15.6 46.0 16.2 83.3
Qtc interval (ms) 406a 23 407 360 456 390a 22 390 339 440
mean t vector (μv) 214a 64 210 96 360 348a 93 338 156 580
t axisazimuth (º) -36
a 13 -37 -60 -5 -47a 13 -48 -71 -15
t axiselevation (º) 21
a 9 21 -1 37 16a 8 16 1 36
t integral (mv*ms) 60.8a 19.0 58.2 28.3 102.7 91.4a 24.4 89.3 41.9 150.0
Descriptive statistics and normal limits for females and males separately. SVG: spatial ventricular gradient. 




Table 4. Several correlations reached significance but were weak. A relatively strong correlation of 
-0.36 in females and -0.46 in males was found between SVG magnitude and heart rate.
As readily appreciable in Figure 4, the distribution of the SVG magnitudes was wider for 
lower heart rates than for higher heart rates. Therefore, SVG magnitudes were logarithmically 
transformed after which a single linear regression of log (SVGmagnitude) on heart rate (HR) was 
made. The following regression equations were found:
Figure 2. Orientation and magnitude of the spatial ventricular gradient. Spatial ventricular gradients as 
measured in our study group. Grey squares = female subjects; black squares = male subjects. Panels A, B 
and C: Projections of the spatial ventricular gradients in the frontal, sagittal and transversal planes. The azi-
muth of SVG can readily be seen in the transversal plane. Combination of these figures demonstrates that 
the ventricular gradient vector points to the left, forward and downward, which is in the direction of the 
cardiac apex. Panel D: Elevation and magnitude of the spatial ventricular gradient. Azimuth, elevation, and 
directions of the positive X-, Y- and Z-axes are in accordance with the AHA vectorcardiography coordinate 
standard.19
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Female subjects: 10log (SVGmagnitude) = 2.18 – 3.95 *10-3 · HR (SD = 0.12)
Males subjects: 10log (SVGmagnitude) = 2.38 – 4.89 *10-3 · HR (SD = 0.11)
Multiple linear regression analysis was performed to investigate the potential influence of 
height, weight, BMI and BSA on the female-male differences found in the SVG and the spatial 
QRS-T angle. This, however, did not yield significant further explanation of the female-male 
differences observed. Also, the sex coefficient did almost not change in the multiple linear 
regression model.
table 3. Correlation between the spatial ventricular gradient, QRS-T angle and the cardiac vector for males 
and females.










SVGmagnitude -0.46a 0.24a 0.17b 0.30a 0.72b 0.29a 0.82a
Females
SVGmagnitude -0.35a 0.56a 0.03c 0.58a 0.80a 0.27a 0.86a
Pearson correlation coefficients between SVG, QRS-T angle and vector characteristics. SVG, spatial ventricu-
lar gradient. a Significant at the P= 0.01 level; b Significant at the P= 0.05 level; c NS
Figure 3. Association between QRS integral, T integral and SVG magnitude. Linear correlations between 
the integrals of QRS and T on one hand and SVG magnitude on the other hand. Panel A shows that a weak 
correlation was present between the QRS integral and SVG magnitude, whereas panel B demonstrates a 
strong correlation between the T integral and SVG magnitude, indicating that repolarization characteristics 




In the present study, we established normal limits of the spatial QRS-T angle and the SVG 
in young adults. Key findings were that all values of male and female subjects, even after 
correction for anthropomorphic measurements, differed significantly. This underscores the 
necessity for defining distinct normal limits for male and female subjects. In addition, the 
correlation of SVG magnitude with the T integral was stronger than the correlation with the 
QRS integral, signifying that repolarization characteristics are more important than depo-
larization characteristics for the magnitude of SVG in ECGs of young adult normal subjects. 
Moreover, there was a significant influence of heart rate on the spatial ventricular gradient 
magnitude: Higher heart rates were associated with smaller magnitudes of the spatial ven-
tricular gradient.
table 4. Correlation between anthropomorphic characteristics, the QRS-T angle and the spatial ventricular 
gradient.
hr height weight bmi bsA
Female QRS-T angle (°) 0.11b 0.05 -0.07 -0.13b -0.04
SVGmagnitude (mV*ms) -0.36
a 0.14a 0.11b 0.05 0.12b
SVGazimuth (°) -0.06 0.07 0.08 0.03 0.08
SVGelevation (°) 0.00 0.05 -0.05 -0.10
b -0.03
male QRS-T angle (°) 0.21a 0.03 -0.04 -0.01 -0.02
SVGmagnitude (mV*ms) -0.46
a 0.06 0.01 -0.04 0.03
SVGazimuth (°) 0.09 -0.02 -0.13 -0.12 -0.12
SVGelevation (°) 0.13 0.05 -0.12 -0.20
a -0.09
Spearman rank correlation coefficients between subject characteristics, the QRS-T angle and the SVG. SVG: 
spatial ventricular gradient; HR: heart rate; BMI: body mass index; BSA: body surface area. aCorrelation is 
significant at the 0.01 level. bCorrelation is significant at the 0.05 level.
Figure 4. Heart rate and the spatial ventricular gradient magnitude. Logarithmic regression of the spatial 
ventricular gradient magnitude on heart rate in male and female subjects. The upper and lower (dashed) 
lines denote the 96% prediction interval.
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Differences between male and female subjects
The spatial QRS-T angle and SVG both strongly depended on sex. In our study, male subjects 
had a larger spatial QRS-T angle and a larger SVG magnitude than female subjects. The most 
important sex-dependent difference in SVG orientation was found in the SVG azimuth, 
which was directed more anteriorly in males than in females. The difference in SVG elevation 
between males and females, albeit significant, was small (3°). Also, normal limits of SVG eleva-
tion were almost equal in males and females, the actual difference in lower and upper bound 
of normal limits being 4° and 1° respectively.
In our study, the mean spatial QRS-T angle was 80° for males and 66° for females. In a 
study by Rautaharju et al.,20 in which ECG predictors of mortality were investigated in a large 
(n=4,912) community-based population of older subjects (ages>65 yrs), similar differences 
between male and female subjects for the spatial QRS-T angle were found. They reported a 
mean spatial QRS-T angle of 81° for males (mean age 72.8 ± 5.7 yrs) and a mean spatial QRS-T 
angle of 67° for females (mean age 72.2 ± 5.3 yrs).
Sex-related differences in SVG magnitude were investigated in a small young (ages 20–30 
yrs) group of 30 male and 30 female Japanese subjects, by Yamauchi and colleagues.21 They 
found comparable differences between the SVG magnitude in males (105 mV·ms vs. 110 
mV·ms in our subjects) and females (81 mV·ms, vs. 81 mV·ms in our subjects).
It is unclear where the differences in spatial QRS-T angle and SVG between male and female 
subjects exactly originate. The orientation of the QRS axis was similar in male and female 
subjects (Table 2). The orientation of the T axis, however, was significantly more anterior in 
male (-47°) as compared to female subjects (-36°). As a consequence, the angle between the 
QRS- and T axis, the spatial QRS-T angle, was wider in male subjects. In general, widening of 
the angle between two vectors results in a smaller vectorial sum of these vectors (assum-
ing a constant magnitude of these vectors, Figure 1). The inverse correlation between the 
spatial QRS-T angle and the SVG in the present study population underscores this principle 
(wide spatial QRS-T angles were associated to small SVGs). However, in our population, male 
subjects have larger QRS and T integrals and therefore we observed a greater SVG magnitude 
in spite of a wider spatial QRS-T angle in male subjects.
In our population of normal subjects, significant correlations between the SVG magnitude 
and vector characteristics were present. Whereas the correlation between SVG magnitude 
and mean QRS vector magnitude was relatively weak, the correlation between SVG magni-
tude and the mean T vector magnitude was much stronger in both male and female subjects 
(Figure 4). This observation demonstrates that, in the normal heart, repolarization (T-wave) 
characteristics are more important for the magnitude of SVG than depolarization (QRS com-
plex) characteristics. As a consequence, the observed differences in the spatial QRS-T angle 
and SVG between males and females are likely to originate from repolarization rather than 
from depolarization characteristics. The anthropomorphic measurements weight, height and 
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thereof derived parameters correlated only weakly correlated to SVG and the spatial QRS-T 
angle (Table 3) in the present study. In a multiple linear regression model, these parameters 
were not explanatory for the differences in the SVG and the spatial QRS-T angle between 
male and female subjects. Possibly, explanation of the male-female difference is partially to 
be found in a different ratio between thorax dimensions and heart size, a different amount 
of subcutaneous fat, and presence of breast adipose tissue in female subjects.22 Furthermore, 
parameters that relate to the difference in cardiac morphology between males and females 
(e.g., ventricular mass, wall thickness) may further explain the difference in spatial QRS-T 
angle, SVG magnitude and SVG orientation.23, 24
comparison with earlier published normal limits
Until now, the publications of Pipberger and associates11, 12 were the only source for normal 
limits of the spatial QRS-T angle and SVG. Important differences in both normal limits and 
means of the SVG magnitude and SVG elevation are present between our study and these 
former studies. The most striking differences in normal limits are found in the ventricular 
gradient magnitude and the ventricular gradient elevation upper limits. In our study, the up-
per normal limit of the ventricular gradient magnitude is 47 mV·ms larger and the elevation is 
16° smaller than reported by the Pipberger group.11, 12 Moreover, differences of the same order 
of magnitude and direction are seen in the mean value of these parameters (31 mV·ms and 
9°, respectively).
Diversity in the composition of the study groups and/or a methodological difference may 
underlie these differences. Firstly, the study group of Pipberger and colleagues consisted 
of hospitalized men without evidence for cardiac disease. In that study group, non-cardiac 
disease and the administration of non-cardiac medication could have induced changes in 
cardiac electrophysiology resulting in (temporary) changes of the spatial QRS-T angle and/or 
SVG.25 Secondly, life-style, dietary and racial differences between the study populations may 
also explain part of the observed differences.26, 27 Thirdly, Pipberger and colleagues excluded 
heart rates lower than 60 bpm and, because lower heart rates are associated with larger SVG 
magnitudes (Figure 4), this may have selectively filtered out large SVG magnitudes. Finally, 
Pipberger and associates used 8-electrode 3-lead Frank VCGs instead of VCGs synthesized 
from standard 10-electrode 12-lead ECGs which is most commonly used nowadays.2, 20 Obvi-
ously, this affects the shape of the vector loop and, consequently, may influence the spatial 
QRS-T angle and/or SVG.
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limitations
In our study, normality of the subjects was not confirmed by obtaining a history, a physi-
cal exam or complementary investigations. However, the ECGs of included subjects were 
closely scrutinized for abnormalities, which makes the likelihood of systematical inclusion 
of abnormal subjects small. A second limitation is that only young subjects (18–29 yrs) were 
investigated in our study. Previous studies demonstrated that particularly SVG is a parameter 
that decreases with age.12, 21 Therefore, further studies should include subjects from all ages.
implications
Recently, the spatial QRS-T angle was described as a risk stratifier for cardiovascular death in 
a study by Kardys et al.2 and by Yamazaki and colleagues.5 In these studies, the upper limit 
of the spatial QRS-T angle in the low risk group was defined as 105° and as 100°, respectively. 
However, our study demonstrates that the normal spatial QRS-T angle can range up to 116° in 
females and 130° in males. In our study group, 44 males and 33 females have a spatial QRS-T 
angle wider than 100° and 32 males and 22 females have a spatial QRS-T angle wider than 
105°. It is unlikely that all these subjects should be classified as at high risk for cardiovascular 
death. This indicates that risk stratification criteria for the occurrence of cardiovascular death 
as applied by Kardys and by Yamazaki may have been too strict. In addition, they should have 
been different for male and female subjects.
conclusions
The spatial QRS-T angle and the spatial ventricular gradient orientation and magnitude differ 
significantly between female and male subjects. In male subjects, the spatial QRS-T angle 
is wider and the spatial ventricular gradient magnitude is larger. Furthermore, the spatial 
ventricular gradient orientation is more anterior in male subjects as compared to female 
subjects. In addition, the spatial ventricular gradient magnitude strongly depends on heart 
rate. High heart rates are associated with small spatial ventricular gradient magnitudes; this 
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The aim was to investigate the use of the ECG-derived ventricular gradient, projected on the 
x-axis (VGx), for detection of pulmonary hypertension (PH) and for prediction of all-cause 
mortality in PH patients.
methods
In patients referred for PH screening (n=216), the VGx was calculated semi-automatically 
from the ECG and was defined as abnormal when <24 mV·ms. The VGx of PH patients was 
compared to the VGx of patients without PH. The association between a reduced VGx and 
mortality was investigated in PH patients.
results
PH patients (n=117) had a significantly reduced VGx:14 ±27 vs. 45 ±23 mV·ms, p<0.001. Fur-
thermore, a severely reduced VGx (<0 mV·ms) was associated with increased mortality in PH 
patients: hazard ratio 1.025 (95% CI 1.006 – 1.045, p=0.012), per mV·ms VGx decrease.
conclusion
Reduced VGx is associated with the presence of PH and, more importantly, within PH patients, 
a severely reduced VGx predicts mortality.
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introDuction
Pulmonary hypertension (PH) is an uncommon, but serious disease, characterized by a 
mean pulmonary artery pressure (MPAP) ≥25 mm Hg.1 PH can be due to a primary disease 
process in the pulmonary arteries, referred to as pulmonary arterial hypertension (PAH).2,3 
Furthermore, PH can be secondary to e.g. left sided heart disease, pulmonary parenchyma 
abnormalities, thromboembolic occlusion of the pulmonary arteries or other diseases that 
lead to pulmonary vascular abnormalities.2,3 As PH is a progressive disease, irrespective of the 
cause, timely detection and treatment is necessary to improve symptoms and prognosis.4–6 
However, symptoms are generally mild until advanced stages of the disease and regular 
screening for PH is frequently required, specifically in patients who are at risk for developing 
PAH (e.g. patients with inflammatory connective tissue diseases, portal hypertension, or con-
genital heart disease).7 Currently, the gold-standard for PH screening is echocardiography, 
in which the systolic pulmonary artery pressure (SPAP) is derived through estimation of the 
peak systolic right ventricular pressure.8 Recently, the vectorcardiogram (VCG), synthesized 
from the standard 12-lead ECG, demonstrated to be of use for detection of elevated right 
ventricular (RV) pressure as a consequence of PH. In a case-control study, the ECG of patients 
with idiopathic PAH was compared to the ECG of matched healthy subjects.9 In that study, the 
ventricular gradient (VG) vector projected on the x-axis (VGx) was strongly associated with 
pulmonary artery pressure. It was shown that the VGx has a positive value in healthy subjects 
and steadily reduces to zero or becomes negative with increasing RV afterload. In addition, 
the VGx demonstrated to have a higher diagnostic accuracy for detecting elevated RV pres-
sure, than other ECG and VCG parameters. This indicated that quantitative ECG screening 
could be a valuable tool for the recognition of elevated pulmonary pressure in suspected 
idiopathic PAH patients. However, it remained to be investigated whether the observations 
were also applicable in the regular patient population of suspected PH patients, in which 
comorbidity is common.10 In addition, the association between a reduced VGx and patient 
survival was not investigated. Therefore, we investigated whether quantitative ECG screen-
ing with the VGx, could also be applied in the more heterogeneous patient population that 
is regularly referred for PAH screening. Furthermore, the association of a reduced VGx and 
all-cause mortality was assessed.
mAteriAls AnD methoDs
Consecutive patients who were referred for diagnosis and treatment of suspected PAH were 
included in the current analysis. First, all patients underwent the standard noninvasive screen-
ing protocol for PAH according to the international guidelines.11,12 As part of this protocol, a 
10s, 12-lead electrocardiogram (ECG) was obtained and echocardiography was performed. 
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Second, if the noninvasive screening protocol indicated the presence of PAH or when the 
absence of elevated pulmonary artery pressure could not be established, right heart cath-
eterization was performed. Thus, through combination of the results from the noninvasive 
screening protocol and right heart catheterization, the final PH diagnosis was established 
and patients were categorized into five different groups according to the WHO classification 
for PH etiology. Treatment was initiated subsequently, and the patients with PH were fol-
lowed regularly during out-patient clinic visits according to current guidelines.10,13,14 Patients 
with PAH were followed-up every three months, specifically when PAH-aimed therapy was 
initiated. Patients with other PH etiologies were followed less frequently, however at least 
bi-annually. For the purpose of the current evaluation; all-cause mortality was noted during 
follow-up.
electrocardiography
The ECGs were first stored digitally, thereafter exported from the ECG database management 
system and analyzed with the MATLAB-based (The MathWorks, Natick, MA) computer pro-
gram LEADS (Leiden, the Netherlands). Details on the technical background of LEADS have 
been reported previously.15 In short, the standard 10s ECG was averaged into one single beat 
that was subsequently converted into a vectorcardiographic beat in a largely automated pro-
cess. Besides heart rate, QRS duration and QT interval (corrected for heart rate according to 
the Fridericia formula), the software quantitated the magnitude and orientation of the mean 
QRS and T integral vectors, defined as azimuth (horizontal vector orientation, in degrees) and 
elevation (vertical vector orientation, in degrees).16 Thus, the angle between QRS and T vec-
tors, the QRS-T angle was calculated and ventricular gradient vector, including the projection 
of the VG vector on the x-axis (VGx), was derived (see Figure 1).9 In a previous study, it was 
demonstrated that normal subjects had a VGx of 24 mV·ms or higher.9 Therefore, with the 
purpose to analyze this cut-off value in a clinical context, the current patient population was 
subdivided into a group with a VGx <24 mV·ms and a group with a VGx ≥24 mV·ms.
echocardiography
Imaging took place in the left lateral decubitus position on a commercially available system 
(Vivid Seven, General Electric-Vingmed, Milwaukee, Wisconsin). Regular images were ob-
tained and specific attention was addressed to the measurement of the RV to RA pressure 
gradient or tricuspid regurgitant jet gradient (TR gradient) and the derived estimation of 
the SPAP.8 The estimated SPAP was defined as the RV to RA pressure gradient added to the 
right atrial pressure. Right atrial pressure was estimated 5 mmHg to 15 mmHg, according to 
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the diameter and inspiratory collapse of the inferior caval vein.17 If adequate measurement 
of the TR gradient could not be obtained in the apical 4 chamber position, the measurement 
was repeated in the short-axis view at the level of the aorta and, if necessary, in the subcostal 
view. If this still did not result in adequate measurement of the TR gradient, agitated saline 
was used to improve the signal intensity of the tricuspid regurgitant jet.14
right heart catheterization
Right heart catheterization was performed according to the international guidelines for 
invasive hemodynamic assessment of PAH.18 For the current analysis, the SPAP, the diastolic 
pulmonary artery pressure (DPAP) and the mean pulmonary artery pressure (MPAP) were 
used. Measurements were obtained with the patient in supine position with a Swan-Ganz 
catheter placed in the pulmonary artery.
Figure 1. Orientation and size of the ventricular gradient. Panel A: The ventricular gradient is the resultant 
vector of the QRS and T integral vector, which have the same orientations as the regular QRS and T axes. 
Panel B: The ventricular gradient projected on the x-axis (VGx) previously demonstrated to be reduced in 
patients with idiopathic pulmonary arterial hypertension (dashed vector) as compared to healthy subjects 




To investigate how elevated pulmonary pressure was reflected in ECG changes, Pearson 
correlation coefficients were determined between ECG characteristics and the echocardio-
graphically estimated SPAP, which is currently the gold-standard for noninvasive pulmonary 
pressure estimation. Furthermore, the odds ratio of a VGx <24 mV·ms as compared to ≥24 
mV·ms, was calculated for the presence of an estimated SPAP ≥40 mmHg, which corresponds 
to the echocardiographical diagnosis of pulmonary hypertension. In addition, the odds 
ratio of an abnormal VGx was calculated for the final diagnosis of PH, which was established 
after patients completed the noninvasive screening protocol and, if necessary, right heart 
catheterization. Furthermore, a receiver operating characteristic (ROC) curve analysis was 
performed, to determine the diagnostic accuracy of the above-described VGx cut-off (<24 
mV·ms) and three other cut-off levels (30, 35 and 40 mV·ms). Thereafter, the 3-year survival 
characteristics were investigated in patients with PH. For this purpose, univariate and multi-
variate (adjusted for sex, age, heart rate and WHO PH classification) Cox’s proportional hazard 
regression analysis was performed, in which the VGx was entered into the regression equation 
as a continuous variable. It was previously noted that PAH patients with most extensive RV 
disease typically present with a VGx <0 mV·ms.9 Therefore, all-cause mortality Kaplan Meier 
curve of patients with a VGx <0 mV·ms was compared to the Kaplan Meier curve of patients 
with a VGx ≥0 mV·ms. A logrank test was performed to assess whether the survival curves 
differed significantly between both groups.
Where appropriate, continuous variables are reported as mean ± SD, binary logistic and 
Cox’s proportional hazard regression coefficients are reported with 95% confidence interval. 
A p-value <0.05 was considered statistically significant.
results
general and disease specific characteristics of the patient population
A total of 216 patients (82 male, 38.8%) were screened for the presence of PAH. Overall the 
average age was 54.6 ±16.4 years at the time of screening. After initial noninvasive screening 
143 patients were suspected of PH (see Figure 2), mainly due to an elevated SPAP (≥ 40 mmHg) 
as estimated echocardiographically (n=114). In 29 of the 143 patients, there was no echocar-
diographical evidence for PH. Nonetheless, a high suspicion of PAH was present in these 
patients, as a consequence of the severity of symptoms, as a result of abnormal functional 
tests or due to radiological findings.
From the group of 143 suspected PH patients, 89 underwent right heart catheterization. 
Right heart catheterization was not performed in the remaining 54 patients in whom an 
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elevated SPAP was found echocardiographically. This group consisted of patients with clini-
cally and echocardiographically established Eisenmenger syndrome, or patients in whom left 
sided heart failure was undisputable and right heart catheterization would have no further 
therapeutic consequences.
After noninvasive screening of all patients, and right heart catheterization in the patients in 
whom it was indicated, PH was diagnosed in 117 patients. The characteristics of these patients 
are listed in Table 1. In 49 patients (42%) WHO group I (previously referred to as primary pul-
monary hypertension) was diagnosed. Left ventricular or valvular disease and hypoxic lung 
disease were other frequently occurring causes of pulmonary hypertension (Table 1).
electrocardiographic diagnosis of elevated pulmonary pressure
The ECG parameters are summarized in Table 2. PH patients had a higher heart rate, a longer 
QRS-duration and QTc-interval as compared to patients without PH. Furthermore, the angle 
Figure 2. Results of the screening algorithm for patients suspected of PAH. In total, 216 patients were 
screened noninvasively. After noninvasive screening, 143 patients were suspected of PH and 73 patients 
had no PH. In 89 patients, suspected of PAH, right heart catheterization was performed, which confirmed 




between the de- and repolarization vector, or QRS-T angle, was significantly wider. However, 
as compared to the other ECG and VCG parameters, the most prominent difference between 
PH patients and patients without PH was observed in the VGx, which was significantly lower 
in PH patients. A less pronounced VGx difference between patients with and patients without 
PH, was observed in those who either had a history of left sided heart disease or a history of 
a WHO group V-related disease (e.g. sarcoidosis) (see Figure 3).
The correlations between the SPAP, as estimated with echocardiography, and the ECG 
parameters are summarized in Table 2. The VG vector demonstrated to be inversely correlated 
with the estimated SPAP, as was the VGx, which demonstrated the strongest correlation with 
the SPAP (R=-0.64, p<0.001). The negative correlation denoted that an increasing SPAP was 
associated with a decreasing VGx. Hence, a reduced VGx represented an elevated SPAP.
To further explore the clinical applicability of the VGx, patients with an abnormal VGx (<24 
mV·ms) were compared to patients with a normal VGx. Thereafter, the odds ratio of having a 
table 1. Patient characteristics. 






 Age (years) 54.1 ± 15.4 55.9 ± 16.1 0.405
 Range 22.4-80.0 17.4-94.1
 Sex (male/female) 39/60 43/74 0.690
 Functional class (NYHA) 1.9 ± 0.8 2.6 ± 0.7 <0.001
main risk factor for developing Ph (n)
 Congenital systemic-pulmonary shunt 5 35
 Connective tissue disease 27 7
 Auto-immune disease 2 5
 Liver Cirrhosis 9 4
 Pulmonary embolism 23 6
 Hypoxic lung disease 13 20
 Left ventricular/valvular disease 5 30
 Other or no specific risk factor 15 4
echocardiography
 Estimated SPAP (mmHg) 31 ± 9 61 ± 20 <0.001
right heart catheterization 26 63
 SPAP (mmHg) 27 ± 6 65 ± 21 <0.001
 DPAP (mmHg) 11 ± 4 27 ± 13 <0.001
 MPAP (mmHg) 17 ± 4 40 ± 13 <0.001
who Ph classification 117
 I (%) 49 (42%)
 II (%) 31 (26%)
 III (%) 14 (12%)
 IV (%) 6 (5%)
 V (%) 3 (3%)
 Combined (%) 14 (12%)
DPAP: diastolic pulmonary artery pressure; MPAP: mean pulmonary artery pressure; PH: pulmonary hyper-
tension; SPAP: systolic pulmonary artery pressure. Numbers correspond to n, unless mentioned otherwise.
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reduced VGx for the presence of elevated pulmonary pressure, was calculated. Patients with 
a reduced VGx (<24 mV·ms, n=97), exhibited an odds ratio of 11.3 (95% CI 5.7 – 22.3, p<0.001) 
for the echocardiographic diagnosis of PH, as compared to patients with a normal VGx. Exclu-
sion of patients with a history of left sided heart disease, resulted in an odds ratio of 17.4 
(95% CI 7.5 – 40.5, p<0.001) Furthermore, in patients with a reduced VGx, the odds ratio for 
the presence of the final PH diagnosis, which was established after patients completed the 
noninvasive diagnostic algorithm and (if necessary) right heart catheterization, was 7.9 (95% 












Heart rate (bpm) 72 ± 13 79 ± 17 <0.001 0.17 0.016
QRS duration (ms) 93 ± 22 102 ± 25 0.007 0.22 0.002
QTc interval (ms) 403 ± 33 417 ± 40 0.004 0.27 <0.001
Mean QRS vector magnitude (μV) 352 ± 175 397 ± 219 0.102 0.24 0.001
QRS axis azimuth (º) 38 ± 45 37 ± 90 0.925 -0.15 0.036
QRS axis elevation (º) 15 ± 24 13 ± 36 0.608 -0.09 0.219
Mean T vector magnitude (μV) 164 ± 76 153 ± 112 0.399 -0.02 0.881
T axis azimuth (º)  -40 ± 32 -11 ± 75 <0.001 0.36 <0.001
T axis elevation (º) 20 ± 17 16 ± 29 0.198 0.04 0.569
QRS-T angle (º) 83 ± 36 111 ± 43 <0.001 0.33 <0.001
Ventricular gradient magnitude (mV*ms) 59 ± 25 41 ± 22 <0.001 -0.34 <0.001
Ventricular gradient azimuth (º) -6 ± 33 24 ± 73 <0.001 0.20 0.004
Ventricular gradient elevation (º) 26 ± 17 22 ± 30 0.315 0.01 0.839
Projection of VG on x-axis (mV*ms) 44 ± 23 14 ± 27 <0.001 -0.64 <0.001
Azimuth: horizontal vector orientation (degrees), Elevation: vertical vector orientation (degrees).
Figure 3. Mean VGx according to patient history. Patients were subdivided into different groups accord-
ing to the world health organization classification for pulmonary hypertension etiology. Group I refers to 
primary forms of pulmonary arterial hypertension. Patients in group II have a history of left sided heart 
disease. Patients in group III have a history of pulmonary disease. Group IV refers to a history of pulmonary 
embolism. Group V is the miscellaneous category and mostly existed of patients with sarcoidosis. Mean and 




CI 4.2-14.7, p<0.001). For the final PH diagnosis, the odds ratio was 9.0 (95% CI 4.4 – 18.4, 
p<0.001), when patients with a history of left sided heart disease were excluded.
ROC curve analysis was done to study the diagnostic performance of the VGx for the 
detection of elevated SPAP as estimated with echocardiography and for the final diagnosis 
of PH, which was established with noninvasive screening and right heart catheterization 
(Table 3). The application of the VGx for detection of an elevated SPAP as estimated with 
echocardiography, revealed an area under the curve of 0.83 (p<0.001). The 24 mV·ms cut-off, 
was associated with a sensitivity of 70% and a specificity of 83%. A VGx cut-off of 40 mV·ms 
yielded a sensitivity of 87% and a specificity of 61%. Exclusion of patients with a history of 
left sided heart disease increased the area under the curve to 0.88 (p<0.001). Whereas the 24 
mV·ms cut-off was associated with a sensitivity of 73% and a specificity of 85% after exclusion 
of patients with left sided heart disease, the 40 mV·ms cut-off had a sensitivity of 90% and a 
specificity of 67% (Table 3).
mortality risk and vgx
During a three year follow-up of the PH patients (n= 117), 23 patients (19.7%) died. The average 
follow-up time was 21.8 ±13.1 months. Univariate survival analysis revealed that a reduced 
VGx was significantly associated with the increased incidence of all-cause mortality. The 
crude hazard ratio was 1.018 (95% CI 1.003 – 1.034, p=0.020), per mV·ms decrease in VGx. After 
multivariate correction for age, sex, heart rate and WHO classification group, the hazard ratio 
was 1.025 (95% CI 1.006 – 1.045, p=0.012) per mV·ms decrease in VGx.
In patients with a VGx ≥0 mV·ms, survival was 88% at one year and 84% at three years 
(figure 4). In patients with a VGx <0 mV·ms, which is associated with more severe RV pressure 
overload, survival was 77% at one year and 66% at three years. This resulted in a 20% three-
year survival difference between patients with a VGx <0 mV·ms as compared to patients with 
a VGx ≥0 mV·ms, logrank p=0.02 (Figure 4).
table 3. Diagnostic accuracy of different VGx cut-offs. 
who group ii patients included who group ii patients excluded
sens (%) spec PPv nPv sens spec PPv nPv
estimated sPAP 
≥40mmhg
< 24 mV·ms 71 81 81 70 73 85 85 73
< 30 mV·ms 77 79 81 75 79 83 85 77
< 35 mV·ms 82 69 76 77 83 73 78 79
< 40 mV·ms 87 61 72 80 90 67 76 85
Numbers correspond with percentage. NPV: negative predictive value; PH: pulmonary hypertension; PPV: 
positive predictive value; Sens: sensitivity; SPAP: systolic pulmonary artery pressure; Spec: specificity.
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Discussion
Key findings were that:1 the VGx correlated inversely with pulmonary pressure,2 an abnormally 
reduced VGx showed a prominent association with the presence of PH,3 a severly decreased 
VGx was related with increased mortality in patients with PH.
In a recent study on normal subjects and patients with idiopathic forms of PH, it was dem-
onstrated that a reduced VGx was related to elevated pulmonary pressures and to increased 
right ventricular mass and size.9 In the current analysis, in which patients with various forms 
of PH were included, a similar association between the VGx and elevated pulmonary pres-
sures was observed. The VGx correlated inversely with the peak right ventricular pressure as 
estimated with echocardiography, and the risk of PH was significantly elevated in patients 
with an abnormally reduced VGx (<24 mV·ms).
PH causes elevated RV wall stress and leads to right ventricular hypertrophy as a conse-
quence of RV remodeling. Both increased wall stress as well as hypertrophy, result in ECG 
changes. The extent and visibility of those changes depends on the height of the pulmonary 
pressure and on the degree of right ventricular remodeling, but also on the ECG parameter 
that is used. Classic 12-lead surface ECG criteria rely on depolarization characteristics that 
relate to RV hypertrophy. Unfortunately, RV hypertrophy is a relatively late phenomenon that 
becomes apparent in advanced stages of PH. Therefore regular surface ECG-derived criteria 
are not well suited for early detection of increased pulmonary pressure. Previous studies 
Figure 4. Survival characteristics in PH patients. The dashed line depicts the survival characteristics of 
patients with a VGx ≥0 mV·ms. The solid line indicates patients with a VGx <0 mV·ms, which previously has 




demonstrated that VCG criteria, specifically the criteria that also incorporate repolarization 
characteristics, can more reliably detect elevated pulmonary pressure, also in earlier stages of 
the disease.19–22 In another study, diagnostic performance of standard ECG criteria was com-
pared to VCG criteria, including the VGx, in a homogeneous population of idiopathic PAH pa-
tients.9 This demonstrated that the T-integral vector was more affected in terms of magnitude 
and orientation as compared to the QRS-integral vector. Nonetheless, the VG vector, which 
incorporates de- and repolarization had the best diagnostic accuracy for the detection of RV 
overload. The current evaluation confirmed these findings in a heterogeneous population of 
patients who were referred for PAH screening. The best correlations were observed between 
the pulmonary pressure and the VCG parameters that incorporated de- and repolarization 
characteristics, such as the ventricular gradient. A VGx < 24 mV·ms, which was the lower limit 
of a normal VGx in the study by Henkens et al., demonstrated to be associated with an almost 
8-fold increased risk for the presence of idiopathic PH as compared to patients with a normal 
VGx. In the current study, an odds ratio of 7.9 was found for an VGx < 24 mV·ms, which is 
comparable to results of the study of Henkens et al.9
The VG, defined as the QRST integral, can be calculated on the standard ECG as well as the 
VCG and represents the heterogeneity in action potential durations within the heart.23 Previ-
ous studies have shown that RV overload causes distinct alterations in QRS and T vectorloops. 
Cowdery et al. indicated the implications of a hypertrophic RV for the QRS vectorloop and 
Kawaguchi and colleagues showed the value of the T vector loop-area.21,24 PH and resultant 
RV overload is associated with a relatively lower contribution of LV electrical forces. As a 
consequence, the VG vector reduces in magnitude and becomes oriented more posteriorly 
(see Figure 1). Both these characteristics are reflected in the projection of the VG on the x-
axis, or VGx. Thus, the VGx is a surrogate measure, optimal for detection of RV overload as 
demonstrated by the current and previous evaluations.9,22
The present study is the first in which the association between a reduced VGx and unfavor-
able survival characteristics is demonstrated. In both the univariate as well as the multivariate 
analysis, a reduced VGx was significantly associated with the increased incidence of all-cause 
mortality. In patients with PH, irrespective the cause, reduced RV function is an important 
predictor of mortality.25,26 Patients with a reduced VGx, who have more elevated right ven-
tricular pressure as compared to patients with a normal VGx, are likely to have more impaired 
RV function. Therefore, a reduced VGx probably identifies the patients who have decreased 
RV function and exhibit worse survival as compared to patients with a higher VGx. The find-
ings in the current study underscore this concept.
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clinical implications
The ECG-derived VGx could be a good screening tool for PH in high risk groups, e.g. patients 
with pulmonary disease and chronic hypoxemia, or patients with inflammatory connective 
tissue diseases. Routine ECG analysis during out-patient clinic visits can be used as an initial 
PH screening, specifically in these risk groups. Referral for echocardiography and further 
analysis could be considered as soon as a reduction of VGx occurs. Nowadays, timely de-
tection is even more important, because early treatment demonstrated to be beneficial in 
patients with PAH.6
Currently, several treatment modalities are available for patients with PAH. Potentially, a 
therapy-induced reduction in pulmonary vascular resistance and decrease in RV overload 
may be reflected by increased VGx. Therefore, further studies should assess the association 
between treatment effect and changes in VGx magnitude. Besides the application of the VGx 
for PH screening and treatment follow-up, the VGx can also be applied to identify patients 
who are at increased risk of all-cause mortality, in whom a more aggressive treatment regi-
men may be required. This however has to be confirmed in clinical trials.
limitations
In the present analysis, the VCG was derived from the standard ECG using the semi-automated 
computer program LEADS, which is a non-commercially available tool for computerized ECG 
analysis. Currently, electrocardiographs do not provide the VGx, thus it has to be calculated 
afterwards using dedicated software. Nonetheless, only limited additions to the ECG analysis 
software would be required to provide the VGx fully automatically.
conclusion
A reduced VGx identifies patients with elevated pulmonary artery pressure in a heteroge-
neous population of patients suspected of pulmonary arterial hypertension. More impor-
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summAry
In the introduction of this thesis (chapter 1), the increasing relevance of right ventricular 
(RV) function measurement is described. Whereas classically the right ventricle was regarded 
a dispensable part of human circulation, investigations in all fields of cardiovascular research 
indicated the importance of normal RV anatomy and function. Recent studies in develop-
mental biology demonstrated that myocardium of the left and right ventricle have a differ-
ent origin. The exact implications of this finding are largely unknown and are still subject 
of research. RV anatomy and function are complicated to assess. Ideally assessment of RV 
performance would include measurement of RV volumes, RV myocardial and valvular func-
tion, RV response to loading conditions and RV electrical properties. Recent improvements 
in imaging techniques and electrocardiographic assessment provided the opportunity to 
better characterize the right ventricle. Nonetheless, it is unclear if these novel techniques 
are superior to those currently used. Furthermore, the position of new techniques in clinical 
practice needs to be established.
Part I of this thesis describes two studies in which normal RV development is investigated. 
In chapter 2, the difference between left and right ventricular myocardial compaction is 
studied. In the mammalian right ventricle, the free wall is thin, whereas the left ventricular 
(LV) wall is thicker and compacted. This difference already occurs during cardiac develop-
ment. It was previously demonstrated that the epicardium plays a crucial role in normal 
ventricular development. Disrupted epicardial development, which occurs in TGFβ2-null 
mice, is associated with ventricular thinning. Potentially, the epicardium may also guide the 
difference between LV and RV compaction. This was investigated in wildtype mouse embryos 
and in TGFβ2-null embryos. In wildtype mouse embryos, differences in epicardial covering 
and timing of formation of epicardium-derived cells was observed between the left and 
right ventricle. Whereas the right ventricle was fully covered by epicardium later than the 
left ventricle, migration of epicardium-derived cells into the myocardium occurred earlier in 
the right as compared to the left ventricle. Furthermore, the number of epicardium-derived 
cells, which play an important role in ventricular compaction, was lower in the right ventricle. 
In TGFβ2-null embryos, the number of epicardium-derived cells was severely reduced, result-
ing in thin, uncompacted ventricles. The fact that the left ventricle was more extensively 
populated by epicardium-derived cells in wildtype mouse embryos, may explain why the left 
ventricle was more severely affected than the right ventricle in TGFβ2-null embryos.
A novel concept for normal outflowtract (OFT) development is presented in chapter 3. 
Early in development, the right ventricle is connected to a single OFT, which contains both 
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the primitive aorta as well as the pulmonary trunk. Normally, embryonic OFT remodeling 
results in a septated aorta and pulmonary artery with a left posterior and right anterior 
position, respectively. Abnormal development of the OFT can cause a side-by-side arrange-
ment of the great arteries as seen in transposition of the great vessels. In this study, OFT 
remodeling was examined in wildtype mouse embryos during cardiac development using 
three-dimensional reconstruction techniques. We observed that, due to the addition of an-
terior heart field-derived myocardium below the left branch of the 6th pharyngeal artery, the 
future pulmonary artery orifice was pushed rightward and anterior. From this observation, it 
can be speculated that rotation occurs during cardiac development, rather than a spiraling 
motion which was previously suggested.
Part II of this thesis describes the clinical application of cardiovascular imaging techniques 
in patients who are at risk for the development of RV dysfunction or failure. In chapter 4 
and 5, patients with transposition of the great arteries and a right systemic ventricle are 
investigated. Due to abnormal embryonic cardiovascular development, these patients have 
a right ventricle which is connected to the aorta and a left ventricle which is connected to the 
pulmonary artery. On the long term, valvular incompetence, mainly tricuspid regurgitation, 
develops intrinsic to the congenital defect or as consequence of the elevated RV pressure. In 
cases of severe tricuspid regurgitation and RV failure, surgical treatment may be necessary. 
As described in chapter 4, an incompetent tricuspid valve can be either repaired by using an 
annuloplasty ring or can be replaced by a mechanical or bioprosthetic valve. Since it was un-
known which strategy was superior, both techniques were analyzed. Studies in other patient 
populations demonstrate that valve repair is preferred in cases of valvular incompetence, 
therefore replacement was only performed when repair was not feasible. In the study popu-
lation of 16 patients (repair, n=8; replacement, n=8), this approach demonstrated short-term 
improvement of tricuspid competence and functional class. However, tricuspid repair was 
associated with rapid recurrence of regurgitation. Moreover, in both groups, RV function did 
not improve, nor decrease peri-operatively measured using conventional echocardiography. 
As such, it can be debated if tricuspid repair should be considered the treatment of choice in 
patients with systemic RV dysfunction due to severe tricuspid regurgitation.
In chapter 5, the association between stress cardiovascular magnetic resonance imaging 
(CMR), a novel technique to study RV dysfunction and outcome of patients with a systemic 
right ventricle is presented. RV volumes and ejection fraction were measured with CMR dur-
ing rest and submaximal exercise or after dobutamine induced stress. Previously, an abnormal 
response to stress was observed in patients with a systemic right ventricle. It was unknown 
whether the degree of abnormal response was related to event-free survival (hospitalization 
for heart failure, cardiac surgery, aborted cardiac arrest, death). This chapter demonstrates 
that in patients with a systemic RV, the inability to decrease end systolic volume or increase 
ejection fraction during stress, is associated with a higher incidence cardiac events. In 
contrast, resting RV volumes and ejection fraction were not related to patient outcome. The 
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abnormal response to stress may reflect an early sign of systemic RV dysfunction and can 
be used to identify patients at risk of adverse outcome. Currently, studies are performed to 
identify medical treatment strategies in this patient population.
In Chapters 6–8 RV longitudinal strain is described in patients at risk for RV dysfunction. 
chapter 6 reports the results of RV longitudinal strain measurement in patients with tetral-
ogy of Fallot. Pulmonary regurgitation is a frequent finding in patients after total correction 
of tetralogy of Fallot. Specifically when severe, pulmonary regurgitation leads to RV dilatation 
and dysfunction. Conventional echocardiography is not recommended for follow-up of RV 
function in these patients as it lacks a strong association with patient outcome. Therefore, 
CMR is the imaging modality of choice in this patient population. In this chapter it is demon-
strated that RV longitudinal strain, measured with echocardiography is reduced in patients 
with tetralogy of Fallot as compared to healthy controls. Furthermore, RV longitudinal strain 
is clearly associated with RV ejection fraction, measured with CMR. Overall, RV dilatation was 
observed whereas ejection fraction was preserved. Simultaneously, RV longitudinal strain 
reduced indicating that RV deterioration may be reflected earlier in reduction of RV longitu-
dinal strain, rather than reduced ejection fraction. Therefore, RV strain could be regarded as a 
novel follow-up measure of RV function in patients with tetralogy of Fallot.
chapter 7 describes ventricular strain patterns in patients with Marfan syndrome. Mild left 
and right ventricular dilatation as well as ventricular dysfunction was previously reported 
in patients with Marfan syndrome. Nonetheless, heart failure is a rare complication of the 
disease and, when present, usually relates to severe mitral or aortic disease. In the study 
presented in this chapter, right (and left) ventricular strain was evaluated during follow-up 
of 50 patients with Marfan syndrome without significant valvular disease. Although strain 
was mildly impaired in Marfan patients as compared to controls, strain did not reduce dur-
ing follow-up. Moreover, the events that were observed during follow-up (supraventricular 
arrhythmias and proximal aorta surgery) were unlikely to be associated to ventricular dys-
function. Cox regression confirmed the absence of an association between ventricular strain 
and outcome in Marfan patients. Consequently, it could be postulated that another stressor 
besides Marfan syndrome is required (mitral regurgitation, aortic regurgitation) to evoke 
manifest ventricular dysfunction.
In chapter 8, the additional value of RV function assessment using RV strain is investigated 
in patients after acute myocardial infarction. Previous studies showed that reduced tricuspid 
annular plane systolic excursion (TAPSE) or RV fractional area change (RVFAC) was related 
to adverse outcome after acute myocardial infarction. It was unknown if measurement of 
RV longitudinal strain would improve prognostication in this patient population. Therefore 
TAPSE, RVFAC and RV longitudinal strain was measured in a large sample of patients after 
acute myocardial infarction (n=621) all treated with primary percutaneous intervention. The 
association between RV function and patient outcome (death, hospitalization for heart failure 
and re-infarction) was investigated. After multivariable correction, RVFAC and RV longitudinal 
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strain were related to patient outcome. Even after correction for RVFAC, RV longitudinal strain 
measurement was of incremental value for assessment of patient outcome. Since preserved 
RV function proves to be such an important determinant of outcome, it should be part of 
regular patient assessment.
In Part III of this thesis, the application of electrocardiography in patients with abnormal 
RV function is presented. Whereas chapter 9 and 10 present the clinical application of classic 
electrocardiography, chapter 11 and 12 report on novel computerized electrocardiographic 
techniques. chapter 9 shows how conventional electrocardiographic criteria can be used to 
detect pulmonary hypertension. This case demonstrated that the occurrence of RV pressure 
overload due to pulmonary hypertension can be accompanied by typical abnormalities on 
the electrocardiogram: QRS axis of 90°, tall R wave in V1 in the absence of an S wave and 
aspecific repolarization disturbances.
In chapter 10, QRS duration is evaluated in 90 patients after total correction of tetralogy of 
Fallot who undergo pulmonary valve replacement for severe pulmonary regurgitation. Pro-
longed QRS duration is a frequent finding in patients with tetralogy of Fallot and is associated 
with RV dilatation due to pulmonary regurgitation. In such cases pulmonary valve replace-
ment is known to reduce QRS duration. However, the position of QRS duration in timing sur-
gery is subject of debate. In the study presented in this chapter, QRS duration was measured 
pre-operatively and 6 months after pulmonary valve replacement. The patients with a QRS 
duration >180ms, either pre- or post-operatively, showed worse survival characteristics as 
compared to patients with a QRS duration ≤ 180 ms. More specifically, after multivariable cor-
rection, prolonged post-operative QRS duration and a lack of peri-operative improvement in 
QRS duration was strongly associated with adverse patient outcome. Therefore, pulmonary 
valve replacement should be considered before severe QRS prolongation occurs.
Although classical vectorcardiography provides a large amount of information about 
cardiac electrical properties, it was largely abandoned in clinical cardiology due to time-
consuming recording techniques. The introduction of conversion algorithms to convert the 
standard 12-lead surface ECG into a vectorcardiogram, renewed the interest for vectorcar-
diography derived variables. In order to obtain normal limits of two of these variables, the 
spatial ventricular gradient and the spatial QRS-T angle were calculated from 660 normal 
standard electrocardiograms. The results of this analysis are presented in chapter 11. Both 
variables differ significantly between male and female subjects. Male subjects typically have 
wider QRS-T angles and larger ventricular gradients. In addition, the spatial ventricular gradi-
ent tends to reduce in response to increases in heart rate.
Clinical application of the ECG-derived ventricular gradient in patients with RV pressure 
overload due to pulmonary hypertension is discussed in chapter 12. In a previous study, 
it was demonstrated that projection of the spatial ventricular gradient on the x-axis (VGx) 
provided the best diagnostic criterion for diagnosis of elevated pulmonary pressures in a 
selected population of idiopathic pulmonary arterial hypertension patients. In this chapter 
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the value of the VGx for diagnosis and assessment of patient prognosis was determined in a 
heterogeneous population of suspected pulmonary hypertension patients. A reduced VGx 
was significantly associated with increased risk of pulmonary hypertension. The discrimina-
tive power of the VGx between normal and elevated pulmonary pressure strongly depended 
on the presence of underlying cardiovascular disease. Interestingly, mortality risk was signifi-
cantly increased in patients with a severely reduced VGx. This indicates that the VGx may be 
a promising novel tool for the assessment of RV overload due to pulmonary hypertension.
conclusions
The right ventricle is an indispensable part of human circulation. Its importance remains 
firmly established in a steeply increasing number of investigations. Many facets of RV devel-
opment, anatomy and function are still unknown. In this thesis, the right ventricle was further 
characterized in three areas of cardiovascular research: Embryonic development, imaging 
and electrocardiography.
Orchestrated contribution of the anterior heart field to the developing OFT is required for 
normal positioning of the aorta and pulmonary artery. Whereas early in development the 
(future) pulmonary trunk has a left-caudal position, the continuing contribution of cellular 
components from the anterior heart field to the subpulmonary myocardium, results in a 
rotational motion of the OFT and normal positioning of the pulmonary artery. Disruption 
of this process is likely to be related to the occurrence of congenital OFT abnormalities such 
as tetralogy of Fallot and transposition of the great arteries. The anterior heart field also 
plays a crucial in normal development of the right ventricle. However, other extra-cardiac 
cell-populations are also relevant for the difference in morphology between the left and right 
ventricle. The epicardium and epicardium-derived cells play an important role in ventricular 
compaction as a result of epicardium-myocardium interaction, thus providing an additional 
explanation for the differences between the left and right ventricle.
The evolution of cardiovascular imaging modalities greatly improved RV function assess-
ment. Nonetheless, uncertainties exist about the way novel imaging techniques should be 
implied in clinical practice. Moreover, it is unclear if novel measures of RV function are, by 
definition, superior to conventional techniques. In selected situations, conventional echocar-
diographic assessment of the right ventricle may be useful. However, RV longitudinal strain 
assessment may be a more reliable method to quantitate RV function in congenital as well 
as acquired heart disease, specifically in situations of subtle but relevant RV dysfunction. 
Furthermore, RV longitudinal strain seems to provide a sensitive measure for follow-up of 
patients prone to development of RV failure. CMR is still regarded the gold-standard for RV 
functional assessment. In patients with a systemic right ventricle, CMR investigations showed 
that an abnormal ventricular response to stress was a frequent finding. The clinical implica-
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tions of this finding were unclear. This thesis demonstrates that the inability to increase ejec-
tion fraction during stress is associated with adverse outcome in patients with transposition 
of the great arteries and a systemic right ventricle.
The standard 12-lead electrocardiogram can provide valuable information in patients 
suspected of RV disease. Characteristic patterns can arise as a consequence of either pres-
sure or volume overload. A rightward rotation of the QRS-axis, in patients who are followed 
regularly at the out-patient clinic may be the result of pulmonary hypertension and increased 
RV pressure. Furthermore, pulmonary regurgitation evokes RV dilatation and prolongation of 
QRS duration in patients after total correction of tetralogy of Fallot. A QRS duration >180ms 
and the lack of peri-operative improvement in QRS duration identifies patients at risk for 
adverse post-operative outcome. Although the standard 12-lead electrocardiogram can be 
helpful in patient assessment, most ECG-derived criteria for detection of RV pressure over-
load lack sensitivity. With use of computer algorithms, the standard ECG can be converted 
to a three-dimensional vectorcardiogram. The QRS-T angle and ventricular gradient (VG) are 
general descriptors of electrical activity of the heart and can be calculated from the vec-
torcardiogram. The VGx can be used to detect elevated RV pressure in patients suspected 
of pulmonary hypertension. Moreover, a severely reduced VGx is associated with increased 
mortality in this patient population.
Future PersPectives
Although major achievements have been made in RV function assessment in recent years, 
after RV dysfunction has been established, treatment options are frequently limited. In 
situations of RV pressure overload, medical therapies aimed at functional improvement of 
the right ventricle are currently lacking. Better understanding of the right ventricle on a 
fundamental level is imperative for the development of novel drugs. Research in embryology 
provides valuable information about the “building blocks” of the right ventricle and can help 
explain how RV cardiomyocytes interact with their surrounding. Furthermore, such research 
is essential for the identification of genes which are relevant for normal RV anatomy and 
function. An interesting challenge for developmental research will be the identification of 
mechanisms that guide the interaction between epicardium, or epicardium-derived cells, 
and RV myocardium. Specifically the role of the extra-cellular matrix will be of interest within 
this context, since this may be a promising target for drug- as well as cell-based therapies.
The important role of RV function assessment in patients with cardiac disease is beyond 
debate. To further optimize risk stratification, research is currently conducted to find out 
which investigations should be performed in clinical practice. More than in the left ventricle, 
it should be noted that response to loading conditions forms an integral part of RV function. 
By convention, most measurements derived from current cardiovascular imaging techniques 
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do not incorporate this loading response. However, with recent technological improvements 
in echocardiography and magnetic resonance imaging it would be feasible to investigate 
this aspect of RV function. Furthermore, the number of possible RV function measurements 
is vastly increasing. It would be of interest to perform large studies aimed at providing a 
core-set of variables that demonstrate the best association with patient outcome.
The introduction of ECG-derived vectorcardiography renewed the interest in classical 
vectorcardiographic variables. In contrast with ECG diagnosis, which mostly relies on quali-
tative judgment of specific patterns, vector-based diagnosis mainly rests on quantitative 
measures. This property makes vectorcardiography an excellent tool for screening purposes 
as it facilitates optimization of sensitivity/specificity characteristics depending on the aim 
of a screening method. With use of computer algorithms, the ECG can be converted into a 
vectorcardiogram in an automated process. Only small changes in ECG software are required 
to make measures such as the VGx and the QRS-T angle readily available on the standard ECG. 
These steps are necessary to expedite the implementation of ECG-derived vectorcardiogra-
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sAmenvAtting
In de inleiding van dit proefschrift (hoofdstuk 1) wordt het toenemende belang van meting 
van rechter hartkamer (RV) functie beschreven. Nog maar kort geleden werd de RV als een 
misbaar onderdeel van de menselijke bloedsomloop gezien, echter onderzoek in alle velden 
van de cardiovasculaire wetenschap heeft het belang van normale vorm en functie van de 
RV bewezen. Recente ontwikkelingsbiologische studies hebben laten zien dat de linker en 
rechter hartkamer een andere embriologisch achtergrond hebben. De exacte consequenties 
van deze bevinding zijn nog onduidelijk en daardoor is het ook een belangrijk onderwerp 
van allerlei onderzoek. RV vorm en functie zijn moeilijk in beeld te brengen en te meten . In 
het ideale geval zouden we RV volumes, RV hartspier en klepfunctie meten in combinatie 
met het in kaart brengen van de elektrische eigenschappen en de reactie op verschillende 
belastingscondities. Recente verbeteringen in beeldvormingstechnieken en electrocardio-
grafie hebben de mogelijkheid geboden om de RV beter te karakteriseren. Desalniettemin 
is het onduidelijk of deze nieuwe technieken beter zijn dan die op dit moment gebruikt 
worden. Daarmee dient de positie van nieuwe technieken in de klinische praktijk nog te 
worden vastgesteld.
In Deel I van dit proefschrift worden twee studies beschreven waarin de normale ont-
wikkeling de RV wordt onderzocht. In hoofdstuk 2 is het verschil tussen linker en rechter 
hartspier ontwikkeling onderzocht. De wand van de RV is dunner dan de linker hartkamer bij 
zoogdieren. Dit verschil is al vroeg in de embryonale ontwikkeling zichtbaar. Eerdere studies 
lieten al zien dat het epicard een essentiële rol speelt bij de ontwikkeling van de hartkamers. 
Verstoorde epicardiale ontwikkeling, wat voorkomt bij de TGFβ2-knockout muis, leidt tot een 
dunne hartspier. In potentie zou het epicard ook een rol kunnen spelen in de verschillen 
tussen de linker en de rechter hartspier. Dit is onderzocht bij wildtype en TGFβ2-knockout 
muizen. Bij de wildtype muizen werd een verschil tussen de linker en rechter hartspier gezien 
in epicardiale bedekking en vorming van epicard afkomstige cellen. In vergelijking met de 
linker hartspier werd de rechter hartspier later bedekt door epicard, maar migreerden de epi-
card afkomstige cellen wel eerder naarbinnen. Daarnaast was het aantal epicard afkomstige 
cellen, wat belangrijk is voor de verdikking van de hartspier, kleiner aan de rechter zijde. Bij 
TGFβ2-knockout muizen waren de epicard afkomstige cellen nauwelijks aanwezig en doordat 
de linker hartspier in de normale situatie meer uitgebreid wordt voorzien, is het voorstelbaar 
dat aan deze zijde de meest verregaande afwijkingen werden gezien.
Een nieuw concept voor de ontwikkeling van de uitstroom van het hart wordt besproken 
in hoofdstuk 3. De RV is verbonden met een enkelvoudige uitstroom, die zowel de primitieve 
aorta als de stam van de arteria pulmonalis bevat. In de normale situatie leidt de embryonale 
ontwikkeling tot een gescheiden aorta en arteria pulmonalis met respectievelijk een links 
posterior en rechts anterior positie. Abnormale uitstroom ontwikkeling kan uitmonden in 
een zij-aan-zij positie en transpositie van de grote vaten. Bij deze studie is de ontwikkeling 
CHAPTER 13
224
van de uitstroom in wildtype (= zonder genetische afwijkingen) muizen onderzocht. Wij 
hebben gezien dat de toevoeging van hartspierweefsel vanuit het voorste hartveld, onder 
de 6e boogarterie, ervoor zorgt dat de stam van de arteria pulmonalis naar rechtsvoor wordt 
geduwd. Hieruit zouden we kunnen veronderstellen dat de embryonale positionering van 
de grote vaten een gevolg is van rotationele groei in plaats van spiralisering, wat in eerdere 
studies werd verondersteld.
In Deel II van dit proefshrift wordt de toepassing van cardiovasculaire beeldvormings 
technieken beschreven bij patienten die risico lopen op RV disfunctie of falen. In hoofdstuk 4 
en 5 worden patienten met transpositie van de grote vaten en een rechter systeemkamer on-
derzocht. Door abnormale embryonale ontwikkeling (zie hoofdstuk 2) is de RV aangesloten 
op de lichaamsslagader en de linker hartkamer (LV) op de longslagader, precies omgekeerd 
in vergelijking met de normale situatie. Op de lange termijn kan dit tot ernstige hartkleplek-
kage (=tricuspidalis kleplekkage) leiden door ofwel de aangeboren afwijking zelf of door de 
chirurgische behandeling ervan. Bij sommige patiënten is er (opnieuw) een operatie nodig 
om dit probleem op te lossen. Zoals beschreven in hoofdstuk 4 kan dit doormiddel van een 
plastiek, waarbij de oorspronkelijke hartklep behouden blijft, of door vervanging met een 
mechanische kunstklep. Omdat het onbekend was welke strategie het beste is, zijn beide 
technieken met elkaar vergeleken. Uit studies in andere patientepopulaties is gebleken dat 
een plastiek in principe de voorkeur heeft boven een vervanging, daarom is bij de huidige 
studiepopulatie alleen een vervanging gedaan als een plastiek beslist niet mogelijk was. De 
studiepopulatie bestond uit 16 patienten (plastiek, n=8; vervanging, n=8). Deze benadering 
heeft tot vermindering van hartkleplekkage geleid en tot verbetering van de (subjectieve) 
inspanningstolerantie. Helaas werd bij de patienten die een plastiek ondergingen een vrij 
snel recidief van lekkage gezien. Daarnaast leidde de ingreep niet tot verbetering van RV 
functie, gemeten met conventionele echotechniek. Om die reden is het maar de vraag of een 
plastiek de chirurgische behandeling van voorkeur is bij patienten met een RV systeemkamer 
en ernstige hartkleplekkage.
Het verband tussen stress cardiovasculaire MRI (CMR), een nieuwe techniek om RV 
disfunctie te onderzoeken, en de prognose van patienten met transpositie van de grote 
vaten, is beschreven in hoofdstuk 5. RV volumina en ejectiefractie werden gemeten tijdens 
submaximale inspanning of dobutamine geinduceerde stess. Uit voorgaande onderzoeken 
was al gebleken dat de reactie van de RV op inspanning of dobutamine stress afwijkend 
is. Het was echter onbekend of de mate waarin dit afwijkend was een relatie had met de 
eventvrije overleving (ziekenhuisopname voor hartfalen, operaties, hartritmestoornissen en 
overlijden). Dit hoofdstuk laat zien dat het onvermogen van de RV om de functie toe te laten 
nemen bij inspanning of dobutamine stress is geassocieerd met het frequenter voorkomen 
van events tijdens het leven. Een dergelijk verband werd bij rustmetingen niet gezien. De 
afwijkende reactie op inspanning zou een vroeg teken kunnen zijn van RV disfunctie en 
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gebruikt kunnen worden om risicopatiënten op te sporen. Op het moment wordt onderzocht 
of medicamenteuze behandelstrategieën werkzaam zijn in deze patiëntencategorie.
De toepassing van RV longitudinale strain wordt beschreven in hoofdstukken 6–8. hoofd-
stuk 6 laat de resultaten zien van RV longitudinale strain meting bij patienten met tetralogie 
van Fallot. Pulmonaalkleplekkage is een veelvoorkomend probleem bij patienten met een 
tetralogie van Fallot die een totale chirurgische correctie hebben ondergaan. Wanneer de 
lekkage ernstig wordt dan kan de RV gaan uitzetten, waarmee de functie achteruit gaat. 
Conventionele echocardiografie wordt niet aanbevolen voor het volgen van RV functie bij 
deze patiëntengroep, omdat het niet voldoende zegt over de prognose. Daarom is CMR de 
aanbevolen beeldvormingstechniek. In dit hoofdstuk wordt beschreven dat RV longitudinale 
strain verminderd is bij patienten met tetralogie van Fallot. Daarnaast bleek longitudinale 
strain duidelijk geassocieerd met RV ejectiefractie (gemeten met CMR). Binnen deze patiën-
tengroep werd geleidelijke verwijding van de RV gezien, met gelijkblijvende ejectiefractie. 
Tegelijkertijd nam de RV longitudinale strain af, ten teken van afname van RV functie. Daarom 
zou RV longitudinale strain gezien kunnen worden als een nieuwe techniek, gebaseerd op 
echocardiografie, waarmee patiënten met tetralogie van Fallot gevolgd zouden kunnen 
worden.
hoofdstuk 7 beschrijft hartkamer strain patronen bij patiënten met het syndroom van 
Marfan. Milde uitzetting van de hartkamers, alsmede verminderde functie van de hartka-
mers is beschreven bij het syndroom van Marfan. Desalniettemin is hartfalen een zeldzaam 
ziektebeeld bij dit syndroom en het wordt in dergelijke gevallen meestal veroorzaakt door 
afwijkingen aan een hartklep. Tijdens deze studie zijn 50 patiënten met het syndroom van 
Marfan zonder afwijkingen aan de hartkleppen gevolgd en zijn de strainpatronen van 
zowel de linker als rechter hartkamer gemeten. Hoewel de strainwaarden minder waren 
in vergelijking met mensen zonder het syndroom van Marfan, bleven de waarden stabiel 
tijdens het vervolg. Daarnaast werd geen associatie gevonden tussen de strainwaarden en 
de midden-lange termijn prognose van patiënten. Dit geeft aan dat de geobserveerde strain 
vermindering vooralsnog geen klinische betekenis lijkt te hebben. Wel zou gepostuleerd 
kunnen worden dat de combinatie van een lekkende hartklep en het syndroom van Marfan 
kan leiden tot (versnelde) hartkamerdisfunctie. Dit is in tegenspraak met de hypothese dat 
het syndroom van Marfan op zichzelf staand ook kan leiden tot belangrijke afwijkingen in de 
hartspier.
In hoofdstuk 8 wordt de toegevoegde waarde van het bepalen van de RV functie met 
behulp van RV strain beschreven in patienten na een acuut myocard infarct. Eerdere onder-
zoeken hebben aangetoond dat verminderde “annular plane excursion” van de tricuspidalis 
ring (TAPSE) of RV “fractional area change” (RVFAC) gerelateerd zijn aan een vermindere uit-
komst na een acuut myocard infarct. Het was onbekend of het meten van de RV longitudinale 
strain een betere prognostische waarde in deze patienten populatie zou bieden. Metingen 
van TAPSE, RVFAC en RV longitudinal strain werden uitgevoerd in een grote groep patienten 
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(n= 621) met een acuut myocard infarct die behandeld zijn met primaire percutane inter-
ventie. Hiermee is de associatie tussen de functie van de RV en de prognose van de patient 
(overlijden, een ziekenhuisopname wegens hartfalen en recidief hartinfarct) onderzocht. Na 
multivariabele correctie bleken RVFAC en RV longitudinale strain gerelateerd met de prog-
nose van de patient. Bovendien bleek dat RV longitudinale strain meting, zelfs na correctie 
voor RVFAC, van grote waarde te zijn voor het inschatten van de prognose van de patiënt. 
Daarom zou het wenselijk zijn om RV functiemeting middels strain te implementeren in de 
reguliere echografische beoordeling van patienten na een acuut myocard infarct.
In het Deel III van dit proefschrift wordt de toepassing van electrocardiografie bij patienten 
met een abnormale RV functie besproken. De klassieke toepassing van het electrocardio-
gram wordt beschreven in de hoofdstukken 9 en 10. Daarnaast wordt in hoofdstuk 11 en 12 
een nieuwe gecomputeriseerde electrocardiografische techniek besproken.
hoofdstuk 9 laat zien op welke wijze de conventionele electrocardiografische criteria ge-
bruikt kunnen worden voor het op spoor komen van pulmonale hypertensie. De verhoogde 
druk in de RV als gevolg van pulmonale hypertensie kan leiden tot typische veranderingen 
op het electrocardiogram: een hartas groter dan 90°, een hoge R-top in V1 met afwezigheid 
van een S-top en de aanwezigheid van repolarisatie stoornissen.
hoofdstuk 10 beschrijft hoe de QRS duur van 90 patienten met een totale correctie van 
de tetralogie van Fallot, die vanwege pulmonalisklep lekkage een donorklep hebben gekre-
gen, is geassocieerd met eventvrije overleving. Verlengde QRS duur wordt veel gezien bij 
patiënten met tetralogie van Fallot en is een gevolg van RV uitzetting door pulmonalisklep 
lekkage. Een pulmonalisklep vervanging kan leiden tot een verkorting van de QRS duur. Het 
is, echter, onduidelijk of de QRS duur gebruikt kan worden bij de timing van vervanging 
van de pulmonalisklep. In dit onderzoek is de QRS duur pre-operatief en 6 maanden na 
pulmonaalklepvervanging gemeten. Het bleek dat patiënten met een QRS duur > 180 ms, 
pre- of post-operatief, een slechtere prognose hadden in vergelijking met de patienten met 
een QRS duur ≤ 180 ms. De patiënten die voor de operatie een QRS duur hadden > 180 ms, 
zonder verkorting na de operatie, hadden de slechtste prognose. Aan de andere kant bleken 
de patiënten met een QRS duur ≤ 180 ms voor de operatie, die een verkorting lieten zien na 
de operatie, de beste prognose te hebben. In deze laatste groep kwamen zelfs helemaal geen 
events voor. Daarom zou pulmonalisklep vervanging overwogen moeten worden voordat 
ernstige QRS duur verlenging ontstaan is.
Hoewel de klassieke vectorcardiografie veel informatie geeft over de elektrische eigen-
schappen van het hart, is de techniek verlaten binnen de klinische cardiologie, omdat het 
opnemen van een vectorcardiogram ingewikkeld en tijdrovend is. Echter, de introductie 
van conversie algoritmen waarmee het standaard 12 afleidingen ECG kan worden omgezet 
in een vectorcardiogram zorgde voor hernieuwde interesse in vectormaten. Om van twee 
vectormaten (de QRS-T ruimtehoek en de ventriculaire gradiënt) de normaalwaarden te kun-
nen bepalen zijn ze van 660 standaard electrocardiogrammen van gezonde proefpersonen 
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berekend. In hoofdstuk 11 worden de resultaten van deze analyse gepresenteerd. Beide 
variabelen zijn verschillend tussen man en vrouw. Mannen hebben een bredere QRS-T ruim-
tehoek en een grotere ventriculaire gradiënt ten opzichte van vrouwen. Bovendien neemt de 
ventriculaire gradiënt af bij toename van de hartslag.
De mogelijke klinische toepassing van deze ECG-afgeleide ventriculaire gradiënt bij pa-
tiënten met een RV overbelasting als gevolg van pulmonale hypertensie, is beschreven in 
hoofdstuk 12. In een eerdere studie is aangetoond dat de x-as-geprojecteerde ventricular 
gradient (VGx) het meest optimale diagnostische criterium is voor het vaststellen van ver-
hoogde pulmonale druk bij patiënten met idiopathische pulmonale arteriële hypertensie. In 
dit hoofdstuk is de waarde van de VGx, ten aanzien van diagnose en prognose, onderzocht 
in een heterogene patiëntenpopulatie waarbij pulmonale hypertensie werd vermoed. Hierbij 
bleek dat een kleine VGx is geassocieerd met een verhoogd risico op de aanwezigheid van 
pulmonale hypertensie. Het vermogen van de VGx om onderscheid te maken tussen normale 
en verhoogde pulmonale druk was sterk afhankelijk van de aanwezigheid van een onderlig-
gende cardiovasculaire ziekte. Een interessante bevinding was bovendien dat het overlij-
densrisico in belangrijke mate verhoogd was bij patiënten met een sterk verlaagde VGx. Dit 
pleit ervoor dat de VGx een belangrijke, nieuwe maat zou kunnen zijn voor de beoordeling 
van RV overdruk als gevolg van pulmonale hypertensie.
conclusies
De rechter hartkamer is een onmisbaar onderdeel van de menselijke circulatie. Ondanks dat 
het belang van de RV wordt bevestigd in een toenemend aantal onderzoeken, zijn tot op 
heden zijn vele facetten van de RV ontwikkeling, anatomie en functie nog onbekend. In dit 
proefschrift worden de eigenschappen van de RV verder uitgewerkt binnen drie gebieden 
van cardiovasculair onderzoek: Embryonale ontwikkeling, beeldvorming en electrocardio-
grafie.
Gereguleerde bijdrage van het voorste hartveld aan de zich ontwikkelende uitstroom is 
noodzakelijk voor normale positionering van de aorta en de arteria pulmonalis. In het begin 
van de ontwikkeling heeft (de toekomstige) de stam van de pulmonalis een links-caudale po-
sitie. Toevoeging van cellen vanuit het voorste hartveld aan het sub-pulmonale myocard, leidt 
tot een rotationele beweging van de uitstroom waardoor de arteria pulmonalis in de juiste 
positie komt. Waarschijnlijk kan verstoring van dit proces leiden tot aangeboren uitstroom af-
wijkingen, zoals tetralogie van Fallot en transpositie van de grote vaten. Het voorste hartveld 
blijkt ook een belangrijke rol te spelen in de normale ontwikkeling van de RV, hoewel andere 
extra-cardiale celpopulaties ook relevant zijn voor de hartspierontwikkeling en het verschil in 
morfologie tussen de linker en rechter hartkamer. Het epicard en de epicard-afkomstige cel-
len reguleren de hartspierontwikkeling door middel van epicardium-myocardium interactie, 
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waarmee een alternatieve verklaring wordt geboden voor het verschil tussen de linker en 
rechter hartkamer.
De evolutie van cardiovasculaire beeldvormingsmodaliteiten leveren een belangrijke toe-
voeging aan de beoordeling van RV functie. Desalniettemin is het nog niet uitgekristalliseerd 
hoe nieuwe technieken in de klinische praktijk kunnen worden toegepast. Daarnaast is het 
de vraag of de nieuwe maten voor RV functie “per definitie” beter zijn dan de conventionele 
technieken. In bepaalde situaties blijkt dat conventionele echocardiografie van de RV van 
toegevoegde waarde is. Echter, RV longitudinale strain bepaling is mogelijk een meer be-
trouwbare methode om RV functie te kwantificeren zijn bij zowel aangeboren als verworven 
hartziekten, specifiek bij patiënten met subtiele maar relevante RV disfunctie. Tevens lijkt RV 
longitudinale strain een geschikte meting te zijn voor het volgen van patiënten die vatbaar 
zijn voor de ontwikkeling van verminderde RV functie. CMR wordt nog steeds gezien als de 
gouden standaard voor bepaling van de RV functie. CMR onderzoek heeft laten zien dat er 
veelal een abnormale ventriculaire reactie op inspanning optreedt bij patiënten met een 
rechter systeemkamer. De klinische relevantie van deze bevinding was nog niet bekend. In 
dit proefschrift wordt aangetoond dat het onvermogen tot het vergroten van de ejectiefrac-
tie gedurende inspanning geassocieerd is met een ongunstige uitkomst.
Het standaard 12-afleidingen elektrocardiogram kan waardevolle informatie geven bij 
patiënten met mogelijk RV pathologie. Als gevolg van een verhoogde druk of toename van 
het volume kunnen karakteristieke patronen ontstaan. Bij patiënten die regelmatig op de 
polikliniek gezien worden kan een rechter asdraai het gevolg zijn van pulmonale hypertensie 
en verhoogde RV druk. Daarnaast leidt pulmonalisklep lekkage tot RV uitzetting en verlen-
ging van de QRS duur bij patiënten na een totale correctie van tetralogie van Fallot. Het blijkt 
dat een QRS duur > 180 ms en het uitblijven van peri-operatieve verkorting van de QRS duur 
de patiënten identificeert die een verhoogd risico hebben op een negatieve post-operatieve 
uitkomst. Ondanks dat het standaard 12-afleidingen electrocardiogram een bijdrage kan leve-
ren aan de beoordeling van patiënten, zijn de meeste ECG-afgeleide criteria om RV overdruk 
vast te stellen weinig sensitief. Met het gebruik van computeralgoritmen kan het standaard 
electrocardiogram worden omgezet in een driedimensionaal vectorcardiogram. De QRS-T 
ruimtehoek en de ventriculaire gradiënt (VG) geven een algemene omschrijving van de elek-
trische activiteit van het hart en kunnen berekend worden uit het vectorcardiogram. De VGx 
kan gebruikt worden om verhoogde RV druk vast te stellen bij patiënten met een verdenking 
op pulmonale hypertensie. Bovendien is een sterk verminderde VGx geassocieerd met een 
verhoogde mortaliteit in deze patiëntenpopulatie.
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vooruitzicht
Ondanks dat er op het gebied van de RV functiemeting grote voortgang is geboekt in de afge-
lopen jaren, zijn behandelingsopties vaak beperkt wanneer RV disfunctie is ontstaan. Bij het 
optreden van een RV druk overbelasting is er tot op heden nog geen medische behandeling 
gericht op de functionele verbetering van de RV. Om nieuwe medicatie te kunnen ontwik-
kelen is inzicht in de RV op een fundamenteel niveau vereist. Embryologisch onderzoek geeft 
waardevolle informatie over de “bouwstenen” van de RV en geeft inzicht over de interactie 
tussen RV hartspiercellen en hun omgeving. Bovendien is dit onderzoek nodig om genen te 
identificeren die een rol spelen bij de normale RV anatomie en functie. Het identificeren van 
de mechanismen die leiden de interactie tussen het epicardium, de epicardafkomstige cellen 
en de RV, is een interessante uitdaging voor het embryonale hartonderzoek. Meer specifiek 
zal de rol van de extra-cellulaire matrix belangrijk blijken te zijn in dit verband, omdat dit een 
veelbelovend doel is voor medicamenteuze en cel-gedreven therapie.
Het belang van evaluatie van RV functie bij patiënten met een hartziekte is onmiskenbaar. 
Resultaten van lopende onderzoeken zullen de risicostratificatie verder optimaliseren en 
hiermee zal duidelijk worden welke onderzoeken in de klinische praktijk moeten worden 
toegepast. De reactie op volumebelasting is een integraal deel van de RV functie, meer dan 
in de linkerventrikel. Echter de meeste metingen binnen de cardiovasculaire beeldvormings-
technieken houden geen rekening met de reactie op volumebelasting. Met de recente tech-
nologische verbetering in echocardiografie en CMR is het mogelijk dit aspect van RV functie 
te onderzoeken. Daarnaast neemt het aantal nieuwe methoden voor RV functie metingen 
nog altijd toe. Het zou interessant zijn om grote studies uit te voeren om een “standaard set” 
aan meetwaarden vast te stellen die de beste associatie met prognose hebben.
De introductie van ECG-afgeleide vectorcardiografie heeft de interesse in klassieke vec-
torcardiografische variabelen hernieuwd. Daar waar ECG diagnostiek vooral gebaseerd is op 
kwalitatieve beoordeling van specifieke patronen, is vectordiagnostiek meestal gebaseerd 
op kwantitatieve meting. Deze eigenschap maakt vectorcardiografie een uitstekend instru-
ment voor screeningsdoeleinden, aangezien het de mogelijkheid biedt tot optimalisatie van 
sensitiviteit en specificiteit verhouding, afhankelijk van het screeningsdoel. Met het gebruik 
van computer algoritmen kan het ECG automatisch geconverteerd worden naar een vec-
torcardiogram. Slechts kleine veranderingen in conventionele ECG software zijn nodig om 
metingen zoals de VGx en de QRS-T hoek te kunnen verkrijgen. Dit is nodig om ECG-afgeleide 
vectorcardiografie in de klinische praktijk te kunnen implementeren, daar het tot op heden 
nog een klein gebied is in het cardiovasculaire onderzoek.
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leven aan te kunnen. Ik ben jullie daar heel erg dankbaar voor en hoop nog lang van jullie te 
mogen genieten.
Lieve Marissa, met jouw liefde en geduld heb je mij alle ruimte gegeven voor het doen 
van mijn onderzoek en alle neven-taken. Ik koester elke dag die wij samen leven en nu het 
schrijven van mijn proefschrift achter de rug is, heb ik nog meer tijd om samen van ons man-
netje Oliver te genieten.
